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Abstract 
 
Serological surveillance involves the detection of Plasmodium species-specific antibodies as 
biomarkers for monitoring recent and historical malaria transmission dynamics at 
population-level. These methods are particularly useful in low transmission settings where 
standard surveillance such as parasitological and entomological approaches are inefficient. 
This thesis explores the use of serological surveillance to estimate the magnitude and 
heterogeneity of malaria transmission using different sampling strategies, mapping 
techniques and serological assays in three areas of differing endemicity in Indonesia. Findings 
suggest that: 1) Analysis of community-based serological data can confirm the 
discontinuation of transmission and be used to identify high-risk areas where malaria is most 
likely to be reintroduced, 2) Mobile technology-based participatory mapping approaches can 
be used to quickly obtain spatial residential information for individuals presenting at health 
facilities in resource poor areas where formal addresses are typically not used and internet 
connectivity is limited, 3) the combination of facility-based sampling, multiplex serological 
assays and participatory mapping can be used as an additional surveillance method to better 
identify and target areas still receptive to malaria in very low transmission area conducting 
elimination, 4) seropositivity to Etramp5.Ag1 is sensitive and specific in predicting 
Plasmodium falciparum PCR positivity in children in a high transmission setting, suggesting 
its potential use as a marker of recent exposure in elimination setting. In conclusion, this 
thesis demonstrates the various applications of serological surveillance at different levels of 
malaria endemicity. Further implementation research is needed to enable the integration of 
these methods to the existing surveillance systems. 
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1. Introduction 
1.1 Global burden and the changing epidemiology of malaria 
In humans, malaria is caused by five species of Plasmodium. Plasmodium falciparum, 
Plasmodium vivax, Plasmodium malariae and Plasmodium ovale are spread from one person 
to another via the bite of female mosquitoes of the genus Anopheles, whereas Plasmodium 
knowlesi is a result of zoonotic transmission when an Anopheles mosquito infected by 
parasites circulating in a macaque then bites and infects humans (1). Of these five species, 
P. falciparum and P. vivax cause the greatest public health challenge because P. falciparum 
is responsible for most of the disease morbidity and mortality whilst P. vivax is the most 
geographically widely distributed and has a hypnozoite, liver stage which is extremely 
difficult to detect and responsible for approximately 80% of infections (1–5). In addition, the 
public health threat caused by P. knowlesi appears to be growing with the number of human 
P. knowlesi cases increasing across Southeast Asia (1,6–13)  with those who visit rural, 
forested areas of the region most at risk (6,14,15). 
 
Globally, there were significant reductions in the number of malaria cases and deaths 
between 2010 and 2017. It was estimated that the number of malaria cases had decreased 
from 239 million cases (95% CI: 219–285 million) in 2010 to 219 million cases (95% CI: 203–
262 million) in 2017(16).  In line with the cases, the estimated number of malaria deaths had 
also decreased from 607,000 deaths in 2010 to 435,000 in 2017. Although there were large 
reductions in the number of malaria cases and deaths, malaria is still a major public health 
problem in many countries of the world. It is reported that almost 80% of all malaria cases 
were in 15 African countries and in India, whilst approximately 82% of estimated P. vivax 
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malaria cases in 2017 occurred in just five countries i.e. India, Pakistan, Ethiopia, Afghanistan 
and Indonesia (16). The spatial distribution of age-standardized P. falciparum parasite rate 
in 2005 and 2017 and the predicted P. vivax parasite rate and change 2005 and 2017 can be 
seen in Figure 1.1 and 1.2, respectively. 
 
Figure 1.1 Spatial distribution of age-standardized P. falciparum parasite rate for children 
aged 2–10 years in 2005 (top) and 2017 (bottom) reproduced from from Weiss et al. (17) 
The grey shades represent low endemic areas with a linear scale between zero and 0·01 P. 
falciparum parasite rate2–10, colors from blue to red represent areas with P. falciparum 
parasite rate2–10 between 0·01 and 1. Areas without endemic P. falciparum are shown in 
white. 
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Figure 1.2 Map of P. vivax parasite rate and change 2005 and 2017 as shown in Battle et 
al.(18) 
Light grey represents endemic areas with insufficient information to generate a prediction. 
The change in parasite rate was calculated by the value for 2005 minus 2017 divided by the 
2005 value and multiplied by 100. A scale of white to green represents a decrease and from 
white to red represents an increase. The darkest green areas have seen a ≥100% decrease in 
prevalence, while the darkest red areas show a ≥100% increase in prevalence from 2005 to 
2017.  
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The significant decline in malaria transmission in many regions has led to optimism that 
malaria elimination might be achieved in numerous countries (19–26). Malaria elimination is 
being considered as an ultimate goal and sustaining a malaria-free status will have 
tremendous benefits in terms of deaths and illness averted, household socioeconomics, and 
the growth of industrial and agricultural benefits for a country (27,28). It was reported that 
there are 91 countries and territories with ongoing malaria transmission (29) , 7 countries 
and territories certified malaria-free (29,30) and there are 21 countries with the potential to 
eliminate by 2020 (Figure 1.3 (31)). 
 
Figure 1.3 Map of 21 countries with the potential to eliminate malaria by 2020 reproduced  
from Rabinovich et al.(31) 
 
A recent review by Cotter et al. (3) has provided a comprehensive picture of the changing 
epidemiology of malaria in areas moving from controlled low–endemic malaria to 
elimination. In East Asian countries, the most common epidemiological shift is the increasing 
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proportion of malaria in the adult male population due to occupational and behavioural 
factors such as plantation work and forest activities, sleeping in fields for farming purposes, 
and travel to endemic areas, which increases risk of exposure (32,33). Whilst in Africa, 
malaria risk is occupationally related to gold miners, loggers, and outdoor activities such as 
sleeping outdoor and social activities. Residual transmission is also typically concentrated in 
hard-to-reach populations whom typically have less access to malaria prevention and 
treatment provided by health facilities (34). Finally, imported malaria and human migration 
may provide a significant source of reintroduction of malaria transmission in the absence of 
strong public health systems (35–37). 
 
1.2 Malaria surveillance in elimination 
 
Figure 1.4 Global technical strategy for malaria 2016-2030: framework, pillars and 
supporting element copied from WHO (38) 
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Transforming malaria surveillance into a core intervention is one of three pillars of the WHO 
global technical strategy for malaria 2016-2030 (Figure 1.4) (38). In an elimination context, 
as transmission declines, monitoring changes in malaria transmission intensity and disease 
prevalence through surveillance becomes increasingly important to allow the evaluation of 
health services and control programs (19,39,40). Moreover, once elimination has been 
achieved, surveillance must continue in order to confirm a region’s elimination status and to 
ensure that outbreaks resulting from re-introduced infections are quickly identified and 
controlled (41). Measuring transmission in these situations is challenging as it tends to  
become more heterogeneous and hotspots of transmission (geographical areas where 
transmission intensity exceeds the average level (42,43)) are increasingly common (Figure 
1.5). 
 
Figure 1.5 Malaria heterogeneity across the transmission continuum 
Schematic of the increasingly focal nature of malaria as transmission decreases, requiring 
increased intensity and frequency of reporting from large geographical areas (e.g., district) 
to reporting near-real-time individual case data in small areas”. Figure from WHO (41).  
 
The WHO framework for malaria elimination defined the following stratification for 
transmission risk (Figure 1.6): 1) Receptive areas (i.e. the ecosystem is suitable for 
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transmission of malaria) and non-receptive areas (i.e. the ecosystem is not suitable for 
transmission of malaria), 2) Receptive areas with and without ongoing transmission, 3) 
Transmission with or without foci, 4) Degree of transmission in diffuse or focal areas. 
 
 
Figure 1.6 Sequential risk stratification based on receptivity and transmission intensity taken 
from WHO (44) 
 
1.2.1 Heterogeneity of transmission 
Heterogeneity of transmission occurs when a small proportion of the population is 
disproportionally affected and experiences the majority of the disease due to 
environmental, social or biological factors (45,46).  To better target interventions in areas 
moving towards elimination, it is increasingly important to identify and target hotspots of 
transmission and understand the factors that may contribute to disease persistence in these 
locations (47,48). However, the assessment of transmission heterogeneity has been focused 
on national level estimates, mainly due to the availability of data (49,50). Previous studies 
reported that the detection of local level clusters of infection has an important role for 
improving understanding of the micro epidemiological patterns of disease transmission, and 
to ensure that control strategies are tailored to the specific epidemiological characteristics 
in an area as much as is feasible (42,43). 
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1.3 Approaches to quantify malaria transmission 
1.3.1 Entomological 
The entomological inoculation rate (EIR) is considered the gold standard for estimating 
malaria transmission. EIR provides a measure of the degree of malaria exposure in the 
population by assessing the average number of infectious bites that a person in a given area 
is expected to receive per unit time (51,52). As it is difficult to directly calculate the 
proportion of host seeking mosquitoes that are harbouring sporozoites (53), using human 
landing catches is considered to be the best proxy. However, as this method involves the risk 
of the workers being exposed to malaria, the use of light and chemical traps have become 
more widely utilised as an alternative method (54,55). Despite it being considered the gold 
standard for estimating transmission intensity, EIR is not extensively used as it is a highly 
seasonal measure with extreme variability over time and space, and is difficult to estimate 
in areas  of low transmission intensity where the density of mosquitoes is low (52,56).  
 
1.3.2 Parasitological 
1.3.2.1 Microscopy 
Microscopy is considered the gold standard of malaria diagnostic tools in the field and the 
estimates of P. falciparum parasite rate (PfPR) generated from microscopy tests are the 
most common malaria burden metric reported worldwide (57). Microscopy is typically the 
recommended diagnostic in a clinical setting and involves reviewing and quantifying the 
presence of parasites in bloods slides that are visualised under an oil immersion microscope 
(58). 
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Although microscopy is able to detect as few as 5 parasites/µl of blood, its sensitivity has 
been reported to vary considerably with some estimates suggesting a more consistent limit 
of detection closer to 100-200 parasites/µl of blood for routine microscopy in clinical 
settings and likely to be more insensitive in low transmission areas where microscopists do 
not see malaria parasites on a regularly basis (59–61). Parasite densities tend to fluctuate 
in most infected individuals, with microscopically detectable malaria likely to be present at 
some points during each infection (62–64). It has been reported that parasite prevalence 
generated from microscopy tests could be negatively biased by at least 20% due to 
fluctuating parasite densities (65). Specifically, for P. vivax, it is impossible for microscopy 
to diagnose individuals with hypnozoites which can result in future infections. 
 
1.3.2.2 Rapid Diagnostic Tests 
Malaria Rapid Diagnostic Tests (RDTs) provide an easy and less technically demanding 
diagnostic tool with similar sensitivity to conventional field based microscopy (66). The 
basis for P. falciparum and P. vivax detection by RDTs is usually detection of histidine-rich 
protein 2 (HRP2) and plasmodium lactate dehydrogenase (pLDH), respectively. The latest 
WHO malaria RDT evaluation reported that most RDTs are showing invalid rate when 
testing samples with parasite densities below 200 parasites/ μl of blood (67). The RDTs are 
also likely to be false-positive, often caused by the detection of HRP-2 that is still circulating 
post clearance of infection. In addition, it was reported that the currently available RDTs 
were less good at detecting P. vivax than P. falciparum infection (67). For an example, a 
study in the high transmission area in Papua province, Indonesia reported that sensitivity 
of Plasmotec Malaria-3 RDT to detect P. falciparum and P. vivax was 78% and 52% when 
parasite densities ranged from 101-1,000/µl then became lower to 60% and 21% when 
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parasite densities were lower than 100/µl (68). Although there is a P. falciparum highly 
sensitive HRP2-based RDT with a reported detection limit 10 folds more sensitive than 
conventional RDTs, assessment of its field performance is still ongoing (69). 
 
1.3.2.3 Molecular methods 
Molecular methods such as polymerase chain reaction (PCR) and loop mediated isothermal 
amplification (LAMP) are more sensitive methods for determining parasite positivity typically 
used in malaria research. Firstly, PCR-based methods have been found to detect as few as 1 
or 2 parasites/μl of blood demonstrating the high sensitivity and specificity of these methods 
(70,71). It has been reported that the increased sensitivity of PCR could overall detect 50% 
more infections than microscopy or RDTs (59,72). However, the field application of PCR is 
limited by technical complexity and high cost of the assay as well as the length of time 
required to process samples (60). LAMP has been reported as the most advanced molecular 
method that may provide a field-friendly sensitive diagnostic tool that can be used in malaria 
endemic countries (73–75). LAMP provides an attractive alternative tool with less technical 
complexity, less time to obtain a result, and with similar sensitivity to PCR (73,76). These 
molecular methods have the potential to become useful tools to quickly detect areas of focal 
transmission when detecting sub patent infections becomes the priority as the malaria 
programmes move towards elimination (72). 
1.3.3 Serological measures 
Malaria infections elicit the production of antibodies in humans which can be used as 
markers of exposure to the disease (77). Studies suggest that antibodies to parasite antigens 
are generated within 2 weeks after infection (78,79) with some variation depending on age 
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(78). Furthermore, previous studies suggested that there are differences in the production 
of antibodies by age, where malaria species specific antibodies may be short‐lived in young 
children (80) but long‐lived in older individuals (81). 
 
As markers of exposure, a memory antibody response exists and can persist for many years 
in adults (82–85). Studies have shown that antibodies can persist for several years without 
re-infection in immigrants to Europe (82,83). It has also been reported that antibodies 
appear very rapidly in individuals re-exposed to malaria during epidemics in Madagascar (84) 
and in populations from which malaria had been eliminated in Vanuatu (85). However, 
evidence suggested that antibody responses in children are not as fixed as they are in adults, 
particularly in areas of seasonal malaria (80,86,87).  
 
Serology provides an alternative approach to indirectly estimate malaria transmission by 
measuring human antibody responses to malaria parasite antigens. The presence of species-
specific antibodies reflects historical (or current) exposure and therefore offers a more 
sensitive measure of transmission, particularly in low endemic settings where other 
approaches become less viable (88–90). This approach has been used to measure 
transmission intensity, primarily through seroconversion rates (SCR, i.e. the annual rate by 
which people seroconvert from negative to positive) derived from age-dependent measures 
of antibody seroprevalence. Serological estimates have been reported as alternative 
measures of medium and long-term transmission intensity (39,40,77,91–95) and strongly 
correlate with estimates of EIR, PR, and clinical incidence (39). Recently, it has been reported 
that SCR has a stronger correlation with EIR, compared to the correlation between PR and 
EIR (Figure 1.7). 
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Figure 1.7 Comparison of EIR, SCR and parasite rate measurements from multiple sites 
taken  from Greenhouse et al. (96) 
 
1.4 Potential use of serological surveillance to aid malaria elimination 
1.4.1 Potential application 
Conventional measures such as entomological estimates and parasitaemia point prevalence 
become less sensitive and relatively expensive as transmission declines (59,97). The 
detection of Plasmodium species-specific antibodies as biomarkers for monitoring exposure 
and transmission  has been utilised in several countries and is a more sensitive tool to assess 
population-level malaria exposure in low-transmission settings (39,98). One of the potential 
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applications of serological surveillance is to confirm malaria elimination and monitor for re-
emergence of malaria (99). Serological surveillance could be used to verify that malaria has 
been eliminated since the absence of antibodies in the youngest age groups indicates that 
malaria transmission has been interrupted (93,98). In addition, it can also be used to identify 
high-risk areas (94,100) and groups suitable for active case detection (34). 
 
Figure 1.8 describes the priority applications of serological markers of exposure in different 
levels of transmission intensity and different target populations. At the population level, 
serological surveillance can be used to generate risk stratification and measure changes in 
transmission due to interventions in areas where transmission is low and/or approaching 
zero, as well as to verify the absence of transmission once zero transmission is achieved. At 
the individual level, serological markers could be used to develop point of care tests to 
identify people who have had recent exposure to infection. This could be particularly 
pertinent for P. vivax exposure as there are currently no tests which detect the hypnozoite 
stage- but the presence of antibodies indicating recent exposure may help to identify 
individuals at risk of carrying hypnozoites in areas approaching zero transmission and also 
can potentially be used as early detection and response tools in areas with very low 
transmission setting where infections are becoming very rare. 
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Figure 1.8 Priority applications of serological markers of exposure from Greenhouse et al. 
(101) 
 
1.4.2 Potential antigens for serological surveillance 
Malaria parasites consist of many antigens, some of which induce strong antibody responses 
in humans depending on their abundance on the parasite, the size of the antigen and their 
availability to the human immune system. For instance, The invasion of erythrocytes involves 
several interactions with proteins on the merozoite surface and those associated with 
invasion organelles – micronemes and rhoptries (Figure 1.9) (102). These antigens are major 
targets for protective antibodies due to their direct exposure to the host immune system and 
their roles in invasion. The antibodies can act either by inhibiting parasite replication, 
blocking binding of merozoite ligands to their receptor or binding partners, or blocking 
processes required for parasite function (103–110). After initial exposure and binding to 
parasite antigens, naïve B cells begin to differentiate into either short-lived plasma cells that 
function to control initial infection or long-lived plasma cells and memory B cells (MBCs) that 
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contribute to the maintenance of sustained antibody-based immunity (111,112). Research 
suggests that short-lived plasma cells secrete primarily immunoglobulin-M (IgM) that only 
persists for several days to a month, while long-lived plasma cells and MBCs secrete 
immunoglobulin-G (IgG) that can persist for years (113). 
 
 
Figure 1.9 Parasite life cycle and antigens that are potential biomarkers of malaria exposure 
adapted from Wu 2018 (114), Winzeler et al 2006 (115) and Cowman et al 2006 (102). 
 
A summary of antigens used in this thesis is presented in Table 1.1. Some of the well-studied 
P. falciparum antigens such as PfAMA1, PfMSP-1-19, MSP2, CSP and PfGLURP have been 
reported to induce long-lived antibodies that can persist years after infection (116,117) and 
have been used to measure transmission intensity in many endemic settings. Some of the 
relatively newly studied P. falciparum antigens such as Etramp5.Ag1, Etramp5.Ag2, Hyp2, 
, PvDBP, PvEBP 
, PvRBP 
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Gexp18, HSP40, PfSEA-1 were recently reported to be associated with short-lived antibody 
responses and can accurately predict days since an individual was last infected and malaria 
incidence in the last 12 months (118). For P. vivax, in addition to the antigens associated with 
long-lived antibodies i.e. PvAMA1 and PvMSP-1-19, there are some new antigens (PvDBP, 
PvEBP, PvRBP1a and PvRBP2b) which are potentially useful for detecting historical exposure 
and hypnozoite carriage. Of these antigens, PvRBP2b was reported as a potential antigen 
associated with short-lived antibodies which could be used to detect recent P. vivax exposure 
(119,120). 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1.1 Summary of antigens used in this thesis 
No Gene ID Acronym Description Location Reference 
1 PF3D7_0304600 CSP Circumsporozoite protein. Most predominant and antigenic 
protein on sporozoite surface. Component of RTS, S vaccine 
Sporozoite (121) 
2 PF3D7_1301600 EBA140 RIII-V erythrocyte binding antigen 140; involved in invasion  Apical organelles, micronemes (122) 
3 PF3D7_0731500  EBA175RII_F2 erythrocyte binding antigen 175; red blood cell (RBC) binding 
region via glycophorin A 
Apical tip (122) 
4 PF3D7_0423700 Etramp 4 antigen 2 Early transcribed membrane antigen. Integral parasitophorous 
vacuole membrane (PVM) protein. C-terminal 
Infected red blood cell (iRBC), 
PVM 
(118) 
5 PF3D7_0532100 Etramp 5 Ag 1 Early transcribed membrane antigen. Integral PVM protein. iRBC, PVM (123) 
6 PF3D7_0402400 GEXP18 Gametocyte exported protein 18. Unknown function. iRBC/Gametocyte (118) 
7 PF3D7_1035300 GLURP R2 Glutamate rich protein R2 Merozoite Surface (124) 
8 PF3D7_0501100.1 HSP40 Ag 1 Heat shock protein 40 iRBC (118) 
9 PF3D7_0501100.1 HSP40 Ag 3 Heat shock protein 40 iRBC (118) 
10 PF3D7_0206800 MSP2 CH150/9 CH150/9 allele of Merozoite surface protein (MSP) 2. Full-length. Merozoite surface (125) 
11 PF3D7_0206800 MSP2 Dd2 Dd2 allele of MSP2. Full-length. Merozoite surface (126) 
12 PF3D7_1133400 PfAMA1 Apical membrane antigen 1 micronemes (127) 
13 PF3D7_0930300 PfMSP-1-19 19kDa fragment of MSP1 molecule.  Merozoite surface (128) 
14 PF3D7_1021800 PfSEA-1 Schizont egress antigen. iRBC (129) 
15 PF3D7_0424100 Rh5 Receptor for human protein Basigin.  Apical tip (130),(131) 
16 PF3D7_0501300 SBP1 skeleton-binding protein; essential for translocation of PfEMP1 
to iRBS surface via Maurer's cleft. 
iRBC (132) 
17 PF3D7_1002000 Hyp2 Plasmodium exported protein iRBC / PVM (118) 
18 PF3D7_1036000 H103 Merozoite surface protein 11/H101/MSP3.7 Merozoite (133) 
19 PVX_092275 PvAMA1 Apical membrane antigen 1 micronemes (134) 
20 PVX_099980 PvMSP-1-19 19kDa fragment of MSP molecule Merozoite (135) 
21 PVX_110810 PvDBP R2 Duffy binding protein region II Merozoite (136) 
22 PVX_110835 PvEBP Erythrocyte binding protein Merozoite (136,137) 
23 PVX_098585 PvRBP1a Reticulocyte binding protein amino acids 160–1170 Apical tip (138) 
24 PVX_094255 PvRBP2b  Reticulocyte binding protein amino acids 161–1454 Apical tip (138) 
  
 
1.4.3 Serological assays 
The refinement of the enzyme linked immunosorbent assay (ELISA) for the detection of 
malaria specific antibodies has increased the applicability of sero-epidemiology (98). Briefly, 
the assay works by coating antigens on to high-binding micro-titre plates and all non-malarial 
antibodies are blocked. The bound antibodies are then detected with an enzyme linked 
secondary antibody. The presence of the target antigens (bound-antigen) is visualised 
through a colour change in the reaction, and quantified using a spectrophotometer (98). 
Advantages of the ELISA include high throughput capability, field applicability, and relatively 
low cost. Many plates can be run simultaneously. However, since antigens are tested 
individually and samples usually in duplicate, the time per antigen tested is relatively long. 
Moreover, the dynamic range (i.e. the width from the minimum to the maximum value of 
the response signal) is narrow in comparison with more advanced the techniques, such as 
bead-based assays (139). 
 
Bead-based assays (CBA: cytometric bead assays) are a relatively new technique which can 
measure the response to multiple antigens in a single sample simultaneously. The assay 
measures antibody responses as median fluorescence intensity (MFI). Current machines can 
perform up to 500 different tests in one sample. One of the key strengths of the assay is the 
ability to multiplex, which allows the potential to detect antibodies to multiple antigens at 
the same time therefore could lead to highly efficient testing. The time to read a single plate 
is relatively slow (1½–3 h), but since multiple antigens are tested simultaneously, the relative 
time per antigen is fast. Furthermore, the dynamic range of this assay is wide which increases 
granularity (level of detail) for low antibody responses (139). 
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The most frequently used source of antibodies in malaria serology research is serum 
collected on filter paper from finger-prick blood samples (140). Although still an invasive 
technique, it is a simple alternative to separating plasma or serum from a blood sample which 
may be impractical in remote field settings with limited laboratory facilities. Additionally, the 
same filter paper blood spots can be a source of parasite DNA for PCR-based testing (141). 
 
1.5 Statistical approaches to serological data 
Seroprevalence and seroconversion rates (SCR) are two key serological metrics that can be 
used to measure malaria transmission in population. These metrics are sensitive to measure 
transmission in low transmission settings but will saturate in high transmission settings as 
the majority of individuals will be seropositive due to cumulative exposure to infection. In 
addition, the utility of these metrics depends on the choice of antibody target. 
 
Seroprevalence is defined as the percentage of individuals in a population who are 
seropositive to a malaria antigen based on a defined cut-off. The seropositivity cut-off is 
typically determined by two methods. The first method is based on antibody responses of 
negative control/non-exposed individuals tested alongside the studied samples, where 
individuals are classified seropositive if the respective antibody levels exceed the mean plus 
3 times the standard deviation of the negative population. The second method is based on 
the two-component finite mixture model (FMM) which relies on the basic assumption that 
the tested sample is composed of a mixture of latent seronegative or seropositive 
populations (142). Using similar criteria, individuals are then classified seropositive if the 
respective antibody levels exceed the mean plus 3 times the standard deviation of the 
seronegative population identified by the FMM. 
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Seroconversion rate (SCR) is defined as the annual rate by which seronegative individuals 
become seropositive upon malaria exposure. SCR can be used to measure population-level 
transmission intensity and temporal changes in transmission from a single cross-sectional 
sampling. Sepulveda et al. (142) have highlighted the reversible catalytic models (RCMs) as 
the most popular models used to estimate SCR. The models rely on assumption that 
individuals are born as seronegative but can convert into seropositive (seroconversion) upon 
malaria exposure, and then can revert to a seronegative state (seroreversion) in the absence 
of frequent malaria exposure. Two models used to estimate SCRs in this thesis are described 
below. 
 
The first model is used to estimate population-level transmission intensity assuming that 
malaria transmission intensity is stable and constant over time. The seroconversion-
seroreversion dynamics of each individual is described by a Markov chain with two states, 
seronegative (𝑆−) and seropositive (𝑆+). The resulting RCM is described by the following 
probability of an individual aged 𝑡 being seropositive: 
𝑝𝑆+(𝑡) =  
𝜆
𝜆+𝜌𝑟
 (1 − 𝑒−(𝜆+𝜌)𝑡),     
where 𝜆 is SCR and 𝜌 is SRR (seroreversion rates). 
The second model allows for a change in transmission intensity from 𝝀𝟏 to 𝝀𝟐 at time or age 
𝝉 assuming there was a rapid reduction of malaria transmission intensity at some time point 
before data collection or there are different risks of exposure due to different behaviour in 
different age groups. Sampled people born after the change in transmission (𝒕 ≤ 𝝉), will 
have a probability of being seropositive with constant transmission (Model 1) subject to the 
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current seroconversion rate 𝝀𝟐. While people born before the change in transmission (𝒕 >
𝝉) will have a probability of being seropositive that is a function of both seroconversion rates 
(past SCR). The 𝝆 value included in Model 2 is a fixed value chosen based on the model with 
the highest log likelihood. 
𝑝𝑆+(𝑡) = {
𝜆2
𝜆2+𝜌
 (1 − 𝑒−(𝜆2+𝜌) 𝑡)                                                                                ∶ 𝑡 ≤ 𝜏
𝜆2
𝜆2+𝜌
 (1 − 𝑒−(𝜆2+𝜌) 𝜏)   +  
𝜆1
𝜆1+𝜌
 (1 − 𝑒−(𝜆1+𝜌) (𝑡 − 𝜏)) 𝑒−(𝜆2+𝜌) 𝜏   ∶ 𝑡 > 𝜏
       
 
Both models described above can be run using package available for Stata or R software. 
When running the models, the package will generate a seroconversion curve describing the 
fitted and observed probability for being seropositive for each age decile and estimate of the 
seroconversion rates. At minimum, individual data on age and seropositivity status are 
required to run the models. 
 
1.6 Statistical approaches to assess spatial heterogeneity 
Spatial analysis of malaria was historically restricted to visual comparisons of the 
geographical distribution of malaria burden (143). However, more robust methods are 
needed to identify malaria risk and disease clustering particularly in highly heterogeneous 
areas (47). Advances in geographical information systems (GIS) and statistical cluster 
detection methods has enabled the more nuanced detection of malaria hotspots (144,145). 
Several methods that are commonly used to detect the spatial heterogeneity of malaria are 
described below. 
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Approaches that can detect spatial clustering of the malaria burden are useful to better 
target surveillance and control programmes. The assumption used in identifying the clusters 
of disease or exposure is that the risk is assumed to be consistent across space. Methods 
then determine if the distribution of cases are likely to be concentrated in particular areas 
and can be considered as clustered (146). Several spatial analysis approaches such 
as kriging (i.e. a weighted moving average technique that interpolates estimates based on 
values at neighbouring locations and parameters from the semi-variogram) or model-
based geostatistics (i.e. classical geostatistics is embedded in the framework of a generalised 
linear model) (147,148) have been used in predicting malaria risk and are useful to capture 
spatial patterns of malaria risk at different scales. However, the use of this approach is 
currently restricted to national and regional level mapping due to the availability of currently 
accessible data (17,18,149,150).  
 
Several spatial clustering methods such as Kulldorff’s spatial scan statistic, kernel density or 
the cumulative X test have similar assumptions and use the likelihood ratio test to determine 
where clustering is occurring (151,152). Of these methods, Kulldroff’s spatial scan statistic 
which is accessible through SatScan software package (Harvard Medical School, Boston, USA) 
is the most popular approach used in malaria research (146,151). This approach uses a series 
of circles or elliptical shaped windows centred on each data point, followed by a likelihood 
ratio test comparing the rate inside the window to the outside. To test the null hypothesis 
that points are distributed randomly, Monte Carlo simulations generating permutations of 
the data across the area are used (146,153). Hotspots (defined as foci by the WHO) are 
identified using points representing the centre and the radius of the cluster size (154,155). 
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This method has been used to identify malaria heterogeneity in several endemic settings in 
Bioko Island (94), Tanzania (151), South Africa (100), and also in Indonesia (156). 
 
Finally, spatial-temporal methods can provide more accurate predictions of malaria risk 
when spatial data are available at different time points. Methods incorporating temporal 
factors for cluster detection using SatScan software have been applied to malaria data using 
two different approaches. The first approach is to independently analyse each time point of 
dataset and visually observe any trends between the generated maps (156–159). The second 
approach is to use the space-time model spatial scan statistic where the moving window 
extends into cylindrical shape with the height reflecting the time aspect (146,160). The first 
approach is the most commonly used and is simpler compared to the second approach, 
especially if there are only few data points are analysed. 
 
1.7 Malaria epidemiology in Indonesia 
Indonesia is an archipelago that is located between two continents, Asia and Australia. It is 
adjacent to other countries i.e. Malaysia, Singapore and Philippines in the North and Papua 
New Guinea and Timor Leste in the East. Indonesia has the highest burden of malaria in the 
South-East Asia region outside of India. It is estimated that 26% of the 255,500,000 
Indonesian population live in malaria endemic areas. Of those at-risk populations, 12% live 
in high transmission areas and 14% in low transmission areas (16).  
 
All species of Plasmodium have been reported in Indonesia including the newly emerging P. 
knowlesi (10–12,161,162). Plasmodium falciparum and P. vivax are the most prevalent 
species causing malaria infections in Indonesia (16). In general, the risk of transmission is 
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higher in eastern Indonesia than the rest of the country (17,18), with most of the endemic 
areas in stable transmission zones with low transmission risk. The latest estimates of age-
standardised parasite prevalence for P. falciparum malaria in children 2-10 years old (PfPR2–
10) and all-age parasite prevalence rate for P. vivax malaria (PvPR1–99) range broadly and are 
highly heterogenous (Figure 1.10 and 1.11). To date, there were several studies reporting a 
notable proportion of P. knowlesi infection in several areas in Sumatera and Kalimantan 
islands where the macaque populations are reported to be prevalent (10–12,162).   
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Figure 1.10 Map of age-standardised parasite prevalence for P. falciparum malaria in 
children 2-10 years old (PfPR2–10) predictions in 2017, adapted from Weiss et al. (17). 
Starred locations i.e. Timika District, Kulon Progo District and Sabang Municipality are 3 sites 
with different level of endemicity studied in this thesis. 
Sabang Municipality 
Kulon Progo District 
Mimika District 
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Figure 1.11 Map of all-age parasite prevalence rate for P. vivax malaria (PvPR1–99) 
predictions in 2017, adapted from Battle et al. (18). Starred locations i.e. Timika District, 
Kulon Progo District and Sabang Municipality are 3 sites with different level of endemicity 
studied in this thesis. 
Sabang Municipality 
Kulon Progo District 
Mimika District 
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Indonesia’s climate is typically of a high temperature (25–29°C) with relatively high humidity 
(76%–105%), and heavy rainfall from October to March across the country. This climate 
favours the survival of Anopheles mosquitoes and allows malaria parasites to develop in the 
mosquito more rapidly (163–165). There are 20 Anopheles species documented as malaria 
vectors in Indonesia with overlapping distributions in all the main islands (Figure 1.12). 
Anopheles balabacensis, Anopheles flavirostris, Anopheles nigerrimus, Anopheles subpictus 
and Anopheles sundaicus are the vectors found circulating in both western and eastern 
Indonesia. Studies suggested that these vectors were more likely to have outdoor biting 
habits and tend to rest outdoors in shaded locations such as in cattle shelters or under tree 
than inside houses (166). These vectors are especially relevant because of the higher malaria 
risk has been reported to be associated with forest-related work and other night outdoor 
activities (163,167,168). 
 
 
Figure 1.12 Distribution of primary Anopheles malaria vector in Indonesia reproduced from 
Elyazar et al. (166) 
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The majority of malaria cases (both falciparum and vivax) in Indonesia occur in adults 
(49,50,168–171), with the exception in high transmission areas, Papua, where the risk of P. 
vivax infection were reported to be higher in children compared to adults (171). A previous 
report suggested that night outdoor activity at the farm or forest e.g. sleeping in the 
plantation increases the risk of malaria infection (163,167,168). Human mobility becomes a 
serious challenge for malaria control in Indonesia. People are travelling domestically for 
several purposes i.e. for working, visiting relatives or just for vacation. The risk of malaria is 
higher for migrants since they are typically moving from densely populated Java and Bali 
Islands to the sparsely populated and usually highly endemic outer Islands (172). These 
migrants then return routinely to Java, either permanently or, more often, for family 
reunions and holidays (161). Mobility has been reported as one of risk factors for malaria 
resurgence in low transmission setting (168). However, little research has been done to 
investigate how significant the influence of human mobility is for reintroducing malaria 
transmission in low endemic area in Indonesia. 
 
1.8 Intervention strategies in Indonesia 
The recent report by the Indonesian Ministry of Health provides a summary of malaria 
elimination strategies and the current achievements in Indonesia as illustrated in Figure 1.13 
(173). The history of malaria control started with the establishment of Indonesia’s National 
Malaria Eradication Unit in 1952. Initially, control efforts were focused on indoor residual 
spraying (IRS) with dichlorodiphenyltrichloroethane (DDT) and chloroquine-based treatment 
in Java island. In 2004, artemisinin combination therapy was introduced as first-line 
treatment with tightly controlled procurement and distribution of the drug. Regular 
therapeutic studies have shown no drug resistance (174). Microscopy confirmation 
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complemented by RDT is mandatory. Long-lasting insecticide-treated bed nets (LLIN) were 
first distributed to eastern Indonesia and parts of Sumatra in 2005, and subsequently nearly 
every 2 years to highly endemic districts and villages resulted in 20 million LLIN distributed 
in the past decade. IRS was done in villages with annual parasite incidence >20 per 1000 
population and in response to outbreaks. In high-transmission areas, malaria screening for 
ill children was introduced into clinical management protocols. Capacity development efforts 
supported case management, vector control, surveillance, and case investigation. The case 
investigation has recently included adoption of the 1-2-5 surveillance and response protocol: 
case management and notification on day 1; case classification and foci investigation on day 
2; and foci response and elimination by day 5. Finally, locally tailored responses have been 
essential for malaria elimination due to the high levels of decentralised authority. 
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Figure 1.13 Changes in malaria incidence and intervention coverage, Indonesia 2004–2017 
adapted from Sitohang et al. (173). 
Starred locations i.e. Timika District, Kulon Progo District and Sabang Municipality are 3 sites 
with different level of endemicity studied in this thesis. *Baseline annual parasite incidence 
(API) data available in 2009–10 for 90% of districts. Major reduction represents downshift in 
transmission strata or three-times reduction in API; no change represents same strata and 
less than three-times reduction in API. Increase represents an upshift in transmission strata. 
†Increase might reflect improved malaria surveillance. ‡Estimates based on expert 
consultation with the Indonesian Ministry of Health and partners. 
 
Despite the recent success in decreasing the malaria burden from API 2.89 per 1000 in 2007 
to 0.9 per 1000 population in 2017, so far, approximately only 60% of total districts and cities 
have been declared as malaria-free areas (173). This makes it difficult to achieve malaria 
elimination by 2030. Specifically, Java, the most populated island that contributes 71.6 
Mimika District 
Kulon Progo District 
Sabang Municipality 
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million people (54%) of total population at risk of P. falciparum in the whole of Indonesia 
(175) has failed to achieve the target of malaria elimination by 2015. The sustained 
transmission of different malaria species combined with the challenge of identifying where, 
and in who, residual transmission is occurring, mean new strategies are needed to target 
transmission and reduce the burden of infection. Key to this will be improved surveillance as 
focus changes to include all infections, not just those that are symptomatic (169). 
 
1.9 Research gaps 
Identifying persistent and intense transmission areas in a smaller geographical scales can 
prevent outbreaks of disease that spread from these areas and support disease elimination 
strategies when overall disease occurrence has declined (176–178). As malaria transmission 
in Indonesia is highly heterogeneous, insights into micro-epidemiological geographic 
variation of malaria infections in sub-national level would give more useful operational 
information on public health intervention planning aim to achieve local elimination. 
Identifying regions with higher disease burden can effectively facilitate control efforts 
prioritization (43,179,180). 
 
As previously described in Section 1.4, serology has potential applications to measure 
population-level of transmission, confirm interruption of transmission in areas approaching 
zero, and characterise spatial patterns of transmission in the population. Only few (~1%)  
malaria parasite antigens have been studied so far (181,182), with the majority of serological 
data currently available at technical level focusing on responses to well-characterised blood-
stage antigens. However, recent identification of alternative P. falciparum antigens 
associated with short-lived antibody responses (i.e. Etramp5.Ag1, Etramp4.Ag2, Hyp2, 
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GexP18, HSP40, and PfSEA-1) suggests they could be used as a potentially key indicator of 
very recent exposure (118). This could provide rapid, cheap estimates of malaria incidence 
to target and evaluate interventions. Moreover, although most serological work has been 
focussed on P. falciparum, there were some promising antigens that can be optimised as an 
additional application of serology for P. vivax (i.e. PvDBPR2, PvEBP, PvAMA-1, PvMSP-119, 
PvRBP1a and PvRBP2b) to identify hypnozoite carriers for treatment; a major challenge for 
control programmes (119,120,134,135,138). Inclusion of these P. falciparum and P. vivax 
antigens in a multiplex bead-based assay could potentially expand the application of 
serological surveillance for malaria elimination. 
 
Despite its potential application, feasibility of implementing serological surveillance utilising 
existing public health surveillance systems has not been evaluated, especially in the context 
of Indonesia. The majority of malaria prevalence studies, including a serological study 
conducted in Indonesia (183) have been based on community-based surveys which require 
large resources and efforts for collecting samples. Several methods have been reported as 
alternative sampling approaches that could provide more cost effective and efficient 
strategies to collect samples and data to assess population-level exposure and infection in 
low transmission areas. These methods target easy access groups such as school children, 
health facility attendees or focus on other high-risk populations such as forest workers, 
miners or farmers. In this thesis, we explore the implementation and evaluation of health 
facility-based surveys where facility attendees and their companions are sampled as an 
alternative sampling strategy to improve malaria surveillance capacity to monitor malaria 
transmission dynamics in the population. 
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Due to limited available data, the majority of the currently available malaria risk maps in 
Indonesia were based on parasitological estimates at the district level resolution (49,50), 
thus its utility in identifying local level hotspots is limited. Adding data collection methods 
that enable surveillance to remotely capture spatial patterns of transmission at the micro 
epidemiological level would be helpful for strategic and operational planning of control and 
elimination programmes. Generally, a basis for the spatial analysis of disease transmission is 
based on adequate address information (184,185) automatically generated by geocoding 
software packages that can generate accurate spatial coordinate data for a large proportion 
of individuals (186,187). In circumstances where formal address data are unavailable, 
catchment areas of, for example, community pharmacies or general practitioners have been 
used for describing spatial patterns in disease occurrence (34,188–190). However, this 
approach is likely to has less utility for resource-poor settings where formal address systems 
are commonly unavailable and where health-facility catchment areas are relatively large and 
poorly defined (191–193).  
 
  
 
2. Aim and objectives 
2.1 Aim 
The main aim of this thesis is to examine approaches to optimise the operational application 
of serological surveillance for monitoring malaria transmission as an additional measure for 
the existing public health surveillance system in Indonesia. A core theme of the thesis is to 
evaluate the use of serology with different data collection methods to assess the additional 
information generated in three areas of differing endemicity. 
 
2.2 Objectives 
• To evaluate the use of sero-epidemiological analysis to investigate heterogeneity of 
transmission in an area conducting malaria elimination in Indonesia. The study 
presented in Chapter 3 aimed to explore the following hypotheses: 
• In the absence of active infections:  
1. Spatial analysis of serological data can identify areas at risk of malaria through 
identifying areas of previously high exposure. 
2.  Seroconversion rate estimates can confirm low levels and historical changes in 
malaria transmission. 
3. Absence of seropositivity in the population under 5 years old can be used as a proxy 
of transmission interruption. 
4. Sero-epidemiological analysis can be used to determine factors associated with 
transmission. 
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• To evaluate the use of mobile technology-based participatory mapping approaches to 
geolocate health facility attendees for disease surveillance in low resource settings. The 
study presented in Chapter 4 aimed to explore the following hypotheses: 
1. Participatory mapping using android tablet-based offline high-resolution maps can 
be used to efficiently geolocate individual residences from health facility. 
2. Open source software and maps offer potential utility to collect spatial information 
for research and disease surveillance purposes. 
 
• To implement and evaluate use of health facility-based serological surveillance to 
investigate P. falciparum and P. vivax transmission dynamics in an elimination setting. 
The study presented in Chapter 5 aimed to explore the following hypotheses: 
1. Estimates of population-level transmission intensity (SCR) generated from a single 
health facility-based survey is similar to the estimate generated from the repeated 
health-facility based surveys. 
2. Repeated health facility-based surveys can capture short-term changes in antibody 
levels over time. 
3. Spatial analysis of antibody responses to multiple malaria antigens can 
prospectively predict areas at high-risk of malaria outbreak. 
4. Sero-epidemiological analysis can be used to determine factors associated with 
transmission in elimination setting where the numbers of active infections are 
insufficient for conducting a risk factor analysis. 
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• To evaluate the use of multiple serological markers to measure transmission level and 
assess its association with active infections in a high transmission setting. The study 
presented in Chapter 6 aimed to explore the following hypotheses: 
1. Population-level seroconversion rate estimates can confirm the high level of 
transmission. 
2. Species-specific serological markers are associated with P. falciparum and P. vivax 
infections. 
3. P. falciparum short-lived markers are sensitive and specific in predicting P. 
falciparum infections. 
 
2.3 Thesis structure 
This thesis consists of an Introduction, four scientific papers and a general Discussion 
summarising the main findings presented in Chapter 2 to Chapter 6, discussing the thesis 
limitations, future directions, and implications for other infectious diseases.  
 
The first paper (Chapter 3) describes how analysis of sero-epidemiological data coupled with 
household GPS coordinates collected through a community-based cross-sectional study can 
be useful in an area reporting zero cases in 3 consecutive years prior to data collection. As 
the absence of infections could not facilitate the identification of the population and areas 
at risk for malaria reintroduction in the future, the study described in this chapter was 
conducted to seek evidence that analysis of serological data could be an alternative tool to 
assess P. falciparum and P. vivax transmission level, to investigate the risk factors for 
transmission and  to describe the heterogeneity of potential transmission in the absence of 
active infections detected by standard malaria diagnostic tool such as microscopy. 
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The second paper (Chapter 4) demonstrates the use of mobile technology-based 
participatory mapping approach for collecting geolocation data for public health research 
and surveillance in low resource settings. The most common mapping approaches usually 
require door to door visit to collect the household GPS coordinates, or use currently available 
data that rely on formal addresses, or remotely collect data using online-based approaches 
that require a stable internet connection. As many malaria endemic areas in Indonesia are 
usually hard to reach, have informal addresses and poor or no internet connection, the study 
presented in this chapter was conducted to evaluate and validate alternative approaches to 
remotely collect household-level spatial data from health facilities using a computer tablet-
based offline high-resolution maps to support the identification of fine scale resolution of 
local-level disease heterogeneity. 
 
The third paper (Chapter 5) describes the application of quarterly health facility-based cross-
sectional surveys and epidemiological analysis of multiple antibody response data generated 
using bead-based multiplex serological assays coupled with household GPS coordinates 
collected using participatory mapping approach (validated in Chapter 4) in a very low 
transmission setting conducting elimination. As the malaria transmission was very low and 
only a few infections were detected by standard microscopy tests, conventional methods to 
measure transmission such as parasite rate and EIR are inefficient due to large sample sizes 
required to detect infections in human and mosquitos, respectively. This paper aimed to 
answer the question on how the advances in serological and mapping methods can be used 
to better understand P. falciparum and P. vivax transmission dynamics by utilising the 
existing health facility-based surveillance systems. 
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The fourth paper (Chapter 6) presents the application of analysing multiple P. falciparum and 
P. vivax serological markers combined with parasitological data generated by microscopy 
and PCR tests to better estimate malaria burden in a high transmission setting. The 
seropositivity to any of several new P. falciparum recently identified as markers of recent 
exposure to infection can be used as a proxy of recent malaria infection. Evaluating the 
sensitivity and accuracy of these serological markers in a high transmission setting will 
provide important information before they can be used to measure recent transmission in a 
lower transmission setting where active infection become rare and difficult to detect by 
standard parasitological diagnostics such as microscopy and RDTs. This paper aimed to 
provide evidence on the potential use of analysis of multiple serological markers to measure 
population-level transmission intensity and predict the current malaria infection. Table 2.1 
presents a summary of the methods used in each paper presented in this thesis. 
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Table 2.1 Summary of methods used in each paper 
Chapter Design Population and 
sample 
Data sources Outcomes 
3 Community-
based cross-
sectional study 
Communities in 
Sabang, 
Municipality, Aceh 
Province, Indonesia 
(n= 1624) 
ELISA, microscopy 
test, paper 
questionnaire and 
handheld GPS 
- Transmission level 
estimates 
- Spatial patterns of 
household-level P. 
falciparum and P. 
vivax exposure 
 
4 Software 
evaluation and 
field testing 
Households in Rizal 
District, Palawan 
Province, the 
Philippines (n=203) 
and Kulon Progo 
District, Yogyakarta 
Province, Indonesia 
(n=400) 
Software review, 
tablet-based GPS 
and questionnaire, 
handheld GPS 
- Review of 
geolocation 
software 
- Accuracy of tablet-
based participatory 
mapping approach 
 
 
5 Quarterly 
health facility-
based cross-
sectional study 
Health facility 
attendees in Kulon 
Progo District, 
Yogyakarta 
Province, Indonesia 
(n=9453) 
Luminex assay, 
microscopy test, 
tablet-based 
questionnaire and 
GPS 
- Transmission level 
estimates 
- Spatial pattern of 
household-level P. 
falciparum and P. 
vivax exposure 
 
6 Community-
based cross-
sectional study 
Communities in 
Mimika District, 
Papua Province, 
Indonesia (n=2496) 
Luminex assay, 
microscopy and 
PCR tests, paper-
based 
questionnaire and 
handheld GPS 
- Transmission level 
estimates 
- Spatial patterns of 
household-level P. 
falciparum and P. 
vivax exposure 
- Predictive models 
of current malaria 
infection 
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3.1 Abstract  
Background 
Analysis of anti-malarial antibody responses has the potential to improve characterization of 
the variation in exposure to infection in low transmission settings, where conventional 
measures, such as entomological estimates and parasitaemia point prevalence become less 
sensitive and expensive to measure. This study evaluates the use of sero-epidemiological 
analysis to investigate heterogeneity of transmission in area conducting elimination in 
Indonesia. 
Methods 
Filter paper bloodspots and epidemiological data were collected through a community-
based cross-sectional study conducted in two sub-districts in Sabang municipality, Aceh 
province, Indonesia in 2013. Antibody responses to merozoite surface protein 1 (MSP-1-19) 
and apical membrane antigen 1 (AMA-1) for Plasmodium falciparum and Plasmodium vivax 
were measured using indirect Enzyme-linked immunosorbent assay (ELISA). Seroconversion 
rates (SCR) were estimated by fitting a simple reversible catalytic model to seroprevalence 
data for each antibody. Spatial analysis was performed using a Normal model (SaTScan 
v.9.4.2) to identify the clustering of higher values of household antibody responses. Multiple 
logistic regression was used to investigate factors associated with exposure. 
Results 
1624 samples were collected from 605 households. Seroprevalence to any P. falciparum 
antigen was higher than to any P. vivax antigen, 6.9% (95% CI: 5.8-8.2) vs 2.0% (95% CI: 1.4-
2.8). SCR estimates suggest that there was a significant change in P. falciparum transmission 
with no exposure seen in children under 5 years old. Plasmodium falciparum SCR in over 5 
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years old was 0.008 (95% CI: 0.003–0.017) and 0.012 (95% CI: 0.005–0.030) in Sukakarya and 
Sukajaya sub-districts, respectively. Clusters of exposure were detected for both P. 
falciparum and P. vivax, most of them in Sukajaya sub-district. Higher age, P. vivax 
seropositivity and use of long-lasting insecticide-treated bed net (LLIN) were associated with 
higher P. falciparum exposure. 
Conclusion 
Analysis of community-based serological data helps describe the level of transmission, 
heterogeneity and factors associated with malaria transmission in Sabang. This approach 
could be an important additional tool for malaria monitoring and surveillance in low 
transmission settings in Indonesia.  
Keywords Serology, epidemiology, surveillance, malaria, P. falciparum, P. vivax, elimination 
 
3.2 Background 
In recent years, there has been a decline in malaria transmission in many regions, leading to 
optimism that malaria elimination might be achieved in numerous countries [1–8]. As 
transmission declines, monitoring changes in malaria transmission intensity and disease 
prevalence through surveillance systems becomes increasingly important to allow the 
evaluation of health services and control programs [9,10]. The latest World Health 
Organization (WHO) malaria surveillance manual confirms that improved surveillance is a 
major component of the WHO strategy [11]. However, conventional measures such as 
entomological estimates and parasitaemia point prevalence become less sensitive and 
relatively more expensive as transmission declines [12,13]. Disease surveillance is further 
compounded by difficult access to remote and isolated communities, increased risks in forest 
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workers and other highly mobile populations and the difficulties of tracking cross-border 
movements [14–20]. 
 
An additional approach to measure malaria transmission is to detect anti-malarial antibodies, 
which provide a marker for exposure to malaria [9]. Malaria infections generate antibodies 
which can be detected for several months and years after the infection has been resolved. 
Although serology is unlikely to be useful for diagnosing actively infected individuals because 
antibodies take days to develop and then persist after infection [9,13], detection of these 
antibodies indicates previous exposure and offers an additional, more sensitive measure of 
infection and transmission, particularly in low endemic settings where the sensitivity of 
parasitological tools is inadequate [21–25] and gold standard tests like the parasite rate and 
the Entomological Inoculation Rate (EIR), may have insufficient statistical power unless the 
sampling is intensively done [26–28]. This approach has been utilized in several countries 
and reported as a more sensitive tool to assess population-level malaria exposure in low-
transmission settings [9,13]. 
 
Seroconversion rate (the proportion of people in the population who are expected to 
seroconvert each year) is a serological parameter used to understand malaria transmission 
dynamics. Previous studies found that seroconversion rate (SCR) provides a proxy measure 
for estimating the transmission intensity in a community as it was strongly correlated with 
the EIR and annual parasite incidence collected by the malaria surveillance programme 
[10,14]. Serological estimates of transmission have been utilized in many low endemic 
settings, including Indonesia [29,30], and have additionally been used to identify populations 
at higher risk of malaria exposure [9,31], foci of transmission [32,33] and to describe 
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historical changes in disease burden [25]. While there is great promise in this approach, it 
needs further refinement. 
 
Recent studies have reported the potential use of recombinant Merozoite Surface Protein 1 
(PfMSP-1-19) and Apical Membrane Antigen 1 (PfAMA-1) as serological parameters to assess 
malaria transmission intensity in Indonesia. First, a population-based cross-sectional study 
conducted in three different endemicity areas showed the potential application of these 
methods for detecting changes in transmission exposure, particularly in lower transmission 
settings and with less immunogenic antigens (such as PfMSP-1-19) [30]. Second, a cohort 
study of Indonesian schoolchildren found that it is possible to assess the interruption of 
transmission by measuring seroconversion rates from individual-level longitudinal data on 
antibody titres [29]. These studies suggested serological analysis has the potential to assess 
malaria burden and heterogeneity of infections in the Indonesian population. As antibodies 
to AMA-1 and MSP-1-19 antigens have been reported to persist for several years after 
infection and in the absence of reinfection, any antibodies detected in younger children 
would reflect more recent infection in low transmission settings [10]. Therefore, as Indonesia 
aims to eliminate malaria by 2030, further implementation and evaluation of sero-
epidemiological analysis in areas moving towards elimination would garner valuable 
information for malaria control programmes. This study explores the use of sero-
epidemiological analysis for assessing the intensity and heterogeneity of malaria 
transmission as well as factors associated with malaria exposure in an area conducting 
elimination in Indonesia. 
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3.3 Methods 
Study site 
 
Figure 3.1  Map showing study sites in two sub-districts in Sabang municipality, Aceh 
province, Indonesia (a). Inset maps showing geographical location of Sabang municipality 
within Aceh province (b), and location of Aceh province within Indonesian archipelago (c). 
 
The study was conducted in Sabang municipality, Aceh province, Indonesia (Figure 3.1). The 
municipality is located at the north-westernmost part of Indonesia and is part of Aceh 
province. The municipality has an area of 153 km2 covering five islands but only the largest 
island, Weh, is permanently inhabited. The population on Weh island is approximately 30, 
000 and it is divided administratively into two sub-districts (Sukakarya and Sukajaya) with 18 
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villages. Sabang has a very low-level annual parasite incidence, 0.13 per thousand population 
in 2011. Based on its geographic position at the western end of the archipelago, its diverse 
mosquito fauna, the presence of both major malaria parasites, and its strong local 
government, Sabang municipality was considered as an appropriate place to pilot malaria 
elimination in Indonesia [34]. 
 
Study design and data collection 
Community-based cross-sectional surveys were performed during the malaria transmission 
season between October and December 2013. Households list were obtained from local 
authorities and were arbitrarily assigned numbers according to their geographic location. 
Households were randomly selected and invited to participate in the study. Households with 
no adult present were excluded from the survey and were replaced by the neighbouring 
households. Individual signed informed consent was obtained from all adults or guardians of 
household member under 18 years of age. Samples were collected from all household 
members present aged over 6 months. The minimum sample size of 439 individuals per sub-
district was met to ensure the antibody SCR of 0.0036 could be estimated with a precision 
level of +/- 0.0013 [35]. Standard microscopy blood smears were collected as per routine 
national diagnostic standards. Filter paper bloodspots were collected on Whatman 3M paper 
(Whatman, UK) as described by Corran et al. [36] and stored at -20oC until transferred to the 
Parasitology Laboratory at Department of Parasitology, UGM, Yogyakarta. Data on age, 
gender, education, occupation, long-lasting insecticide-treated bed net (LLIN) use, indoor 
residual spraying (IRS) in last 12 months and auxiliary temperature were recorded using a 
short questionnaire form, and household GPS coordinates were collected using handheld 
GPS.  
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Laboratory methods 
Giemsa-stained thick and thin malaria films reading was performed by trained laboratory 
technicians to identify active infections. For serological assays, the recombinant proteins 
Plasmodium falciparum MSP-1-19, P. falciparum AMA-1, Plasmodium vivax MSP-1-19 and P. 
vivax AMA-1 were used as antigens in indirect enzyme-linked immunosorbent assay (ELISA) 
as described in [9]. Briefly, antigens were coated on 96 well plates at the concentration of 
0.5 µg/mL in coating buffer and incubated at 4oC overnight. The plates were washed in 
phosphate buffered saline with tween (PBST) and blocked with 1% (w/v) skimmed milk 
solution for 3 hours. After washing, samples were added in duplicate at a final dilution of 
1:1000 to each plate using a pool of hyperimmune serum as a positive control and the plates 
were incubated overnight at 4oC. The plates were washed and 50µl of HRP-conjugated rabbit 
anti Human IgG (DAKO, #P0214) were added into each well and incubated for 3 hours. After 
a further series of washes substrate solution (OPD, Sigma #P8287, in PBS) was added and the 
reaction was allowed to develop for 15-20 minutes before addition of stopping solution (2M 
H2SO4). The optical density was read using ELISA reader at 450nm. All serology was 
performed by trained laboratory technicians at the Department of Parasitology, UGM, 
Yogyakarta. 
 
Statistical analysis 
All statistical analyses were conducted in Stata IC 15 (Stata Corp, College Station, TX, USA). 
Infants under 1 year of age were excluded from each dataset to remove any influence of 
maternally derived antibodies [10]. Raw OD measurements were averaged and normalized 
against the positive control curve on each plate. A cut-off for seropositivity was determined 
for each antigen by calculating the mean plus 3 standard deviation values of OD values from 
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serum samples of 40 Javanese individuals who had no history of travel to malaria endemic 
areas in Indonesia. Cut-offs were generated separately for each antigen [13]. Individuals 
were categorized as seropositive for P. falciparum if their antibody responses were above 
the cut-off for PfAMA-1 and/or PfMSP-1-19 and seropositive for P. vivax if their antibody 
responses were above the cut-off for PvAMA-1 and/or PvMSP-1-19. Seroconversion rates 
were estimated by fitting a simple reversible catalytic model to seroprevalence data for each 
antibody [10]. Models with two SCRs allowing detection of changes in SCR were fitted and a 
likelihood test ratio was performed to decide the most appropriate model. Bivariate and 
multivariable analysis were performed to identify potential factors associated with P. 
falciparum (and P. vivax) exposure among study participants. Logistic regression models 
were performed to estimate odds ratios (ORs) of factors associated with being seropositive 
to P. falciparum or P. vivax, respectively. Adjusted odds ratios (aORs) were obtained using a 
multivariable model, including the following covariates: age, gender, seropositivity to P. 
vivax, education status, employment status, LLIN use, IRS in last 12 months, fever status, and 
altitude. Samples from participants aged under 18 years old were excluded from analysis of 
education and employment status. Statistically significant variables (p < 0.05) detected in 
bivariate analysis were included in a multivariable model. The final model was developed 
using the forward stepwise approach which compared multivariable models to the most 
significant bivariate model using p-values calculated from likelihood ratio tests. Scatter plots 
matrix and coefficient correlation analysis were done to assess potential cross-reactivity 
between P. falciparum and P. vivax antigens. 
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Spatial analysis 
The spatial software SaTScan (v.9.4.2) was used to detect clusters of higher than average 
age-adjusted antibody responses to PfAMA-1, PfMSP-1-19, PvAMA-1 and PvMSP-1-19. The 
Normal model was used to detect clusters of households with higher than average age-
adjusted antibody responses to PfAMA-1, PfMSP-1-19, PvAMA-1, PvMSP-1-19 antibody 
responses. This method has been previously utilized in several studies investigating malaria 
transmission heterogeneity in low endemic setting [25,37]. Antibody responses data were 
first log10 transformed and then adjusted for age. The residuals from linear regression (log 
titre regressed against age in years, performed in Stata IC 15) were used to determine 
whether antibody responses were higher or lower than expected for any given age assuming 
a homogeneous distribution of risk. Residuals less than zero represent individuals whose 
responses were lower than or average for their age group whilst residuals above zero 
represent individuals whose responses were higher than average. These data were then 
averaged per household and categorized, based equally around the median, as ‘lower than 
average’, ‘average’, ‘slightly higher than average’, ‘higher than average’, and ‘much higher 
than average’ to generate an antibody response heat map. The scan statistic was set to 
calculate non-overlapping, statistically significant (p < 0.05) clusters with a maximum set 
radius of 3 km and with minimum 2 observations detected in a cluster. Data generated from 
SatScan were then plotted using ArcGIS software (v10.5). 
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3.4 Results 
Study population 
General characteristics of the sampled population is presented in Table 3.1. There were 1624 
samples collected in the surveys from 605 households. The average number of people 
sampled per household was 3 (SD: 1.64). The proportion of females sampled (61%) was 
slightly higher than males. The majority of the samples came from Sukajaya sub-district 
(63%), and the median age of participants was 22 years (IQR: 9-38). Educational attainment 
was high, with only 0.34% of adults ≥ 18 years old who had not completed primary education. 
More than half (57%) of the working-age population (≥ 18 years old) were unemployed. The 
population LLIN coverage was 60%, with 68% of those who owned nets reporting to have 
slept under it the night before. Only 15% of study households had received IRS in the 
previous 12 months. 9% of the population had fever with body temperature reading > 37.5oC.  
Examination of microscopy slides found no malaria infections.  
 
Seroprevalence and associated factors 
Seropositivity to P. falciparum antigens was higher than seropositivity to P. vivax antigens, 
with seroprevalence 6.89% (95% CI: 5.76-8.24) and 1.97% (95% CI: 1.39-2.77), respectively. 
Seroprevalence ranged from 1.2 to 11.4 % for P. falciparum and 0.5 to 2.8% for P. vivax across 
age groups. Notably, there were no seropositive individuals aged under 5 years old identified 
for either P. falciparum or P. vivax (0/210). Seroprevalence to each antigen can be found in 
Additional file 1.  
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Multivariable analysis in Table 3.1 shows that age, seropositivity to P. vivax and use of LLINs 
were significantly associated with P. falciparum seropositivity, after controlling for other 
covariates. As would be expected, seroprevalence increased with age. Adults were more 
likely to be seropositive compared to children under 15 years old, with adjusted OR 5.69 
(95% CI: 2.43-13.37), 12.05 (95% CI: 5.59-25.94) and 10.27 (95% CI: 4.74-22.27) for age group 
16-24, 25-40 and over 40 years old, respectively. Seropositivity to P. falciparum was also 
significantly associated with higher proportion of LLIN use, with adjusted OR 1.80 (95%: 1.20-
2.72). In addition, people who were seropositive to any P. vivax antigen were 3 times more 
likely to be seropositive for P. falciparum, with adjusted OR 3.47, (95% CI: 1.48-8.12). Other 
factors such as gender, residence, education, employment, IRS, fever and altitude were not 
significantly associated with P. falciparum seropositivity. Multivariable logistic regression 
revealed that there were no factors significantly associated with P. vivax seropositivity 
(Additional file 2). 
Table 3.1 Demographic characteristics and factors associated with P. falciparum 
transmission in Sabang, Indonesia, 2013 
 
Variable (n = 1624) 
Total P. falciparum seropositive Multivariable  
N (%) n % (95% CI) aOR (95% CI) 
Age (years) 
<15 years old 
16-24 years old 
25-40 years old 
>40 years old 
 
656 (40.39) 
270 (16.63) 
347 (21.37) 
351 (21.61) 
 
8 
19 
45 
40 
 
1.2 (0.6-2.4) 
7.0 (4.5-10.8) 
13.0 (9.8-16.9) 
11.4 (8.5-15.2) 
 
1 
5.69 (2.43-13.37)** 
12.05 (5.59-25.94)** 
10.27 (4.74-22.27)** 
P. vivax seropositive 
No 
Yes 
 
1592 (98.03) 
32 (1.97) 
 
104 
8 
 
6.5 (5.4-7.9) 
25.0 (12.9-42.9) 
 
1 
3.47 (1.48-8.12)** 
LLIN use 
No 
Yes 
 
1098 (68.28) 
510 (31.72) 
 
63 
48 
 
5.7 (4.5-7.3) 
9.4 (7.2-12.3) 
 
1 
1.80 (1.20-2.72)** 
 
* p value < 0.05 ** p value < 0.01. Individual level data: age, gender, education status, 
employment status and fever. Household level data: LLIN use, IRS in last 12 months and 
altitude 
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Plasmodium falciparum and Plasmodium vivax transmission intensity 
Figure 3.2 describes the SCR estimates for P. falciparum and P. vivax in Sukakarya and 
Sukajaya sub-districts, Sabang municipality, Indonesia in 2013. The SCR estimates suggested 
that there was a significant change in P. falciparum transmission in both Sukakarya and 
Sukajaya sub-districts, with no exposure seen in children under 5 years old. The data 
suggested that the P. falciparum transmission intensity in people aged over 5 years old was 
SCR 0.008 (95% CI: 0.003–0.017) and SCR 0.012 (95% CI: 0.005–0.030) in Sukakarya and 
Sukajaya, respectively. The SCR estimates for P. vivax (Fig. 3.2c and 3.2d) also suggested a 
very low level of transmission, SCR 0.001 (95% CI: 0.000-0.005) and 0.002 (95% CI: 0.001-
0.006), respectively. There was no evidence for a difference in SCR between people aged 
under 5 and over 5 years old in either Sukakarya or Sukajaya. Overall, these model SCRs 
estimates suggested that the magnitude of transmission in population level was likely to be 
similarly very low for P. falciparum and P vivax. 
 
Heterogeneity of P. falciparum and P. vivax 
Spatial analysis of higher than average age-adjusted antibody responses identified 5 
significant clusters for PfAMA-1 and 3 clusters for PfMSP-1-19. All 5 of the PfAMA-1 clusters 
were seen in Sukajaya (Figure 3.3a), whilst 2 of 3 PfMSP-1-19 clusters seen in Sukajaya and 
spatially overlapped with the PfAMA-1 clusters (Figure 3.3b). One additional PfMSP-1-19 
cluster was identified in Sukakarya. The analysis of age adjusted antibody responses to P. 
vivax antigens identified 2 clusters for PvAMA-1 and 3 clusters for PvMSP-1-19 in Sukajaya 
(Figure 3.4). The clusters identified for PvAMA-1 spatially overlapped the PvMSP-1-19 clusters. 
All of these P. vivax clusters were seen in Sukajaya, whilst no clusters were identified in 
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Sukakarya. Overall, the clusters identified for P. falciparum and P. vivax were seen in the 
same areas. 
 
Figure 3.2 Age-seroprevalence plots for P. falciparum in Sukakarya (a), Sukajaya (b), for P. 
vivax in Sukakarya (c) and in Sukajaya (d), 2013. Solid lines represent the fitted probability 
for being seropositive to either MSP-1-19 or AMA-1 antigen, dashed lines represent the 95% 
confidence interval of these fits and red triangles represent the observed proportion of 
seropositive per age decile. SCR value represent the average annual rate at which the 
population become seropositive to any of P. falciparum or P. vivax antigen.  
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Figure 3.3 Spatial distribution of household-averaged, age-adjusted antibody responses to a) 
PfAMA-1  and to b) PfMSP-1-19 in Sukakarya and Sukajaya sub-districts, Sabang, Indonesia. 
The resultants residual values were categorised as: ‘lower than average’ (−4.326 to −0.499), 
‘average’ (−0.500 to 0.500), ‘slightly higher than average’ (0.501 to 1.000), ‘higher than 
average’ (1.001 to 1.500 ) and much higher than average (1.501 to 2.842). Black circle 
indicates a cluster of significantly higher than expected antibody responses detected using 
SaTScan (p value < 0.05).  
  
72 
 
 
Figure 3.4 Spatial distribution of household-averaged, age-adjusted antibody responses to a) 
PvAMA-1  and to b) PvMSP-1-19 in Sukakarya and Sukajaya sub-districts, Sabang, Indonesia. 
The resultants residual values were categorised as: ‘lower than average’ (−4.933 to −0.499), 
‘average’ (−0.500 to 0.500), ‘slightly higher than average’ (0.501 to 1.000), ‘higher than 
average’ (1.001 to 1.500 ) and much higher than average (1.501 to 2.117). Black circle 
indicates a cluster of significantly higher than expected antibody responses detected using 
SaTScan (p value < 0.05). 
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3.5 Discussion 
This study describes the analysis of community-based serological data to investigate malaria 
transmission dynamics in a low transmission setting, Sabang, Indonesia. The seroprevalence 
and SCR data represent exposure to infection and demonstrate that the population level of 
transmission intensity were similarly very low for both P. falciparum and P. vivax. The 
seroprevalence in children under 15 years old was negligible, 1.2% and 0.5% for P. falciparum 
and P. vivax, respectively. The spatial analysis of household-level data on antibody responses 
to any of the antigens tested describe the heterogeneity of both P. falciparum and P. vivax 
exposure in the study area. These results supported previous utilization of sero-
epidemiological analysis in assessing population–level transmission intensity and 
differentiating between areas of different endemicity in Indonesia [30]. Moreover, 
multivariable analysis utilizing serological and epidemiological data collected through 
community-based survey identified that age, P. vivax seropositivity and LLIN use were 
significantly associated with P. falciparum seropositivity. These associations are likely related 
to historical exposure as P. falciparum seroprevalence was estimated to be low and parasite 
screening found no active infections detected by microscopy. Although sub-microscopic 
infections might present in the community, a previous study suggested that the proportion 
of sub-microscopic infections detected via PCR (polymerase chain reaction) was very low 
0.07% (11/16,229) in the region [34]. However, though PCR is very sensitive, a smaller 
proportion of individuals with sub-microscopic parasitaemia will be detected if smaller 
volumes of samples such as on filter paper bloodspot were used. One ml of whole blood is 
often used for DNA extraction and PCR for detecting sub-microscopic parasitaemia. 
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The P. falciparum SCR estimates suggest that there was no exposure seen in children under 
5 years old in both sub-districts in Sabang municipality. These results could represent a step 
change in P. falciparum transmission due to the successful impact of malaria control 
programme implemented in the study area, evidenced by lower antibody prevalence in 
children born after the intervention scale-up. This finding was supported by a previous study 
documenting a significant drop in malaria cases after the launch of the control program in 
2004. Malaria cases in Sabang declined from 88 cases per 1000 population in 2004 to 1 per 
1000 by 2010. The decline in malaria transmission in Sabang is likely related to an extensive 
IRS programme immediately following the tsunami in 2004, large scale LLIN distribution, and 
a change in malaria treatment policy to artemisinin-based combined therapy as first-line 
treatment for uncomplicated malaria [34]. Sabang was certified as a malaria-free region by 
the Indonesian Government as a result of successfully maintaining zero cases since the last 
locally transmitted case reported in 2011. Since then, the surveillance system detected 12 
imported cases consisting of 6 P. vivax, 4 P. falciparum and 2 mixed P. vivax and P. falciparum 
infections from 2011 to 2013, with no local transmission. However, the surveillance system 
detected 15 PCR confirmed Plasmodium knowlesi infections that classified as an outbreak in 
2014 [38]. 
 
Consistent with the higher P. falciparum SCR estimates in people over 5 years old, 
multivariable analysis revealed that adults were more likely to be seropositive compared to 
children under 15 years old. This is likely the result of higher exposure by staying overnight 
in high-risk areas. A recent study revealed that the clusters of malaria (P. knowlesi) infections 
in Sabang was associated with people who had a history of staying overnight in the forest, 
without protection from mosquitoes, in an area where macaques are common [38]. 
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Unfortunately, data on travel behaviour and occupation in these surveys were not recorded 
to enable testing of these hypotheses. Future research would need to include more detailed 
questions regarding travel behaviour, occupation and other essential risk factor data such as 
travel history to high-risk areas, night outdoor activities, sleeping in plantation or forest, 
housing, personal protection, etc. Several programme initiatives, for example a multi-
country study on vector control tools to address outdoor transmission and project 
management quality improvement for national malaria program workforce carried out 
under the Asia Pacific Malaria Elimination Network would be beneficial for the malaria 
elimination effort in the region. In addition, the use of LLIN was almost two times higher in 
area where P. falciparum seroprevalence was higher. Consistent with previous report 
suggesting high coverage of LLINs (over 75%) in six malaria focal villages in Sabang, this 
finding suggests that people living in higher risk of exposure were aware of the importance 
of LLIN to prevent malaria transmission in those areas [34]. 
 
The estimated age-seroprevalence curves and SCR value suggested that age was not 
associated with P. vivax transmission in either sub-district in Sabang. Plasmodium vivax 
seroprevalence was very low (2.0%) and, therefore, the absence of any associations is likely 
due to the statistical limitations of the low number of seropositive samples. The other 
possible explanation is that P. vivax infections may induce lower antibody responses or 
shorter-lived responses which the current assay may miss. Work is ongoing to identify P. 
vivax antigens that elicit short-term responses for easy identification of very recent exposure 
[39,40]. The need for testing more potential P. vivax antigens is supported by a previous 
study showing that the number of P. vivax cases tend to be higher than the number of P. 
falciparum cases in Sabang [34]. 
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The spatial analysis of age-adjusted antibody responses to either antigen (AMA-1 or MSP-1-
19) identified significant clusters of higher exposure (hotspots) for both P. falciparum and P. 
vivax exposure across the study areas. Although multivariable risk factors analysis found 
there was no significant association between residence and higher seroprevalence to P. 
falciparum and P. vivax, the spatial analysis suggested that the risk of malaria transmission 
in the study setting is heterogeneous with people experiencing higher exposure in Sukajaya 
sub-district. The spatial analysis also suggest that the clusters identified for P. falciparum and 
P. vivax were seen in the same areas. Being able to characterize the micro-epidemiology of 
malaria exposure could assist malaria control programme to better allocate resources and 
target the intervention to achieve their goal of elimination. Targeting hotspots could be a 
highly efficient way to reduce malaria transmission at all levels of transmission intensity [41]. 
Although this study identified potential high-risk areas using historical data collected in 2013, 
being able to identify areas which had the most recent exposure is useful for malaria 
surveillance. A recent study suggested that one of two clusters of P. knowlesi infections in 
Sabang  were identified in similar high-risk areas identified in this study [38]. As suggested in 
the latest WHO malaria surveillance manual [11], maintaining surveillance activities in the 
most receptive areas could be useful to prevent potential reintroduction or resurgence of 
the disease in the future. Therefore, utilizing antibody responses data to identify recent or 
historical hotspots of transmission could be a powerful alternative approach where gaining 
direct evidence of an increased exposure to infectious mosquito bites is no longer ideal in 
low transmission settings. 
 
Finally, people who were seropositive to any P. vixax antigen were 3 times more likely to be 
P. falciparum seropositive, after controlling for age, gender, residence, employment, 
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education, IRS, fever status, and altitude. In addition, clusters of high antibody responses 
suggest that P. falciparum and P. vivax receptive areas were seen in the same areas. As there 
was no cross-reactivity evident from the serological data (Additional file 3), these findings 
could suggest that people were historically exposed to both infections, potentially due to the 
presence of efficient vectors in those identified areas. 
 
Findings in this study are based on community-based samples and data collected during the 
malaria transmission season. Although this study describes the potential use of serological 
data analysis in estimating malaria transmission intensity, heterogeneity and factors 
associated to disease exposure, the results generated would need to be carefully 
interpreted. Previous studies suggested that malaria transmission in other areas of Indonesia 
was affected by seasonality [30,34,42–44] and behavioural factors such as farm or forest-
related night outdoor activity (e.g. sleeping in forest gardens) [45,46] and domestic travel to 
higher endemic areas [47]. However, due to limited data collected, our study could not 
examine the effect of behavioural factors such as forest-related activities or recent travel 
history to high-risk areas outside Sabang. Therefore, future studies measuring population 
level antibody responses coupled with collecting more data that could describe behavioural 
factors associated to higher risk of exposure would be more epidemiologically informative 
to assist malaria surveillance and control programme to achieve elimination in the region.  
 
3.6 Conclusion 
In conclusion, these data add to the body of evidence that sero-epidemiological analysis of 
community-based surveys are an important additional tool to investigate malaria 
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transmission dynamics in area aiming for elimination in Indonesia. Recent identification of 
alternative antigens associated with short-lived antibody responses suggests a potentially 
key indicator of very recent exposure which would be a very important information for public 
health surveillance [48]. The addition of a novel panel of P. knowlesi antigens [49] would 
enhance understanding of malaria transmission dynamics as recent studies reported that 
although laboratory identification of P. knowlesi in Indonesia is challenging [50], surprisingly, 
there were two clusters of P. knowlesi cases detected in Sabang after the municipality 
successfully eliminated P. falciparum and P. vivax cases [38]. Moreover, another recent study 
also reported there was a considerable proportion of P. knowlesi infection in another 
western part of Indonesia, in North Sumatera province [51]. Exploratory work employing 
techniques such as multiplex fluorescent magnetic bead-based serological assay to 
investigate and validate a panel of potential antigens for these applications is underway 
[40,52]. The development and validation of a standardized serological sample and data 
collection methods utilizing existing public health surveillance system, for example as 
described in [53] will also facilitate the optimization of serological surveillance in 
understanding transmission dynamics to support malaria control programme in achieving 
elimination. 
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3.8 Supplementary information 
 
Additional file 1. Seroprevalence for each antigen studied 
Antigen N Number  
positive 
% (95% CI) 
PfAMA-1 1615 85 5.3 (4.3-6.5) 
PfMSP-1-19 1624 58 3.6 (2.8-4.6) 
PvAMA-1 1624 19 1.2 (0.8-1.8) 
PvMSP-1-19 1624 17 1.2 (0.7-1.7) 
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Additional file 2. Demographic characteristics and factors associated with P. vivax 
transmission in Sabang, Indonesia, 2013 
 
Variable (n = 1624) 
Total P. vivax seropositive Bivariate  
p 
N (%) n % (95% CI) OR (95% CI) 
Age (years) 
<15 years old 
16-25 years old 
25-40 years old 
>40 years old 
 
656 (40.39) 
270 (16.63) 
347 (21.37) 
351 (21.61) 
 
3 
11 
8 
10 
 
0.5 (0.1-1.4) 
4.1 (2.3-7.2) 
2.3 (1.2-4.5) 
2.8 (1.5-5.2) 
 
1 
9.24 (2.56-33.41) 
5.14 (1.35-19.49) 
6.38 2 (1.75-23.35) 
 
 
0.001 
0.016 
0.005 
Gender 
Female 
Male 
 
984 (60.55) 
641 (39.45) 
 
23 
9 
 
2.3 (1.6-3.5) 
1.4 (0.7-2.7) 
 
1 
0.59 (0.27-1.29) 
 
 
0.190 
Residence 
Sukakarya 
Sukajaya 
 
603 (37.13) 
1021 (62.87) 
 
11 
21 
 
1.8 (1.0-3.3) 
2.1 (1.3-3.1) 
 
1 
1.13 (0.54-2.36) 
 
 
0.745 
Education 
None 
Primary education 
Higher education 
 
3 (0.34) 
764 (86.33) 
118 (13.33) 
 
1 
27 
3 
 
0.4 (0.1-2.6) 
2.2 (1.5-3.2) 
2.5 (0.8-7.5) 
 
1 
6.14 (0.83-45.38) 
6.97 (0.72-67.75) 
 
 
0.075 
0.094 
Employment 
Unemployed 
Non-office-based job 
Office-based job 
Student 
 
516 (57.33) 
215 (23.89) 
105 (11.67) 
64 (7.11) 
 
20 
4 
2 
6 
 
2.5 (1.6-3.8) 
1.8 (0.7-4.8) 
1.9 (0.5-7.1) 
1.2 (0.6-2.7) 
 
1 
0.73 (0.25-2.16) 
0.73 (0.17-3.19) 
0.48 (0.19-1.22) 
 
 
0.572 
0.681 
0.123 
LLIN use 
No 
Yes 
 
1098 (68.28) 
510 (31.72) 
 
19 
13 
 
1.7 (1.1-2.7) 
2.5 (1.5-4.3) 
 
1 
1.48 (0.73-3.03) 
 
 
0.278 
IRS last 12 months 
No 
Yes 
 
1376 (84.83) 
246 (15.17) 
 
25 
7 
 
1.8 (1.2-2.7) 
2.8 (1.4-5.9) 
 
1 
1.58 (0.68-3.70) 
 
 
0.290 
Fever 
No 
Yes 
 
1483 (91.26) 
142 (8.74) 
 
31 
1 
 
2.1 (1.5-3.0) 
0.7 (0.1-4.8) 
 
1 
0.33 (0.45-2.45) 
 
 
0.280 
Altitude (meter) 
< 120 
> 120 
 
716 (50.46) 
703 (49.54) 
 
13 
10 
 
1.8 (1.1-3.1) 
1.4 (0.8-2.6) 
 
1 
0.78 (0.34-1.79) 
 
 
0.559 
Individual level data: age, gender, education status, employment status and fever. 
Household level data: LLIN use, IRS in last 12 months and altitude 
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Additional file 3. Scatter plots matrix of antibody responses (optical density) to P. falciparum 
and to P. vivax antigens tested in the study describing the absence of cross-reactivity 
between the P. falciparum and P. vivax antigens 
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4.1 Abstract  
Background:  Identifying fine-scale spatial patterns of disease is essential for effective 
disease control and elimination programmes. In low resource areas without formal 
addresses, novel strategies are needed to locate residences of individuals attending health 
facilities in order to efficiently map disease patterns. We aimed to assess the use of Android 
tablet-based applications containing high resolution maps to geolocate individual 
residences, whilst comparing the functionality, usability and cost of three software 
packages designed to collect spatial information. 
Results: Using Open Data Kit GeoODK, we designed and piloted an electronic questionnaire 
for rolling cross sectional surveys of health facility attendees as part of a malaria 
elimination campaign in two predominantly rural sites in the Rizal, Palawan, the Philippines 
and Kulon Progo Regency, Yogyakarta, Indonesia. The majority of health workers were able 
to use the tablets effectively, including locating participant households on electronic maps. 
For all households sampled (n = 603), health facility workers were able to retrospectively 
find the participant household using the Global Positioning System (GPS) coordinates and 
data collected by tablet computers. Median distance between actual house locations and 
points collected on the tablet was 116 m (IQR 42–368) in Rizal and 493 m (IQR 258–886) in 
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Kulon Progo Regency. Accuracy varied between health facilities and decreased in less 
populated areas with fewer prominent landmarks. 
Conclusions: Results demonstrate the utility of this approach to develop real-time high-
resolution maps of disease in resource-poor environments. This method provides an 
attractive approach for quickly obtaining spatial information on individuals presenting at 
health facilities in resource poor areas where formal addresses are unavailable and internet 
connectivity is limited. Further research is needed on how to integrate these with other 
health data management systems and implement in a wider operational context. 
Keywords: Electronic data collection, mHealth, Geographical information systems, 
Surveillance, Mobile technology, Participatory mapping 
 
4.2 Background 
Infectious disease risks can be highly heterogeneous at fine spatial scales due to 
environmental, social and biological factors [1]. As infectious disease control programmes 
move towards elimination, it is increasingly important to identify and target foci of 
transmission areas and understand the factors that may contribute to disease persistence in 
these locations [2–4]. Disease reports aggregated at coarser spatial scales, such as district or 
regional levels, may not capture these differences in micro-epidemiology [5, 6]. 
 
Numerous studies have utilised global positioning system (GPS) technology to develop fine-
scale maps of disease infection and exposure (e.g. [7, 8]), identify hotspots of disease 
transmission (e.g. [9, 10]) and target control measures (e.g. [11, 12]). These studies typically 
use population-based cross-sectional surveys including GPS coordinates for patient 
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households or frequently visited locations to map disease risks. Alternatively, when 
household surveys are not feasible, convenience sampling approaches targeting easy access 
groups can be used to estimate risks in a population. Examples of these approaches include 
school-based surveys (e.g. [13, 14]) and surveys of clinic attendees (e.g. [15]). These 
methods may not fully capture risks in the wider population but are substantially more cost 
effective to implement and may be more feasible in low resource settings. 
 
A key limitation of convenience sampling approaches is that the interviewer does not visit 
the patient household and therefore cannot collect GPS coordinates at the site. If formal 
address information is available for a region, the patient address can be used to identify the 
GPS coordinates. However, this type of information is often not available for many countries 
or high-risk groups, such as migrant or mobile populations. In these situations, other 
methods can be used to estimate locations of patient households, such as identifying the 
nearest landmark, clinic or school catchment area or using participatory mapping techniques 
in which the patient identifies the location of their house on a paper map [16, 17]. These 
methods can be used to yield maps of relatively high spatial accuracy however, digitising 
maps and data management may be time consuming. 
 
To address this issue, we assessed the use of tablet- based applications to geo-locate patient 
households remotely. Tablets are widely used to administer questionnaires and collect 
health information electronically as well as to scan barcodes and track samples [18–21]. 
Digital data collection can improve data quality and completeness as well as increase 
efficiency of data cleaning and analysis [22]. While these applications are frequently used to 
record GPS coordinates of the current location, the utility for participatory mapping for 
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health surveys has not currently been assessed. We evaluated multiple software programs 
for use in rural resource poor settings with no internet connectivity as part of a malaria 
elimination research project. As such, a core requirement was the ability to load satellite 
images for use offline. We aimed to (1) identify appropriate tablet-based applications and 
assess the functionality, cost and technical expertise required to set up and use the 
programs; and (2) assess the accuracy of data collected using offline maps for the selected 
application. 
 
4.3 Methods 
Study areas 
We evaluated different software programs for use in malaria surveillance of clinic attendees 
in two rural sites in Southeast Asia: Rizal Muncipality, Palawan, Philippines (1256 km2, 
estimated population 50,100, 15 health facilities) and Kulon Progo Regency, Yogyakarta, 
Indonesia (586 km2, estimated population 430,500, 8 health facilities). These sites are 
targets of on-going research projects to enhance surveillance for malaria elimination aiming 
to establish, integrate and evaluate combinations of laboratory, clinical and epidemiological 
data collected during health facility surveys to estimate the magnitude and heterogeneity of 
malaria transmission. Kulon Progo Regency is the site of one of the few remaining foci of 
malaria transmission in Java Island, Indonesia and was chosen as epidemiologically 
representative of a pre-elimination area where researchers and local control programmes 
are actively working towards elimination for Indonesia’s national strategic plan for malaria. 
Rizal, Palawan was selected as representative of an area in the Philippines transitioning from 
reduction of disease burden to malaria elimination. Samples were collected from patients 
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and companions attending health facilities and microscopy, molecular and serological 
methods were used to identify infections and characterise transmission intensity. Both sites 
had multiple health facilities with poor or no internet connectivity. For each site, significant 
landmarks such as clinics, mosques, churches and schools were identified by local personnel 
and geolocated using a handheld GPS (Garmin, USA). Other spatial data, such as locations of 
roads and administrative boundaries, were assembled from available sources including 
government departments, freely accessible geospatial databases and open source GIS 
platforms such as OpenStreet Map (www.openstreet map.org) and Global Administrative 
Areas (GADM; www.gadm.org). 
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Figure 4.1 Study areas 
 
Data collection methods and survey 
To develop data collection methods for these activities, we first evaluated multiple mobile-
based data collection systems with the capacity to collect questionnaire data, GPS 
coordinates, and to take photographs of rapid diagnostic test results and scan barcodes used 
for sample tracking. For each software program, we set up a questionnaire as well as an 
offline map using best available satellite and GPS data for the health facility catchment area 
(Additional file 1). These questionnaires were tested by project staff in each site. All 
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questionnaires were set up on Android tablets with 8 GB of internal memory and additional 
memory on external SD cards. Based on initial testing and map development, final data 
collection tools were designed using GeoODK and trialled in health facility surveys in the 
Philippines and Indonesia (Figure 4.1). Maps were produced in Mapbox Studio, including 
high resolution satellite data, administrative boundaries and key landmarks and available 
census data. 
 
For multiple health facilities in each site, we conducted rolling cross sectional surveys of 
clinic attendees as part of larger malaria surveillance projects. During these surveys, 
consenting clinic attendees participated in a short questionnaire survey in Tagalog or Bahasa 
Indonesia and were asked to geo-locate their household using the digital maps provided. 
Initial 2 days training sessions were conducted for health facility personnel, followed by 
routine field supervision during the first week and regular meetings to identify any 
outstanding issues. Questionnaires were administered by the trained health facility 
personnel using Android-based tablets (Figure 4.2). Data collected was checked for 
completeness and field and data management staff were interviewed on the ease of use and 
any issues with questionnaire or map data. Multiple health facilities from each site (3 
facilities in Rizal and all 8 in Kulon Progo Regency) were selected to be representative of the 
data collected in each region, including the main regional health facility and several smaller 
satellite facilities in more remote areas. As this survey had an opportunistic sampling design, 
this population is not representative of the wider population in the study areas but rather 
individuals attending these health facilities. To assess the accuracy of reported GPS points, 
randomly selected households reporting to selected health facilities were followed up in 
both sites and GPS points of actual house locations were recorded using a handheld GPS. 
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Although accuracy of the handheld GPS units could be impacted by poor satellite signal or 
high canopy or building coverage, the mean accuracy of these devices was within 5 m of the 
recorded household location and we considered this measurement the actual location of 
the household. Root mean square error of the Euclidean distance in meters between the 
actual and reported household locations was calculated to assess accuracy of participant’s 
estimates collected by tablets and identify factors affecting this accuracy. 
 
 
 
   
Figure 4.2
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4.4 Results and discussion 
Software programs and characteristics 
We initially identified three data collection programs capable of using offline maps: GeoODK 
(University of Maryland and International Institute for Applied Systems Analysis, College 
Park, USA), Survey123 for ArcGIS (Esri, Redlands, USA) and ePAL (Tripod Software, Salford, 
UK) (Table 4.1). GeoODK is an Android- based open source platform for form design, mobile 
data collection and data management system. Survey123 is a mobile data collection 
application which integrates into the Esri ArcGIS platform. ePAL is a custom-built application 
interfacing with other open source data collection systems (ODK and CommCare) to add 
capacity to use offline maps. While GeoODK was freely available, there were some developer 
costs for ePAL and ArcGIS Survey123 required the purchase of a software licence. 
Correspondingly, software programs had varying levels of technical support available. For 
GeoODK, part of the ODK open data kit, tutorials and manuals were available online in 
addition to active web forums for software developers and users. Product developers 
provided quick responses to technical queries and, in one instance, reviewed our 
questionnaires and maps to assist with troubleshooting. ArcGIS also had extensive user 
guides and tutorials available online. The software licence purchased included access to Esri 
technical support as well as online forums. While no formal documentation or support was 
available for ePAL, the software developers were available to address questions. 
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Table 4.1 Characteristics of software applications assessed 
 
 
 GeoODK ArcGIS Survey123 ePAL 
Types of spatial data 
collected 
Points, polygons and GPS 
tracks 
Points, lines and polygons Point 
Able to load background 
maps offline 
Yes Yes Yes 
Format of offline maps MBTile ArcGIS Tile Package PNG format tile dataset 
Access to satellite 
imagery 
External data only Access to World Imagery and 
other ArcGIS layers 
External data only 
Storage space for 
imagery 
Tablet internal memory Tablet memory or external 
storage 
Tablet memory or external 
storage 
Questionnaire set up XLS form XLS form Integrates with other data 
collection software 
Integration Integrates with barcode 
scanner and other 
software 
Limited Integrates with CommCare 
and ODK 
Downloading data Upload to server or 
download as XML file 
offline 
Upload to server or download 
as SQLite database offline 
Download as part of data 
from CommCare or ODK 
Technical knowledge 
required 
Some programming 
required to create 
MBTiles 
Basic GIS knowledge only Basic GIS knowledge only 
Analysis Summary statistics 
available from data on 
online server 
Summary statistics available 
from data on online server 
None 
Cost and licencing Free, open source 
software 
Purchase of licence required 
(over USD 5000 for multiuser 
licence) 
Limited purchase costs 
(less than USD 5000 
developer costs) 
  
 
Sources of satellite imagery and spatial data 
In order for individuals to geo-locate their households, base maps must be assembled with 
sufficient spatial data on local geography and key landmarks. Freely available high resolution 
satellite data, such as Google Earth (www.google.com/earth ), OpenStreetMap (www.opens 
treet map.org) and Bing Maps (www.bing.com/maps), are increasingly used in public health to 
develop sampling frames [23, 24], collect spatially referenced disease data [25, 26] and target 
interventions [12, 27]. These data are usually of sufficient resolution to allow identification of 
individual houses and may contain further data on nearby points of interest. However, although 
these data can be freely accessed online, exporting imagery to raster datasets or other formats 
required for offline use is frequently covered by intellectual property agreements and may 
require user agreements or payments. Additionally, high resolution data is not always available 
in remote, sparsely populated areas and available data may not be temporally accurate, 
presenting a challenge in areas with high rates of change or following natural disasters. 
 
Alternatively, very high-resolution imagery is available through aerial photography or 
commercial satellite-based remote sensing sources, such as SPOT 6-7, Quickbird and IKONOS 
(www.digitalglobe.com). These data have resolutions of 1.5 m per pixel or less and have 
accurate data on the time of collection or can be tasked to collect data following significant 
changes. However, collecting these data can be prohibitively expensive in many low income 
settings and processing and usage requires significant technical expertise. High resolution data 
may also be available through licensed software, for example Esri imagery through ArcGIS. 
Although accessing this imagery requires purchase of a software licence, high resolution imagery 
from aerial and satellite-based remote sensing is available for most of the world for offline use. 
These data are pre-processed and available in easy to use formats including metadata on the 
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date of collection and temporal accuracy. Selecting the most appropriate imagery depends on 
the rates of land use change and development and availability of data for a particular region as 
well as the resources and technical expertise available. 
 
In addition, the inclusion of geo-referenced information on key landmarks can help participants 
identify their houses or neighbourhoods [16]. This may include spatial point data on schools, 
clinics and other points of interest in addition to line or polygon data on roads, rivers and 
administrative districts. These datasets may be assembled from a range of sources such as 
government mapping departments, open source spatial data platforms (e.g. OpenStreet Map or 
GADM) or through collecting GPS data on the ground. In some instances, where previous 
community-based surveys have been conducted or censuses have collected GPS coordinates, 
point data may be available for individual houses. For each site, we used all available vector 
data, including any household head names, emphasising labels for commonly identified 
features. 
 
Setting up questionnaires and imagery 
All software programs trialled used XLS forms to design questionnaires or, for ePal, integrated 
with other data collection software using XLS forms. However, each program required a 
different format for offline maps. ArcGIS Survey123 was the most user-friendly option, allowing 
tile packages to be exported directly from ArcGIS with only basic GIS knowledge required. Both 
ePAL and GeoODK required additional processing time and expertise; ePAL required the creation 
of tiled PNG (Portable Network Graphics) datasets and GeoODK required MBTiles, a format 
storing tiled map data in SQLite databases which is commonly used by Android mapping 
applications. Production for both file types could be done using open source software such as 
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Quantum GIS (www.qgis.org) and Mapbox Studio (www.mapbox.com) however MBTiles 
required some programming knowledge to correctly format maps. 
 
For all formats, there were trade-offs between map resolution and speed. Producing high 
resolution maps resulted in large file sizes and consequently increased times to open maps on 
tablets. While both ArcGIS Survey123 and ePAL could store map files on either internal tablet 
memory or external SD cards, GeoODK could only use files stored on internal memory, limiting 
the possible size. For sites with more detailed spatial data relating to households and other 
landmarks, we reduced the resolution of the satellite data. If limited vector data were available, 
we increased the resolution but created multiple tiled datasets with smaller geographic areas 
to optimise rendering of maps on mobile devices. 
 
Field testing of data collection method 
Based on the initial questionnaire testing, we chose to use GeoODK due to better integration of 
barcode scanners and other functionalities as well as faster loading of maps. Accuracy was not 
assessed for all software as all had similar map interfaces and accuracy was primarily dependent 
on the quality of the maps and the participant and interviewer abilities to use geographic 
information. GeoODK questionnaires and maps were set up on all tablets in the office while 
connected to the internet and data management staff were trained on setting up the 
questionnaire and downloading data offline. Training sessions were conducted to introduce 
fieldworkers to the use of the tablet and questionnaire; these field workers included community 
health workers and clinic staff, many of whom had not used electronic data collection methods 
or tablets prior to this work. Most fieldworkers were able to use the software effectively, 
although a few reported still preferring previously used paper data collection forms. Although 
  
105 
 
there were some technical issues, such as forms freezing or crashing, the majority of data (over 
99%) was complete and collected without any problems. Despite the inclusion of satellite 
imagery, most participants relied on names of household owners included on maps or labelled 
local landmarks rather than satellite imagery to locate the participant’s households. In some 
cases, when clinics were busy and maps were slow to load, fieldworkers did not wait for maps 
to load and fully zoom into an area, resulting in less accurate household geolocation; this issue 
was addressed by including maps with lower resolutions or smaller geographical areas which 
were faster to load. 
 
An additional consideration is the availability of electricity; as not all clinics surveyed had reliable 
access to electricity or generators, we used external batteries or solar chargers in areas without 
constant power supplies. This did not result in the loss of any data but should be accounted for 
in budgeting and planning. Although data could be uploaded to an online server if an internet 
connection was available, the internet connection was poor and intermittent, resulting in the 
loss of data when the connection was interrupted during upload. Instead, all data was 
downloaded offline by copying XML files from the tablet memory to office computers. While 
GeoODK had functions to quickly produce summary statistics from data uploaded to the online 
server, we used R statistical programming language to read, merge and produce summary 
statistics for XML files (R statistical software, www.R-project.org). 
 
Accuracy of tablet‑based geo‑location strategies 
To assess the accuracy of reported coordinates, we manually traced and recorded GPS points 
for 203 households in Rizal, Palawan and 400 households in Kulon Prugo Regency, Yogyakarta 
(Figure 4.3). All households could be identified by fieldworkers using the name and locations 
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collected by tablet and all households were located to their correct logistical unit used for 
interventions by the malaria control programme (sitios in the Philippines and desain Indonesia). 
Within these selected households, participants included 112 women and 91 men with a median 
age of 11 (range under 1–84 years) in Rizal, Palawan and 259 women and 143 men with a median 
age of 42 (range under 1–80 years) in Kulon Progo. In Rizal, 59 individuals had fever and 3 
individuals were identified as malaria positive by microscopy while 34 individuals were febrile 
and 5 microscopy positive malaria cases were identified in Kulon Progo. 
 
The median distance between house locations and points recorded by the tablet was 116 m (IQR 
42–368) in Rizal and 493 m (IQR 258–886) in Kulon Progo Regency. Root mean squared error 
was 895 and 702 m for Rizal and Kulon Progo Regency respectively. While most locations 
recorded by tablet were fairly accurate, a minority of points (6% in Rizal and 5% in Kulon Progo 
Regency) were over 2 km away from the actual house, primarily in areas where few landmarks 
were recorded. Although there was no clear relationship between accuracy of reported house 
locations and distance from the health facility, data collected on households over 2 km from the 
health facility were less accurate overall (Figure 4.4). As geo-referenced point data was not 
available for all landmarks, we assessed whether areas with higher population density (places 
likely to have more distinct landmarks) were associated with accuracy of reported points. 
Gridded population density at 100 m resolution was obtained from WorldPop [28]; population 
density was not correlated with accuracy of reported points (p value = 0.11). These data may be 
improved by the inclusion of higher resolution maps or improved spatial information on remote 
areas. However, despite these limitations, data collected was of sufficient quality to identify 
houses of all sampled health facility attendees and enabled accurate fine-scale mapping of 
participants for these areas. 
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To assess the variability in accuracy between different health facilities in the same site, we 
compared spatial accuracy in records collected at all 8 facilities in Kulon Progo Regency. The 
accuracy of the mapping exercise varied within the 8 health facilities, with the closest accuracy 
measured in Samigaluh 1 (RMSE 353 m), and the least accuracy found in Girimulyo 2 (RMSE 817 
m). Moreover, the exercise was able to locate 50.3% (95% CI 45.3–55.2%) and 78.3% (95% CI 
74.2–82.3%) of households within an accuracy of ≤ 500 and ≤ 1000 m, respectively. The highest 
proportion of households that were located within < 1000 m were Samigaluh 1 (97.9%, 95% CI 
93.8–100%), whilst the lowest proportion of households correctly located were Kokap 2 (53.1%, 
95% CI 38.9–67.2). Of households that were not located within 1000 m (n = 86), 40.7% were in 
Kokap district, 31.4% in Girimulyo, 11.6% in Samigaluh and 8.1% in Kalibawang and 8.1% in 
Pengasih district. While accuracy of GPS points was not significantly correlated with distance 
Figure 4.3 Comparison between house locations collected by tablet and actual house locations in 
a Rizal, Palawan b Kulon Progo 
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from the health facilities for the Regency overall (p value = 0.98), distance from the health facility 
was associated with decreased accuracy in the catchment area of Kokap 2 (p value = 0.003) 
(Figure 4.5). This area is heavily forested and less densely populated, with very limited 
landmarks. Data suggests reported household locations in Kokap 2 were more accurate if they 
lived closer to the health facility or in close proximity to other landmarks such as mosques, 
schools or shops that were available on the map. In addition, the accuracy was higher in more 
populated health facility catchment areas where more landmarks were available. 
 
 
Figure 4.4 
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4.5 Conclusions 
Tablet-based applications are an effective method of geolocating participant households when 
it is not feasible to visit individual households. While numerous software platforms are available, 
selection should be based on the setting and resources available. Field testing of this software 
in the Philippines and Indonesia suggests data collection is sufficiently accurate to identify most 
households and would be appropriate for monitoring fine-scale spatial patterns of disease. 
Implementing this strategy could extend health facility capacity to remotely collect spatial 
information and monitor areas where infections are most regularly occurring. The rapid 
assessment of spatial representation of the population and any foci of infection or exposure can 
prevent spread of disease and support health programs to better target disease control and 
elimination activities. 
 
  Figure 4.5  
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The choice of software and spatial data to include should be guided by availability of data, 
technical expertise, required data resolution and resources. For sites with a stable internet 
connection and good coverage by Google Earth or other free imagery, software can be used with 
free online imagery. If no internet coverage is available, software such as GeoODK, ArcGIS 
Survey123 and ePAL can be used to incorporate offline maps. Licenced software such as ArcGIS 
Survey123 provides good access to high resolution imagery, technical support and requires only 
basic GIS knowledge to set up; however, this software requires the purchase of licences and may 
require additional costs. Alternatively, if other spatial data is available, open source software, 
such as GeoODK, or applications designed to interface with open source software, such as ePAL, 
can be used to include custom designed maps. This involves limited to no software costs but 
requires more technical expertise and may require additional costs for purchase of satellite 
imagery. The types of data to be collected, such as spatial points, line or polygon data, barcodes 
or images, should also be evaluated. For example, programmes with a sampling unit at an 
individual level is likely to require higher resolution point household locations while 
programmes targeting larger administrative units may require lower resolution polygon data. 
An additional consideration is whether geo-location data collection software will need to 
integrate with other data management systems, such as larger national health data 
management systems. As technology continues to develop, the functionalities of these 
programs as well as additional new software applications may continue to expand. 
 
The geolocation strategy tested in our study offers an alternative approach for obtaining spatial 
information from health-facility attendees in a setting that is typical for much of rural Southeast 
Asia and other parts of the world. The accuracy of the strategy in this setting improved in areas 
where more landmarks were available. This method could also be employed with other EAG 
  
111 
 
(Easy Access Group) surveys such as school-based surveys that have been reportedly able to 
identify geographical variation in malaria transmission in different settings [13, 29– 31]. 
Moreover, the GIS data collected in this study can be incorporated into a database that enables 
the display of information in the form of a basic map to enable reactive surveillance and other 
public health activities. In addition, this data should be linked to other environmental and spatial 
data so statistical analysis can identify associations between disease and environmental factors 
[4]. This can facilitate the identification of transmission hotspots are occurring and be used to 
target interventions [2]. 
 
Tablet-based geolocation strategies provide an important method of collecting spatial data in 
low resource settings when it is not feasible to visit patient households to directly collect GPS 
data and no formal address system is available. We have applied this approach in two settings 
in Southeast Asia, this approach is also being utilised in the Caribbean and African settings for 
both malaria and tuberculosis and therefore is applicable globally. While further research is 
needed to investigate the utility and feasibility of this method in a range of settings before 
implementing in a broader operational context, this study highlights the tools available and how 
these may be employed in low resource settings. 
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4.7 Supplementary information 
Table SI1: Example questionnaire and associated data types 
Field ID Question Data type 
date_consultation 1) Date of Consultation: Date/ time 
barcode 2) Participant's Barcode: Barcode reader 
I. TYPE AND LOCATION OF HEALTH FACILITY 
type_facility 1) Type of health facility: (Select one) Field-list 
oth_facility 1-a) Other health facility: (Select one) String 
province 2) Province: (Select one) Field-list 
municipality 3) Municipality: (Select one) Field-list 
barangay 4) Barangay: (Select one) Field-list 
sitio 5) Sitio: (Select one) Field-list 
other_sitio 5-a) Other Sitio: String 
 II. PARTICIPANT'S PROFILE 
participant_select 1) Patient or Companion of Patient? (Select one) Field-list 
surname_name 2) Last Name: String 
firstname_name First Name: String  
middlename_name Middle Initial: String 
suffix Name Suffix, if any (Jr. Sr., I, II, III, etc.): String 
gender 3) Gender: (Select one)  Field-list 
age 4) Age   
age_year 4-a) Year: Integer 
age_months 4-b) Months: Integer 
contact_number 5) Contact Number: (Optional) String  
ethnicity 6) Ethnicity: (Select one) Field-list 
oth_ethnicity 6-a) Other name of Ethnic Group: String 
education 7) Educational Attainment (Select one): Field-list 
occupation 
8) Current occupation (by industry): - Select all that 
apply 
Field-list  
oth_occupation 8-a) Other occupation String 
III. RESIDENCE AND GPS COORDINATES 
stay_length 
1) How long have you been living at your present 
address? (Select one) 
Field-list 
barangay_2 1-a) Barangay: (Answer without abbreviating) Field-list 
sitio_2 1-b) Sitio: (Answer without abbreviating) String 
gps_tag 
1-c) Has the Location of Primary Residence been 
identified? 
Yes/ No 
residence_primary 1-d) Location of Primary Residence: GPS coordinates 
other_residence 2) Do you have any other residence? Yes/ No 
visited_secondary 
2-a) If YES, Have you visited your other residence 
these past 4 weeks? 
Yes/ No 
barangay_3 2-b) Barangay: (Answer without abbreviating) Field-list 
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sitio_3 2-c) Sitio: (Answer without abbreviating) String 
residence_secondary 2-d) Location of Secondary Residence: GPS coordinates 
IV. TRAVEL, AND ACTIVITIES 
travel 1) Have you traveled anywhere in the past 4 weeks? Yes/ No 
places_visited1 1-a) If YES, what places have you visited? Field-list 
places_visited2 Other places: String 
places_visited3 Other places: String 
activities1 2) What activities did you do these past 2 weeks? String 
activities2 Other activities: String  
activities3 Other activities: String 
V. BEDNET OWNERSHIP 
bednet_use 1) Do you own a bed net? Yes/ No 
bednet_ins 1-a) If YES, was the bednet treated with insecticide? Yes/ No 
bednet_use 1-b) If YES, do you use the bednet? Yes/ No 
VI. HEALTH INFORMATION 
temp_fever 
1) What is your temperature on the day of 
consultation? (Select one) 
Field-list 
axillary_temperature 
1-a) After getting you axillary temperature, does it 
indicate of having a fever? 
Yes/ No  
fever_length 
1-b) If YES, how many day/s has it been since the 
onset of your fever? (Select one) 
Field-list 
fever_length_meds 1-c) Did you take any medicine for your fever? Field-list 
fever_drugs 1-d) If YES, what fever medicine did you take? Field-list 
oth_fdrugs Other fever medicine: Field-list 
oth_symptoms_select 2) Are you experiencing any other symptom? Yes/ No 
symptoms_select 
2-a) If YES, what other symptoms are you 
experiencing? (Select all that apply) 
Field-list 
symptoms_select_other1 Other symptoms: String 
symptoms_select_other2 Other symptoms: String 
symptoms_select_other3 Other symptoms: String 
symptoms_length 
2-b) How long have you had these symptoms? (Select 
one) 
Field-list 
VII. DIAGNOSTIC TESTS 
filter_paper 1) Sample specimen for Filter Paper collected? Yes/ No 
bsmp 2) Sample specimen for Blood Film collected? Yes/ No 
rdt 
3) Was Malaria Rapid Diagnostic Test (RDT) 
performed? 
Yes/ No 
VIII. RAPID DIAGNOSTIC TEST RESULT 
blood_examined 1) Date of Blood Examined: Date/ time 
rtd_type 2) Type of RDT Kit used: Field-list 
rdt_result 3) RDT Result: Field-list 
rdt_positive 3-a) Type of Malaria Infection: Field-list 
image_RDT 3-b) Take a picture of the RDT kit result. Image 
rdt_treatment 4) Treatment for Malaria-infected individual: field-list 
referred 5) Reason for referral: field-list 
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Figure SI1: Screenshots of GeoODK questionnaire on Android tablet 
a. Offline map loaded on GeoODK questionnaire 
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b. GPS coordinates collected using offline map  
 
c. Barcode scanner used to scan sample barcode labels 
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d. Example of collection of multiple choice questionnaire data 
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5.1 Abstract 
Background: In order to improve malaria burden estimates in low transmission settings more 
sensitive tools and efficient sampling strategies are required. This study evaluated the use of 
serological measures from repeated health facility-based cross-sectional surveys to investigate 
P. falciparum and P. vivax transmission dynamics in an area nearing elimination in Indonesia. 
Methods: Quarterly surveys were conducted in 8 public health facilities in Kulon Progo District, 
Indonesia, May 2017 to April 2018. Demographic data were collected from all clinic patients and 
their companions, with household coordinates collected using participatory mapping methods. 
In addition to standard microscopy tests, bead-based serological assays were performed on 
finger-prick bloodspot samples from 9453 people. Seroconversion rates (SCR, i.e. the proportion 
of people in the population who are expected to seroconvert per year) were estimated by fitting 
a simple reversible catalytic model to seroprevalence data. Mixed effects logistic regression was 
used to examine factors associated with malaria exposure and spatial analysis was performed to 
identify areas with clustering of high antibody responses. 
Results: Parasite prevalence by microscopy was extremely low (0.06% (95% confidence interval: 
0.03-0.14, n=6) and 0 for P. vivax and P. falciparum, respectively). However, spatial analysis of P. 
vivax antibody responses identified high-risk areas that were subsequently the site of a P. vivax 
outbreak in August 2017 (62 cases detected through passive and reactive detection systems). 
These areas overlapped with P. falciparum high-risk areas and were detected in each survey. 
General low transmission was confirmed by the SCR estimated from a pool of the four surveys 
in people aged 15 years old and under (0.020 (95% confidence interval: 0.017–0.024) and 0.005 
(95% confidence interval: 0.003–0.008) for P. vivax and P. falciparum, respectively). The SCR 
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estimates in those over 15 years old was 0.066 (95% confidence interval: 0.041-0.105) and 0.032 
(95% confidence interval: 0.015-0.069) for P. vivax and P. falciparum, respectively. 
Conclusions: These findings demonstrate the potential use of health facility-based serological 
surveillance to better identify and target areas still receptive to malaria in an elimination setting. 
Further implementation research is needed to enable integration of these methods with existing 
surveillance systems. 
Keywords: serology, surveillance, mapping, malaria, elimination 
 
5.2 Background 
Transforming malaria surveillance into a core intervention is one of the three pillars of the WHO 
global technical strategy for malaria elimination [1]. As transmission declines, malaria risk 
becomes more heterogeneous and is often clustered in specific localities or populations [2,3]. 
Identifying areas of ongoing infection or areas at risk of outbreaks is important to ensure that 
control strategies can be deployed in the most efficient manner [4–6]. In many South East Asian 
settings, surveillance becomes more challenging with the presence of multi-species infections 
combined with the difficulty of identifying where, and in which populations, residual 
transmission might be occurring [7,8].  
 
In many countries, surveillance has focused on passive case detection performed via health 
facilities [9,10]. However, innovative additional strategies are needed in countries nearing 
elimination as malaria cases become increasingly rare and disproportionately affect high-risk 
populations, who may not utilise public health facilities [10]. Studies suggest that passive 
surveillance will miss a large proportion of asymptomatic and sub-microscopic infections 
  
127 
 
present in the community [8,11,12] and may also not optimally capture imported infections 
occurring in temporary visitors who may be unable or unlikely to visit a health facility. Effectively 
targeting both of these groups is likely to hasten progress toward elimination. 
 
Resurgence of malaria is often associated with imported infections and/or P. vivax relapsing 
infections in areas that remain highly receptive to malaria [13–16]. Studies have demonstrated 
the usefulness of spatially referenced entomological data to characterise the  heterogeneity of 
malaria receptivity in areas approaching elimination to prevent outbreaks in the future [17–19]. 
However, entomological surveillance can often be logistically challenging in low transmission 
areas due to the difficulty of catching meaningful numbers of mosquitoes. An alternative 
approach is to identify areas where the population show evidence of current or previously high 
malaria exposure.  This can be done using serological markers of infection and identifying 
populations with higher than average anti-malaria antibodies [20–23]. Serological measures are 
a sensitive tool to estimate current and previous transmission intensity in a population and their 
use has been particularly well validated in low transmission areas where the sensitivity of 
parasitological tools is inadequate [24–27]. However, these studies used community-based 
cross-sectional surveys that often require large resources to visit households for collecting 
samples and household global positioning system coordinates to map the transmission risk. In 
order to further reduce logistical constraints, convenience sampling approaches targeting health 
facility attendees can be used to estimate and map risks in a population when household surveys 
are not feasible [28] and has been shown to be a good proxy for malaria transmission in the 
community [29]. Moreover, the simple addition of a geolocation approach to remotely record 
the residence of health facility attendees in the survey [30] allows for rapid assessment of the 
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micro-epidemiology of malaria cases in the community and could help to identify geographical 
foci of exposure. 
 
Indonesia is one of countries facing challenges in eliminating both P. falciparum and P. vivax 
infections. Previous studies in Indonesia suggest that the current diagnostic sensitivity 
(microscopy and rapid diagnostic test (RDT)) and timeliness of transmission measurement are 
not sufficient to describe and predict decreasing numbers of cases and potential outbreaks in 
low transmission areas striving for elimination [31–33]. The risk of outbreaks is high where there 
are larger numbers of migrants or travellers [31,34–36] and/or where residents with 
asymptomatic infections are not actively seeking treatment for malaria [37–45]. Therefore, 
surveillance systems need to be improved to better locate and target infections and further 
reduce transmission [32,46]. This study evaluated the use of serology, geolocation tools, and 
repeated health facility-based surveys for capturing malaria transmission dynamics in 
conjunction with existing surveillance system in an area conducting elimination in Indonesia. 
 
5.3 Methods 
Study setting 
Indonesia has the second highest burden of malaria in the South-East Asia region, with an 
estimated 16 million people (~6% of the population) living in high-risk areas [47]. All species of 
Plasmodium have been reported in Indonesia with the majority of infections caused by P. 
falciparum and P. vivax [35,48–51]. Malaria transmission is highly heterogenous [52,53], with 
large areas being transmission free, leading to a governmental target of achieving malaria 
elimination across the country by 2030 [46]. This study was conducted in Kulon Progo District, 
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Yogyakarta Province, Indonesia, located on the south coast of Java Island. Kulon Progo is one of 
the few remaining foci of malaria transmission on Java Island, Indonesia (Figure 5.1). The study 
site consists of 12 sub-districts (586 km2 in total) with a population of approximately 430,500 
people in 2016. Each district has at least one public health facility (21 in total). Malaria 
transmission is concentrated in the forested hillside area that border with other endemic areas 
of Central Java Province [54]. Transmission occurs during the wet season between August to 
December, with very low or zero cases during the other months. Based on routine passive data 
recorded in local health facilities, there was a significant decline in malaria annual parasite 
incidence from 0.48 per 1000 population in 2012 to 0.22 per 1000 population in 2016. Eight 
health facilities in 5 sub-districts where P. falciparum and/or P. vivax transmission was ongoing 
were chosen as study sites. An. maculatus and An. balabacencis are the main malaria vectors in 
Kulon Progo [55]. 
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Figure 5.1 Maps showing the location of Yogyakarta Province in Indonesia (a), location of Kulon 
Progo District in Yogyakarta Province (b), and the location of 8 studied health facilities in Kulon 
Progo District (c). Tree cover data, derived from classified Landsat imagery at 30 metres 
resolution, were obtained from Hansen et al. [56] 
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Survey design and data collection 
The study population included all attendees of the 8 selected public health facilities. Surveys 
were conducted quarterly during the period of May 2017 to April 2018. Each survey continued 
until the minimum sample size was met. The sample size calculation was performed using 
methods specific for estimating antibody seroconversion rates (SCR, i.e. the proportion of people 
in the population who are expected to seroconvert per year) [56]. The SCR to either P. falciparum 
apical membrane antigen 1 (PfAMA1) or merozoite surface protein 1 (PfMSP-1-19) in Kulon Progo 
was expected to be lower than the SCR reported in the neighbouring pre-elimination setting, 
Purworejo District, Indonesia (SCR 0.019 (95% CI: 0.015-0.022)). Therefore, a minimum sample 
size of 248 individuals per facility was set to ensure an antibody SCR of 0.0036 could be estimated 
with a precision level of +/- 0.0018. 
Finger prick blood samples were collected as dried bloodspots together with thick and thin blood 
smears from all consenting participants attending the facilities. Patients who were very ill and 
required urgent care, and children <6 months of age were excluded. Data on age, gender, axillary 
temperature, patient (versus accompanying person) status, permanent residence, travel 
behaviour, occupation, bed net use and current symptoms or reasons for attending the clinic 
were collected. Fever status was defined as having axillary temperature >37.5 ◦C and/or reported 
having fever in the previous 24 hours of sample collection. Participants were asked to geolocate 
their household using high-resolution digital offline maps via the open source GeoODK. The 
validation of this mapping approach was performed at the beginning of our first survey and has 
been reported in Fornace et al. [30]. All data were collected via interview using open data kit 
[57] on tablets (Samsung Galaxy Tab 3 SM-T210). Demographic data on reported cases, 
surveillance (passive and reactive case findings) and control programme activities were collected 
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from the District Health Office of Kulon Progo in between every serological survey. Data on the 
age distribution of the population in the study area was obtained from the 2016 census 
published by the Central Agency on Statistics of Kulon Progo. Tree cover data, derived from 
classified Landsat imagery at 30 meter resolution, were obtained from Hansen et al. [58]. 
 
Laboratory methods 
Thick and thin blood smears were read by trained health facility lab technicians at each facility. 
Bloodspot samples were tested against a panel of P. falciparum and P. vivax antigens including 
apical membrane antigen 1 (PfAMA1; PvAMA-1), merozoite surface protein 1 (PfMSP-1-19; 
PvMSP-1-19), erythrocyte binding protein (PvEBP), reticulocyte binding protein 1a [amino acids 
160–1170] (PvRBP1a) and reticulocyte binding protein 2b [amino acids 161–1454] (PvRBP2b) 
using a bead-based assay as described by Wu et al. [59] and read using Luminex MAGPIX© 
(Luminex Corp, Austin, TX). For serological data analysis, infants under 1 year of age were 
excluded from each dataset to remove any influence of maternally derived antibodies [60]. 
Antibody responses measured as median fluorescence intensity (MFI) values were normalised 
against the MFI values of the positive control run on each plate. For each plate, the percentage 
of plate-to-reference standard MFI difference was calculated and used to adjust the median MFI 
values. 
 
Statistical analysis 
All statistical analyses were conducted in Stata IC 15 (Stata Corp, College Station, TX, USA). A cut 
off for seropositivity was determined based on finite mixture models according to the mean of 
log MFI values plus three standard deviation of the seronegative population. Separate cut off 
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values were generated for each antigen [61]. Individuals were categorised as seropositive for 
each species if their antibody responses were above the cut-off for either of the two or five 
antigens for P. falciparum and P. vivax, respectively. SCR were estimated by fitting a reverse 
catalytic model to seroprevalence data for each species  [60]. Models allowing two forces of 
infection in SCR were fitted if deemed a better fit, using likelihood ratio methods. Mixed effects 
logistic regression models were performed to examine risk factors associated with being 
seropositive to P. vivax. Variables with evidence of an association (p < 0.05) in bivariate analysis 
were included in a multivariable model. Health facility was treated as a random effect variable 
in both bivariate and multivariable models. 
 
Spatial analysis 
The ‘Normal model’ in the spatial software SaTScan (v.9.4.2) was used to detect clusters of 
individuals with higher than average age-adjusted antibody responses to each antigen per 
survey.  In order to obtain age-adjusted values, the MFI data were log10 transformed and the 
residuals from linear regression were used to determine whether antibody responses were 
higher or lower than expected for any given age assuming a homogeneous distribution of risk 
across age. Firstly, residuals were categorised into 4 categories i.e. below 25th percentile, 25th–
75th percentile, 75th–90th percentile and above 90th percentile for each antigen. Individuals were 
then assigned score 4 (highest) if they had residual values above the 90th percentile, 3 (higher 
than average) for 75-90th percentile, 2 (average) for 25-75th percentile and 1 (low) for residual 
below the 25th percentile to any of the two or five antigens for P. falciparum or P. vivax antigen, 
respectively. The residual scores were then used to calculate non-overlapping, statistically 
significant (p <0.05) clusters of higher than average age-adjusted antibody responses with a 
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maximum radius of 3 km, minimum 2 observations detected in a cluster using the Purely Spatial 
scan. The analysis was run separately for each survey to ascertain spatial pattern at each survey 
time point. Clusters identified from SatScan were then plotted in QGIS software (v.3.6.3) to 
identify the potentially receptive areas. Spatial autocorrelation for each survey time point was 
assessed using Moran’s I in ArcGIS (v.10.5) using the age-adjusted antibody residuals from the 
regression model. 
 
5.4 Results 
Study enrolment and population demographics 
A total of 9453 individuals were sampled during four repeated cross-sectional surveys performed 
in 8 health facilities in Kulon Progo District, Yogyakarta Province, Indonesia during the period of 
May 2017 to April 2018 (Table 5.1). Blood smears and dried bloodspot samples were collected 
from >98% of attendees and their companions. Participation rates were above 90% for all 
surveys, ranging from 82 to 100% across facilities. Study participants were mostly female (65%), 
the median age was 42 years old (IQR: 27–55), and the majority attended the facilities as patients 
(78.6%). Children were underrepresented in the sample, in comparison to the general 
population. Approximately 30% of the study population were forest workers involved in 
coconut/palm tapping, fruit farming, logging, and other related jobs. 42% of the study population 
reported having at least one bed net in their house, resulting in overall usage of 27% in the study 
population. Only 16% of the population reported recent travel; with the highest proportion of 
travel recorded during quarter 1 and 2 (May to October 2017). Approximately 5% of the study 
population were febrile or reported having fever in the previous 24 hours.  
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Table 5.1 Number of samples, participation rates and general characteristics of health facility 
attendees per survey 
 Quarter 1  Quarter 2  Quarter 3  Quarter 4  Total 
 (May-July) (August-October) (November-January) (February-April)  
Sample size, n 2363 2370 2379 2341 9453 
n per facility 
Kokap 1 
Kokap 2 
Samigaluh 1 
Samigaluh 2 
Kalibawang 
Girimulyo 1 
Girimulyo 2 
Pengasih 2 
 
299 
298 
298 
300 
296 
285 
300 
287 
 
300 
298 
300 
297 
300 
299 
276 
300 
 
286 
297 
298 
300 
298 
300 
300 
300 
 
300 
301 
299 
280 
263 
299 
299 
300 
 
1185 
1194 
1195 
1177 
1157 
1183 
1175 
1187 
      
Participation rates      
Mean %  95 96  91 96  94 
Range* 91–99 90–99 82–99 90–100 91–96 
      
Female, n (%) 1578 (66.8) 1527 (64.4) 1530 (64.3) 1502 (64.2) 6137 (64.9) 
      
Age, median (IQR) 40 (25–54) 41 (27–54) 42 (27–55) 43 (30–57) 42 (27–55) 
      
Patients, n (%) 1803 (76.3) 1939 (81.8) 1878 (78.9) 1812 (77.4) 7432 (78.6) 
      
Occupation, n (%)      
Forest workers 655 (27.7) 709 (29.9) 620 (26.1) 800 (34.2) 2784 (29.5) 
Non-forest workers 685 (29.0) 647 (27.3) 738 (31.0) 678 (29.0) 2748 (29.1) 
Not working 1023 (43.3) 1014 (42.3) 1021 (42.9) 859 (36.8) 3917 (41.5) 
      
Lives in a house with 
bed net, n (%) 
1091 (46.2) 1132 (47.8) 999 (42.0) 777 (33.3) 3999 (42.3) 
      
Slept under the bed 
net, n (%) 
710 (30.1) 685 (28.9) 666 (28.0) 527 (22.5) 2588 (27.4) 
      
Recent travel, n (%) 595 (25.2) 581 (24.6) 211 (8.9) 111 (4.7) 1498 (15.9) 
      
Fever, n (%) 127 (5.4) 116 (5.0) 146 (6.1) 93 (4.0) 484 (5.2) 
      
 
* Range of health facility level summaries 
 
Data captured by routine passive surveillance during the study period 
The routine passive and reactive case detection in the study area detected 72 P. vivax and 8 P. 
falciparum microscopy positive infections out of 15,067 slides read in 2017, with the majority of 
infections found in males (70.2%) and adults over 15 years old (89.0%). All P. falciparum 
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infections were classified as imported. The majority of the P. vivax infections (86.1%, n=62) were 
found in Kokap 1 health facility catchment area in quarter 2 (74%, n=46). Of all of the infections 
detected, 39% (n=24) were detected passively at the health facility, with the rest being detected 
via door to door active case detection performed by the village malaria workers (i.e. screening 
of suspected cases based on clinical signs). The P. vivax cases found through active case detection 
in Kokap 1 area were classified as a malaria outbreak by local authorities as there had been no 
indigenous case reported in the area since 2016, with only 2 P. vivax relapsed cases reported in 
July 2017.   
 
Health-facility based serological surveillance 
Few microscopy positive infections were detected; 6/9356 (0.06%, 95% CI: 0.03-0.14) for P. vivax 
and no P. falciparum positive individuals were identified. All infections were found in Kokap 1 
health facility, with 5 infections detected in quarter 2 and 1 in quarter 4. Of these infections, 1 
was from a companion, and 5 were from patients not suspected of having malaria. Most of the 
infections were asymptomatic (66.7%) (i.e. afebrile). Seroprevalence to P. vivax antigens was 
higher than seroprevalence to P. falciparum antigens in all surveys (Table 5.2). As expected, the 
seroprevalence increased with age for both species and varied between health facilities and over 
time. The highest overall seroprevalence was found in quarter 2 (August to October 2017), 46.3% 
(95% CI: 44.2-48.3) and 23.9% (95% CI: 22.2-25.7) for P. vivax and P. falciparum, respectively 
with similar patterns observed according to proportion of higher than average age-adjusted 
antibody responses to multiple antigens (Figure 5.2).  
 
 
  
 
Table 5.2 Seroprevalence to P. vivax and P. falciparum at quarterly surveys 
 Quarter 1 
(May-July) 
Quarter 2 
(August-October) 
Quarter 3 
(November-January) 
Quarter 4  
(February-April) 
 Number 
positive 
Seroprevalence
% (95% CI) 
Number 
positive 
Seroprevalence 
% (95% CI) 
Number 
positive 
Seroprevalence 
% (95% CI) 
Number 
Positive 
Seroprevalence 
% (95% CI) 
P. vivax         
Age group         
1-15 years old 
>15 years old 
All ages 
44 
1014 
1058 
12.1 (8.0-17.8) 
41.0 (38.9-43.1) 
38.8 (36.8-40.8) 
24 
1000 
1024 
11.2 (7.6-16.2) 
50.1 (47.9-52.3) 
46.3 (44.2-48.3) 
26 
906 
932 
17.6 (12.2-24.6) 
41.6 (39.6-43.7) 
40.1 (38.2-42.1) 
9 
918 
927 
10.5 (5.5-18.9) 
41.8 (39.8-43.9) 
40.7 (38.7-42.7) 
         
P. falciparum         
Age group         
1-15 years old 
>15 years old 
All ages 
6 
405 
411 
3.4 (1.6-7.5) 
18.8 (17.3-20.6) 
17.7 (16.2-19.3) 
8 
521 
529 
3.7 (1.9-7.3) 
26.1 (24.2-28.1) 
23.9 (22.2-25.7) 
5 
489 
494 
3.4 (1.4-7.9) 
22.6 (20.9-24.4) 
21.4 (19.8-23.1) 
1 
504 
505 
1.2 (0.2-7.8) 
23.0 (21.3-24.8) 
22.1 (20.5-23.9) 
 
  
 
 
 
Figure 5.2 Proportion of level of age-adjusted antibody responses to multiple (a) P. vivax and (b) 
P. falciparum antigens by survey time. Blue represent proportion of individuals with the highest 
antibody below the 25th percentile, yellow 25th–75th percentile, orange 75th–90th percentile and 
red above 90th percentile. 
 
Transmission intensity and factor associated with transmission 
Based on the population-level SCR values, and consistent with microscopy and routine reporting 
data, the transmission intensity was higher for P. vivax than P. falciparum. The SCR model 
estimates (Figure 5.3) suggested that there was evidence for two forces of infection. The P. vivax 
SCR was 0.020 person-year (95% CI: 0.017–0.024) and 0.066 person-year (95% CI: 0.041–0.105) 
for ≤ 15 and over 15 years old, respectively. The P. falciparum SCR was 0.005 person-year (95% 
CI: 0.003–0.008) and 0.032 person-year (95% CI: 0.015–0.069) for ≤ 15 and over 15 years old, 
respectively. At health facility-level, P. vivax SCR model estimates (Figure 5.4) showed evidence 
for two forces of infection only in two health facilities where active cases were identified. 
However, number of samples were low in the youngest age groups which may have influenced 
the fitting and estimates. Multivariable analysis found, gender, occupation, time of survey and 
bed net use were significantly associated with being P. vivax seropositive, after controlling for 
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other covariates factors (Table 5.3). The odds of being seropositive was higher in males (aOR 1.3, 
95% CI: 1.2-1.5), forest goers (aOR 1.2, 95% CI: 1.0-1.3), those reporting sleeping under a bed 
net (aOR 1.2, 95% CI: 1.1-1.3) and during quarter 2 (aOR 1.5, 95% CI: 1.3-1.6). 
 
Table 5.3 Factors associated with P. vivax transmission in Kulon Progo District, Indonesia, 2018 
 
Variable 
Total P. vivax seropositive Bivariate Multivariable 
n (%) n % (95% CI) ORa (95% CI) p aORb (95% CI) p 
Age (years) 
≤15  
16-30 
31-45 
>45 
 
623 (6.8) 
2108 (23.1) 
2531 (27.7) 
3880 (42.4) 
 
80 
750 
1115 
1836 
 
12.9 (10.5-15.7) 
35.6 (33.6-37.6) 
44.1 (42.1-46.0) 
47.3 (45.8-48.9) 
 
1 
4.6 (3.6-5.9) 
6.5 (5.0-8.3) 
7.5 (5.9-9.7) 
 
 
0.000 
0.000 
0.000 
 
1 
5.1 (3.9-6.6) 
6.6 (5.1-8.7) 
7.7 (5.9-10.0) 
 
 
0.000 
0.000 
0.000 
Gender 
Female 
Male 
 
5945 (65.0) 
3206 (35.0) 
 
2309 
1476 
 
38.8 (37.6-40.1) 
46.0 (44.3-47.8) 
 
1 
1.3 (1.2-1.4) 
 
 
0.000 
 
1 
1.3 (1.2-1.5) 
 
 
0.000 
Status 
Accompanying 
Patients 
 
1960 (21.4) 
7191 (78.6) 
 
895 
2889 
 
45.7 (43.5-47.9) 
40.2 (39.0-41.3) 
 
1 
0.9 (0.8-1.0) 
 
 
0.028 
 
 
 
Occupation 
Non-forest goers 
Forest goers 
Unemployed 
 
2653 (29.0) 
2685 (29.4) 
3810 (41.6) 
 
1023 
1393 
1368 
 
38.6 (36.7-40.4) 
51.9 (50.0-53.8) 
35.9 (34.4-37.4) 
 
1 
1.6 (1.4-1.8) 
0.9 (0.8-1.0) 
 
 
0.000 
0.011 
 
1 
1.2 (1.0-1.3) 
1.0 (0.9-1.1) 
 
 
0.012 
0.446 
Survey time 
Quarter 1 
Quarter 2 
Quarter 3 
Quarter 4 
 
2324 (25.4) 
2217 (24.2) 
2328 (25.4) 
2283 (24.9) 
 
903 
1024 
930 
928 
 
38.9 (36.9-40.9) 
46.2 (44.1-48.3) 
40.0 (38.0-42.0) 
40.7 (38.6-42.7) 
 
1 
1.4 (1.2-1.5) 
1.1 (0.9-1.2) 
1.1 (1.0-1.2) 
 
 
0.000 
0.348 
0.196 
 
1 
1.5 (1.3-1.6) 
1.0 (0.9-1.2) 
1.0 (0.9-1.2) 
 
 
0.000 
0.524 
0.799 
Bed net use 
No 
Yes 
 
6650 (72.7) 
2502 (27.3) 
 
2556 
1229 
 
38.4 (37.3-39.6) 
49.1 (47.2-51.1) 
 
1 
1.2 (1.1-1.3) 
 
 
0.000 
 
1 
1.2 (1.1-1.3) 
 
 
0.001 
Fever 
No 
Yes 
 
8640 (94.9) 
465 (5.1) 
 
3604 
164 
 
41.7 (40.7-42.8) 
35.3 (31.1-39.7) 
 
1 
0.6 (0.5-0.8) 
 
 
0.000 
 
 
 
 
Recent travel 
No 
Yes 
 
7681 (84.1) 
1457 (15.9) 
 
3171 
609 
 
41.3 (39.3-44.4) 
41.8 (40.2-42.4)  
 
1 
0.9 (0.8-1.1) 
 
 
0.243 
  
 
a bivariate OR adjusted by correlation at health facility level 
b multivariable OR adjusted by other covariates with bivariate p value < 0.05, and correlation at health facility level  
Quarter 1: May-July 2017, Quarter 2: August-October 2017, Quarter 3: November 2017-January 2018, Quarter 4: 
February-April 2018 
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Figure 5.3 Age-seroprevalence plots for P. falciparum (a) and for P. vivax (b). Solid lines represent 
the fitted probability for being seropositive to either of the two or five antigens for P. falciparum 
and P. vivax, respectively. Dashed lines represent the 95% confidence interval of these fits and 
red triangles represent the observed proportion of seropositive per age decile. SCR value 
represent the average annual rate at which the population become seropositive to any of the P. 
falciparum or P. vivax antigen, respectively. 
 
Figure 5.4 P. vivax age-seroprevalence plots and total number of P. vivax microscopy infections 
per health facility. Solid lines represent the fitted probability for being seropositive to either of 
the five P. vivax antigens. Dashed lines represent the 95% confidence interval of these fits and 
red triangles represent the observed proportion of seropositive per age decile.  
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Heterogeneity of transmission 
Moran’s I suggested significant spatial autocorrelation for both species at each time point. The 
spatial analysis of higher than average age-adjusted antibody responses to multiple P. vivax 
antigens (Figure 5.5) identified the same village in the Kokap 1 catchment area prior to when the 
P. vivax outbreak occurred during the quarter 2 (outbreak started in early August 2017, in 
between the first and second survey). The analysis consistently identified significant clusters of 
P. vivax exposure in catchment areas of Kokap 1 and Kokap 2 in each survey. These catchments 
were areas where active infections were detected by the existing surveillance in quarter 1, 2 and 
3, with no cases in quarter 4. Significant clusters were also identified in Samigaluh 2 in quarter 2 
and 4, and in Girimulyo 2 in quarter 4. The same areas were also identified using P. falciparum 
antigens (Additional file 1). In addition, the spatial analysis suggest that the P. vivax clusters 
identified were also the place where the majority of fever cases were seen in quarter 2 when the 
outbreak occurred (Additional file 2). 
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Figure 5.5 Spatial distribution of age-adjusted antibody responses to multiple P. vivax antigens 
over time of surveys overlaid with P. vivax microscopy infections captured by the current 
surveillance systems. Black triangles represent P. vivax microscopy positive households. Black 
circle indicates a cluster of significantly higher than expected antibody responses detected using 
SaTScan (p value < 0.05).  
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5.5 Discussion 
The study found that analysing serological and spatial epidemiological data collected via health 
facilities in quarterly cross-sectional surveys was a useful supplement to passive data collection 
and could potentially be used to identify and target areas that remain receptive to malaria, and 
therefore at risk of outbreaks (Additional file 3, 4, 5 and 6). Consistent with the parasitological 
data, the population-level SCR estimates suggest very low level of transmission in the ≤ 15 years 
old population (current transmission). The SCR’s equate to 5 per 1000 and 20 per 1000 people 
seroconverting per year for P. falciparum and P. vivax, respectively. For comparison, the SCR’s 
in adults over 15 years old (historical transmission), were 32 per 1000 and 66 per 1000 people 
for P. falciparum and P. vivax, respectively. Moreover, spatial analysis of age adjusted antibody 
responses identified clusters of high antibody responders in areas which subsequently report P. 
vivax cases. These findings support the potential utility of serological tools to improve malaria 
surveillance in the absence of active cases, and their incorporation in malaria elimination 
programmes. Multivariable analysis suggests that surveillance could potentially prioritise 
targeting males and forest goers as they were the high-risk populations who might reintroduce 
infections to a community in the future. 
 
Although the accuracy of the mapping exercise varied within the 8 health facilities (353-817 
meters), the addition of a relatively simple tablet-based participatory mapping approach with a 
short questionnaire administered during facility attendees’ interviews allowed the collection of 
fine-scale spatial variation of malaria infections and exposure. If employed, this approach could 
iteratively improve spatial accuracy of public health mapping at the local level [30]. Integrating 
spatial data with age adjusted antibody responses to a panel of malaria antigens identified health 
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facility catchment areas with significantly higher antibody responses than the population 
average. These clusters of high antibody responses were detected in the same areas across all 4 
surveys for both species and were the location for a malaria outbreak during the study period.  
Importantly, the serological outcomes highlighted the area prior to the outbreak and had this 
area been subject to targeting with interventions or more in-depth surveillance, the outbreak 
may have been prevented.  Areas that were most recently receptive to transmission could be 
targeted with interventions as these are places that may be most susceptible to outbreaks and 
this strategy is likely to be more efficient than untargetted approaches to reduce transmission 
in low transmission settings [5].  Two other clusters in Girimulyo 2 and Samigaluh 2 were 
identified, suggesting that other  high-risk areas are located in the most forested areas of the 
region which also bordered with another malaria higher endemic setting with ongoing 
transmission [62].  
 
Whilst the microscopy data collected during the repeated surveys identified very few infections, 
and therefore could not be utilised to identify risk factors, the numbers of serological positives 
enabled the examination of risk factors for exposure to infection within the population. Our 
analysis found that people who were P. vivax seropositive were 3-fold more likely to be P. 
falciparum seropositive. As there was no cross-reactivity evident from the serological data, this 
suggests that the population have been exposed to infections with both species, although this 
exposure could have been historical. This implies that both species are transmitted in similar 
areas and that these places are, or were, particularly receptive to the transmission of malaria. 
Risk factor analysis for P. vivax seropositivity confirmed that people aged over 15 years old, 
males and forest-related activities were associated with higher exposure to malaria. These 
findings are consistent with findings from previous studies in the area suggesting that malaria 
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infection is expected to be less common among children compared to adults most likely due to 
a different level of behavioural risk (night outdoor activities and forest-related jobs such as 
loggers, coconut/palm tapper, fruit farmer, etc.) which leads to higher exposure among males 
and adults [7,10,31,35]. Interestingly, higher exposure was also associated with bed net use. The 
coverage and usage of bed nets was relatively low in this study setting and may be indicative of 
people living in higher risk areas being more likely to use a net, potentially due to the presence 
of more mosquitoes. The data suggest that people ≤ 15 years old were more likely to be sleeping 
under a bed net compared to adults over 15 years old. This finding may also suggest that bed 
net is no longer effective to prevent transmission in the studied population. Therefore, an 
alternative intervention such as targeted repellent distribution for adults or impregnated 
hammocks for forest workers could be useful to reduce transmission in the future. 
 
P. vivax seroprevalence was highest during the period of August to October. This overlaps with 
the expected high transmission season (August to December) and was also the period when 
people in the study were most likely to report recent travel. However, our analysis suggested 
that the clusters of high exposure identified in this study were not necessarily the place where 
recent travel from was reported. A possible explanation of these findings is that the transmission 
occurred after Ramadhan where people were more likely to return to their region after several 
days or weeks of traveling to areas of higher endemicity to gather and celebrate Eid day with 
their family. Previous studies indicated migration and high rates of imported cases from higher 
transmission areas as factors that linked to malaria resurgence and outbreaks in low 
transmission settings [10,13,31,63]. A study in Zanzibar estimated that residents travelling to 
other endemic settings contribute 1 to 15 times more imported cases than visitors, highlight the 
importance of strengthening surveillance to capture infection in travellers in countries nearing 
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elimination [64]. However, the investigation conducted by the surveillance program did not 
identify if there was a link between migration during or after Ramadhan with the outbreak 
occurred in the period. These findings suggest that surveillance needs to be intensified in periods 
with high population movement such as during and/or after Ramadhan and during fruit (i.e. 
durian) harvesting time which often coincides with the wet season in the region, to enable early 
detection and responses to prevent transmission in the future, particularly in receptive areas 
identified in the study.  
 
Our findings suggest that serological analysis can be used to estimate heterogeneity of P. 
falciparum and P. vivax transmission and predict high-risk areas from a single health facility-
based cross-sectional survey. This sampling approach could be a more efficient surveillance 
strategy as the serological sampling is performed (in addition to parasitological diagnosis) in well-
established health infrastructures therefore allowing rapid treatment and surveillance response 
if clinical cases are detected. On the other side, the repeated surveys might potentially be more 
useful in informing short-term changes in malaria exposure in other endemic settings where 
malaria transmission is still ongoing and more intense. 
 
Although the health facility surveys provide sufficient samples to estimate burden of infection 
and transmission level in the population, there were several limitations to be considered when 
implementing the methods. Firstly, we found that the facility survey approaches captured only 
a small proportion of children under 15 years of age compared to the general population. Whilst 
we have observed risk is significantly higher in adults and the underrepresentation of children 
may not be an issue for malaria in this setting, it could limit the approach for general disease 
surveillance. Routine data collected by the district health office surveillance suggest that this 
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could be due to the low proportion of children attending public health facilities in some areas 
where private health facilities may be easier to access. This phenomenon might not be the case 
in many other countries where often young children are the most common demographic to 
attend health facilities. Future studies in Indonesia could consider attendees to private health 
facilities as an easy access group to improve the facility-based sampling approach. In addition, 
surveys based in facilities are likely to miss asymptomatic infections, as well as those occurring 
in people who choose not to use public facilities. This is indicated by our finding suggesting that 
majority of cases (61%) were captured by the active case surveillance. Secondly, people living 
further from facilities may be less likely to attend health facilities resulting in the methods being 
less likely to detect clusters of high exposure further from facilities. However, it is conceivable 
that iterative refinements of the maps over time with clinical and demographic data would 
improve this. Inclusion of a mapping exercise in active surveillance performed by community 
health workers would be useful to capture heterogeneity in areas further from the facilities or 
those not seeking care. It may also help to identify if there are any spatial aspects to specific 
movement and behaviours. Recent travel was not significantly associated with increased 
seropositivity but being male and working in the forest were and whilst there was some evidence 
of spatial autocorrelation in the data, this was not accounted for in the regression modelling 
meaning estimates are likely to be over-precise. There are potential benefits to understanding 
the spatial context for risk behaviours which may be influenced by season for farming or 
harvesting and for traditional and religious holidays. The fourth limitation is in the analysis and 
interpretation of the serological data. Whilst outwardly the multiplex assay for serological 
screening is attractive in increasing the number of antigenic targets to both reduce the likelihood 
of missing individuals non-responsive to specific antigens and simultaneously screen for multiple 
species, the best analytical approaches in combining data are still relatively undeveloped and 
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validated. Using standard approaches based on seroprevalence, SCR and regression analysis has 
generated important observations but in future it will be important to combine these into more 
readily usable metrics and/or platforms such as serological lateral flow devices that offers more 
rapid test [65].  
 
5.6 Conclusion 
The health facility-based serological surveillance implemented and evaluated in this study 
provide an alternative approach for quickly obtaining parasitological, serological, geolocation 
and risk factor data. A single survey is efficient in supplementing the existing surveillance in very 
low endemic areas approaching zero cases, although the repeated surveys might be more useful 
in informing short-term changes in exposure in other higher endemic settings. Combining these 
methods with novel multiplex serological techniques could improve malaria surveillance 
capacity and result in a better understanding of transmission dynamics, in the absence of 
infection detected by standard diagnostic tools such as microscopy. Future work could expand 
the use of multiplex bead-based assays to include a panel of other species of Plasmodium 
antigens as well as to other available neglected tropical diseases (NTDs) antigens such as soil 
transmitted helminths, filariasis, etc. to similarly improve surveillance of these infections. How 
this approach is incorporated as a practical tool into programmes will requires significant 
technological and operational refinement [66] and financial assessment of the potential benefit. 
However, the argument for serological surveillance is particularly strong for P. vivax as there are 
no current diagnostics to detect latent hypnozoites and this is what the approach described in 
the manuscript hast detected. Finally, reliability of implementing these methods would need to 
be evaluated in other areas aimed at eliminating malaria. Future works will need to assess the 
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bottleneck of implementing these methods to allow further integration into existing surveillance 
systems. 
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5.8 Supplementary information 
 
 
Additional file 1. Spatial distribution of age-adjusted antibody responses to multiple P. 
falciparum antigens over time of surveys overlaid with P. vivax microscopy infections captured 
by the current surveillance systems. Black triangles represent P. vivax microscopy positive 
households. Black circle indicates a cluster of significantly higher than expected antibody 
responses detected using SaTScan (p value < 0.05). 
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Additional file 2. Maps showing cluster of significantly higher than expected antibody responses 
to multiple P. Vivax antigens over time of surveys overlaid with fever status and P. vivax 
microscopy infections captured by the current surveillance systems. 
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Additional file 3. Maps showing cluster of significantly higher than expected antibody responses 
to PvAMA-1 antigen over time of surveys overlaid with P. vivax microscopy infections captured 
by the current surveillance systems. 
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Additional file 4. Maps showing cluster of significantly higher than expected antibody responses 
to PvMSP-1-19 antigen over time of surveys overlaid with P. vivax microscopy infections captured 
by the current surveillance systems. 
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Additional file 5. Maps showing cluster of significantly higher than expected antibody responses 
to PfAMA1 antigen over time of surveys overlaid with P. vivax microscopy infections captured 
by the current surveillance systems. 
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Additional file 6. Maps showing cluster of significantly higher than expected antibody 
responses to PfMSP-1-19 antigen over time of surveys overlaid with P. vivax microscopy 
infections captured by the current surveillance systems 
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Additional file 7. Graphs showing summary of straight-line distance travelled by the health facility 
attendees (a) and population age distribution compared to the age distribution of those sampled in the 
health facility surveys (b). Data on age distribution of population of the studied areas i.e. Kokap, 
Samigaluh, Girimulyo, Kalibawang, and Pengasih districts were obtained from the 2016 population data 
published by the Central Agency on Statistics of Kulon Progo.   
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Additional file 8. Seropositive cut offs based on finite mixture model. Cut off was defined as the 
log MFI (median fluorescence intensity) plus three standard deviations of the seronegative 
component of each antigen. Broken red line represents the cut off. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Additional file 9. Seroprevalence to each antigen per survey 
Seroprevalence 
% (95% CI) 
n Q1 (May- 
July 2017) 
n Q2 (August- 
October 2017) 
n Q3 (November 2017-
January 2018) 
n Q4 (February- 
April 2018) 
PfAMA-1 
1-4 years old 
5-14 years old 
All ages 
 
0 
2 
135 
 
0 
1.56 (0.39-6.03) 
5.78 (4.91-6.81) 
 
0 
3 
434 
 
0 
 1.85 (0.60-5.59) 
19.58 (17.98-21.28) 
 
0 
3 
415 
 
0 
2.83 (0.92-8.41) 
17.90 (16.39-19.51) 
 
0 
0 
383 
 
0 
0 
16.75 (15.28-18.34) 
PfMSP-1-19 
1-4 years old 
5-14 years old 
All ages 
 
3 
1 
389 
 
10.71 (3.49-28.45) 
0.78 0.11-5.34) 
16.71 (15.25-18.28) 
 
1 
4 
319 
 
2.50 (0.35-15.74) 
2.47 (0.93-6.40) 
14.40 (13.00-15.93) 
 
0 
3 
299 
 
0 
2.83 (0.92-8.41) 
12.91 (11.60-14.34) 
 
0 
1 
340 
 
0 
1.85 (0.26-12.02) 
14.89 (13.48-16.41) 
PvAMA-1 
1-4 years old 
5-14 years old 
All ages 
 
2 
1 
532 
 
7.14 (1.79-24.49) 
0.79 (0.11-5.38) 
22.90 (21.24-24.66) 
 
0 
0 
538 
 
0 
0 
24.27 (22.53-26.10) 
 
0 
4 
542 
 
0 
3.77 (1.42-9.63) 
23.37 (21.69-25.13) 
 
0 
4 
506 
 
0 
7.55 (2.86-18.46) 
22.21 (20.55-23.96) 
PvMSP-1-19 
1-4 years old 
5-14 years old 
All ages 
 
1 
1 
429 
 
3.57 (0.50-21.44) 
0.78 (0.11-5.34) 
18.38 (16.86-20.00) 
 
0 
0 
271 
 
0 
0 
14.68 (13.14-16.37) 
 
0 
2 
280 
 
0 
1.89 (0.47-7.23) 
12.12 (10.85-13.52) 
 
0 
3 
345 
 
0 
5.77 (1.87-16.43) 
15.61 (14.16-17.19) 
PvEBP 
1-4 years old 
5-14 years old 
All ages 
 
2 
0 
133 
 
7.14 (1.79-24.49) 
0 
5.70 
 
1 
2 
151 
 
2.50 (0.35-15.74) 
1.23 (0.31-4.80) 
6.81 
 
0 
1 
146 
 
0 
0.94 (0.13-6.39) 
6.28 
 
0 
1 
129 
 
0 
1.85 (0.26-12.02) 
5.68 
PvRBP1a 
1-4 years old 
5-14 years old 
All ages 
 
0 
11 
373 
 
0 
8.59 (4.82-14.86) 
15.98 (14.55-17.52) 
 
2 
17 
516 
 
5.00 (1.25-17.92) 
10.49 (6.62-16.24) 
23.26 (21.55-25.07) 
 
2 
16 
378 
 
8.00 (2.01-26.96) 
15.09 (9.46-23.23) 
16.29 (14.85-17.85) 
 
2 
0 
372 
 
10.53 (2.64-33.76) 
0 
16.85 (15.35-18.46) 
PvRBP2b 
1-4 years old 
5-14 years old 
All ages 
 
0 
0 
22 
 
0 
0 
0.94 (0.62-1.43) 
 
1 
0 
383 
 
2.50 (0.35-15.74) 
0 
17.30 (15.78-18.93) 
 
0 
2 
387 
 
0 
1.89 (0.47-7.23) 
16.78(15.31-18.36) 
 
0 
0 
326 
 
0 
0 
14.37 (12.99-15.88) 
 
  
 
Additional file 10. Complete list of antigens tested in the study 
No Gene ID Acronym Description Location Reference 
1 PF3D7_0304600 CSP Most predominant and antigenic protein on sporozoite surface. 
Component of RTS, S vaccine 
Sporozoite (121) 
2 PF3D7_1301600 EBA140 RIII-V erythrocyte binding antigen 140; involved in invasion  Apical organelles, micronemes (122) 
3 PF3D7_0731500  EBA175RII_F2 erythrocyte binding antigen 175; RBC binding region via 
glycophorin A 
Apical tip (122) 
4 PF3D7_0423700 Etramp 4 antigen 2 Early transcribed membrane antigen. Integral PVM protein. C-
terminal 
iRBC, PVM (118) 
5 PF3D7_0532100 Etramp 5 Ag 1 Early transcribed membrane antigen. Integral PVM protein. iRBC, PVM (123) 
6 PF3D7_0402400 GEXP18 Gametocyte exported protein 18. Unknown function. iRBC/Gametocyte (118) 
7 PF3D7_1035300 GLURP R2 Glutamate rich protein R2 Merozoite Surface (124) 
8 PF3D7_0501100.1 HSP40 Ag 1 Heat shock protein 40 iRBC (118) 
9 PF3D7_0501100.1 HSP40 Ag 3 Heat shock protein 40 iRBC (118) 
10 PF3D7_0206800 MSP2 CH150/9 CH150/9 allele of Merozoite surface protein (MSP) 2. Full-length. Merozoite surface (125) 
11 PF3D7_0206800 MSP2 Dd2 Dd2 allele of MSP2. Full-length. Merozoite surface (126) 
12 PF3D7_1133400 AMA1 Apical membrane antigen 1 micronemes (127) 
13 PF3D7_0930300 MSP1-19 19kDa fragment of MSP1 molecule.  Merozoite surface (128) 
14 PF3D7_1021800 PfSEA-1 Schizont egress antigen. iRBC (129) 
15 PF3D7_0424100 Rh5 Receptor for human protein Basigin.  Apical tip (130),(131) 
16 PF3D7_0501300 SBP1 skeleton-binding protein; essential for translocation of PfEMP1 
to iRBS surface via Maurer's cleft. 
iRBC (132) 
17 PF3D7_1002000 Hyp2 Plasmodium exported protein iRBC / PVM (118) 
18 PF3D7_1036000 H103 Merozoite surface protein 11/H101/MSP3.7 Merozoite (133) 
19 PVX_092275 PvAMA1 Apical membrane antigen 1 micronemes (134) 
20 PVX_099980 PvMSP1-19 19kDa fragment of MSP molecule Merozoite (135) 
21 PVX_110810 PvDBP R2 Duffy binding protein region II Merozoite (136) 
22 PVX_110835 PvEBP Erythrocyte binding protein Merozoite (136,137) 
23 PVX_098585 PvRBP1a Reticulocyte binding protein amino acids 160–1170 Apical tip (138) 
24 PVX_094255 PvRBP2b Reticulocyte binding protein amino acids 161–1454 Apical tip (138) 
  
 
Unpublished data 
There were some unpublished data generated as part of the health facility-based serological 
surveillance study presented in this chapter. Some P. falciparum antigens associated with short-
lived antibody responses (Etramp5.Ag1, GexP18 and PfSEA-1) were included on the panel of 
antigens tested against the samples, in addition to the other P. falciparum and P. vivax antigens 
reported in the paper. The measurement of the P. falciparum short-lived responses was strongly 
relevant and important as P. falciparum infection was historically more dominant than P. vivax 
in the studied region. However, recently, there was a significant change in transmission where 
P. falciparum seem to be disappeared, and P. vivax infections are increasing. Unfortunately, we 
do not have defined P. vivax antigens that elicit short-term responses that can be included in the 
panel at the time of the study was conducted. In addition, the number of human P. knowlesi 
infections are increasingly reported in other parts of Indonesia i.e. Kalimantan and Sumatera 
Islands, and the presence of macaques and efficient vector of P. knowlesi in the studied region 
support the rationale of including P. knowlesi antigens on the panel. Therefore, we aimed at 
evaluating the use of these antigens for investigating recent P. falciparum exposure as well as to 
describe the possibility of P. knowlesi exposure in the region. 
 
Analysis of short-lived antibody responses to P. falciparum antigens illustrated some potential 
use for detecting malaria exposure in population. The seroprevalence data presented below 
showed there were individuals seropositive to each of these antigens. However, further analysis 
to assess the sensitivity and accuracy of the P. falciparum antigens could not be done due to the 
very low number of P. falciparum infection detected by microscopy in the study. Therefore, we 
could not make a clear interpretation of the seroprevalence to the P. falciparum short-lived 
antibody responses, although they have been reported as important serological markers to 
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detect recent exposure (i.e. can strongly predict infection in the last year). Based on this 
rationale, the results generated from these antigens were not included on the published paper 
and discussed separately. The sensitivity and accuracy of these antigens in predicting P. 
falciparum PCR positive infection was studied using a different dataset from a high transmission 
setting and is presented in the next chapter (Chapter 6). 
 
The presence of P. knowlesi seropositive individuals showed the possibility of P. knowlesi 
exposure in the studied region. However, absence of evidence on P. knowlesi cases both in 
human and macaque populations suggested further study is needed to confirm the presence of 
P. knowlesi transmission in Kulon Progo.  Potential future work is to perform molecular assays 
using blood spot samples collected in this study to validate initial results generated from the 
serological assay. Further investigation for risk factors and spatial distribution of P. knowlesi 
antibody responses will be conducted and discussed separately from this thesis. 
Seropositivity cut-offs 
 
 
Additional file 8. Seropositive cut-offs for P. falciparum antigens (top row) and for P. knowlesi 
(bottom row) based on finite mixture model. Cut off was defined as the log MFI (median 
fluorescence intensity) plus three standard deviations of the seronegative component of each 
antigen. Broken red line represents the cut off. 
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6.1 Abstract 
Background 
Measurement of malaria species-specific antibody responses can potentially inform the 
assessment of transmission intensity, by quantifying recent exposure to infection. This study 
aimed to evaluate the use of multiple serological markers to estimate transmission levels 
and assess the association between serological markers with Plasmodium infections in a high 
transmission setting.  
Methods 
Demographical data, peripheral blood smears and capillary blood samples were collected 
during a community-based cross-sectional survey conducted in Mimika District, southern 
Papua, Indonesia, in 2013. Slide microscopy and polymerase chain reaction (PCR) were 
performed to estimate parasite prevalence and identify sub-patent infections. Antibody 
responses to apical membrane antigen 1 (PfAMA1; PvAMA-1), merozoite surface protein 1 
(PfMSP-1-19; PvMSP-1-19), merozoite surface protein 2 (MSP2.Ch150), duffy binding protein 
region 2 (PvDBPR2), erythrocyte binding protein (PvEBP), reticulocyte binding protein 1 
[amino acids 160–1170] (PvRBP1a), early transcribed membrane antigen 5 Antigen 1 
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(Etramp5.Ag1), gametocyte exported protein 18 (GexP18), and schizont egress antigen 1 
(PfSEA-1) were measured using a bead-based assay.  Receiver operating characteristic (ROC) 
analysis was used to quantify the sensitivity and specificity of each P. falciparum and P. vivax 
antigens in predicting concurrent infection. Seroconversion rates (SCR) were estimated by 
fitting a simple reversible catalytic model to seroprevalence data. 
 
Results 
A total of 2496 patients from 747 households provided samples. The overall parasite 
prevalence by microscopy and PCR was 17% (411/2496) for P. falciparum, 20% (489/2496) 
for P. vivax. The majority of infections were sub-patent with only 38% (154/411) of P. 
falciparum and 31% (149/489) of P. vivax parasitaemic individuals detected by microscopy. 
65% of P. falciparum PCR positive children aged 1-5 years old were also seropositive to 
Etramp5.Ag1 antigen, with 76% prediction accuracy. The SCR to the most immunogenic 
antigen (PfMSP-1-19 and PvEBP) was 0.156 person-year (95% Confidence Interval: 0.138-
0.177) for P. falciparum and 0.141 person-year (95% Confidence Interval: 0.124-0.159) for P. 
vivax.  
Conclusion 
This study highlights the potential of serological responses to multiple P. falciparum and P. 
vivax antigens to estimate transmission intensity and predict parasite prevalence in children 
in high transmission areas.  
Key words: serology, surveillance, transmission, malaria, P. falciparum, P. vivax 
 
6.2 Introduction 
Microscopic examination of peripheral blood smears remains the gold standard diagnosis of 
malaria [1], with parasite prevalence used to estimate malaria transmission intensity in 
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endemic areas [2]. However, the derived estimates can be highly variable [3-5], dependent 
upon the skill of the microscopist or prevalence of malaria. Furthermore, microscopy can 
miss a high proportion of infections due to fluctuating parasite densities [6]. Sub-microscopic 
low-level parasitaemia, are not detected in clinical settings by standard diagnostic 
algorithms, and if left untreated these can result in subsequent clinical infection, severe 
malaria, and ongoing transmission of the parasite [7-9].  
 
Although Rapid Diagnostic Tests (RDTs) are widely available and often used to diagnose 
malaria, the latest WHO malaria RDTs evaluation highlight that many RDTs result in poor 
specificity and sensitivity, especially when parasite densities are below 200 parasites/μl of 
blood [10]. RDTs are also significantly less accurate for diagnosing P. vivax infections 
compared to P. falciparum. Whilst molecular methods such as polymerase chain reaction 
(PCR) are highly sensitive [9,11] and can detect up to 50% more infections than microscopy 
[3,12], its application in the field is limited by high cost, time to process and the laboratory 
equipment and skills needed to perform the test [4]. 
 
Serology is an alternative approach to estimate malaria transmission. Utilising species-
specific malaria antibodies as a proxy of infection can facilitate quantifying disease burden. 
The seroconversion rate (SCR) is used to define the annual rate at which individuals become 
seropositive [13-15]. Although the presence of long-lived antibodies such as P. falciparum 
and P. vivax apical membrane antigen 1 (PfAMA1 and PvAMA-1) and P. falciparum merozoite 
surface protein 1 (PfMSP-1-19) reflect cumulative exposure over time [13], seropositivity to 
any of these antigens in younger children are more likely to be an indicator of recent 
infection in the population [16,17]. Furthermore, several newly identified P. falciparum 
antigens such as Early transcribed membrane protein 5 (Etramp5) and gametocyte exported 
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protein 18 (GexP18) appear to elicit short-term antibodies and are therefore ideal for 
indicating recent infections [18]. 
 
Advances in the development of multiplex serological assays and novel informative 
antibodies have generated renewed interest in the use of serological to guide clinical practice 
and public health interventions. In this study we evaluated the use of P. falciparum and P. 
vivax serological markers in addition to microscopy and PCR data to estimate the level of 
transmission intensity and assessed the association between seropositivity and infection in 
a high transmission setting in Indonesia. 
 
6.3 Methods 
Study site 
This study was conducted in five sub-districts with ongoing malaria transmission in Mimika 
District (21,522 km2), the southern part of Papua Province, Eastern Indonesia (Fig. 1). The 
district had a population of approximately 196,401 in 2013, with the majority of the 
population (65%) living in Mimika Baru Sub-District [19]. The district is heavily forested [20], 
has a high humidity (average of 87%), with peak rainfall occurring between July and 
December [19]. There is significant economic migration due to the presence of a local mine 
resulting in the diverse ethnic origin of the population i.e. low lander Papuan, high lander 
migrant Papuan and Non-Papuan migrants living in the region [21]. Malaria transmission is 
restricted to the lowland areas, with three mosquito vectors: Anopheles koliensis, An. farauti, 
and An. punctulatus [22]. Despite extensive ongoing malaria control efforts, this region 
remains one of the highest malaria burdens in Indonesia, with an incidence rate of 249 per 
1000 person-years for P. falciparum and 239 per 1000 person-years for P. vivax [23].   
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Figure 6.1 Maps showing a) location of Papua Province in Indonesia b) location of Mimika 
District in Papua Province, and c) geographical distribution of sampled households in Mimika 
District. 
 
Study design and data collection 
Community-based cross-sectional surveys were conducted between April to July 2013. 
Household lists were obtained from local authorities and were arbitrarily assigned numbers 
according to their geographic location. Households were proportionally selected to 
represent each of the five sub-districts studied. Households were then randomly selected 
and invited to participate in the study. Households with no adult present were excluded from 
the survey and were replaced by neighbouring households. Individual written informed 
consent was obtained from all adults or guardians of the household members under 18 years 
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of age. Data on age, gender, ethnicity, history of fever in the last 30 days, bed net use, body 
mass index (BMI) to assess nutritional status, and pregnancy status among women aged over 
14 years old were recorded using a short paper questionnaire. Samples were collected from 
all household members present if aged six months or older. Standard microscopy blood 
smears were collected as per routine national diagnostic standards. A 500 µl capillary blood 
sample was collected into a coded Microtainer® containing lithium heparin and fractionated 
then stored at -20oC at the laboratory at the Timika Research Unit, Papua. Household GPS 
coordinates were collected using handheld GPS, and shapefiles were obtained from the 
global administrative areas (GADM; https://gadm.org/), and the tree cover data derived 
from classified Landsat imagery at the 30-m resolution, were obtained from Hansen et al. 
[20]. 
 
Laboratory methods 
Parasite species was assessed from Giemsa-stained thick blood films. All positive films and 
10% of the negative slides were cross-checked by a second microscopist at the Eijkman 
Institute for Molecular Biology (EIMB) in Jakarta and discrepancies reviewed by two expert 
microscopists for final assessment. PCR testing was performed by trained staff at EIMB, as 
described previously in Pava et al. [24]. Individuals were categorised as P. falciparum and P. 
vivax malaria infections if the malaria parasite was detected by either microscopy and or 
PCR. Serum samples were transported to the Parasitology Laboratory at the Department of 
Parasitology, UGM, Yogyakarta for serological testing using Luminex MAGPIX© (Luminex 
Corp, Austin, TX). A panel of P. falciparum and P. vivax antigens were assessed including 
apical membrane antigen 1 (PfAMA1; PvAMA-1), merozoite surface protein 1 (PfMSP-1-19; 
PvMSP-1-19), merozoite surface protein 2 (MSP2.Ch150) duffy binding protein region 2 
(PvDBPR2), erythrocyte binding protein (PvEBP), reticulocyte binding protein 1 [amino acids 
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160–1170] (PvRBP1a), early transcribed membrane antigen 5 Antigen 1 (Etramp5.Ag1), 
gametocyte exported protein 18 (GexP18) and schizont egress antigen 1 (PfSEA-1) using a 
bead-based assay as described by Wu et al. [25] and read. To reduce confounding by the 
presence of maternally derived antibodies, results from infants under one year of age were 
excluded from the analysis [13]. MFI (median fluorescence intensity) values of samples were 
normalised against the MFI values of the positive control run on each plate, as described by 
Wu et al. [25]. 
 
Statistical analysis 
All statistical analyses were conducted in Stata IC 15 (Stata Corp, College Station, TX, USA). 
Parasite prevalence was defined as the proportion of infections detected by PCR in the 
sampled population. A cut off for seropositivity was defined as the mean MFI values plus 
three standard deviation of the seronegative population. Separate cut-off values were 
generated to determine seropositivity for each of the P. falciparum and P. vivax antigens 
tested [17]. Seroconversion rates (SCR) were estimated by fitting a reverse catalytic model 
to seroprevalence data for each antigen [13], except for three antigens associated with 
recent exposure (Etramp5.Ag1, GexP18, and PfSEA-1). Models allowing two forces of 
infection in SCR were fitted if deemed a better fit, using likelihood ratio methods. Receiver 
operating characteristic (ROC) analysis was performed to determine the sensitivity, 
specificity, and accuracy of serological markers in predicting PCR positive in comparison with 
microscopy. 
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6.4 Results 
Study population 
Table 6.1 Characteristics of sampled population and PCR positivity 
Variables (n=2496) N % 
P. falciparum P. vivax 
n % (95% CI) n % (95% CI) 
Age 
< 5 
5-15 
> 15 
 
426 
638 
1432 
 
17.1 
25.6 
57.4 
 
34 
123 
254 
 
8.0 (5.8-11.0) 
19.3 (16.4-22.5) 
17.7 (15.8-19.8) 
 
68 
160 
261 
 
16.0 (12.8-19.8) 
25.1 (21.9-28.6) 
18.2 (16.3-20.3) 
Gender 
Male 
Female 
 
1011 
1485 
 
40.5 
59.5 
 
178 
233 
 
17.6 (15.4-20.1) 
15.7 (13.9-17.6) 
 
198 
291 
 
19.6 (17.3-22.1) 
19.6 (17.7-21.7) 
Ethnic 
Non-Papuan 
Papuan 
 
1434 
1062 
 
57.5 
42.5 
 
141 
270 
 
9.8 (8.4-11.5) 
25.4 (22.9-28.1) 
 
244 
245 
 
17.0 (15.2-19.1) 
23.1 (20.6-25.7) 
Sub districts 
Mimika Baru 
Wania 
Iwaka 
Kuala Kencana 
Kwamki Narama 
 
1345 
487 
426 
162 
76 
 
53.9 
19.5 
17.1 
6.5 
3.0 
 
154 
84 
107 
47 
19 
 
11.4 (9.9-13.3) 
17.2 (14.1-20.9) 
25.1 (21.2-29.5) 
29.0 (22.5-36.5) 
25.0 (16.5-35.9) 
 
270 
99 
85 
25 
10 
 
20.1 (18.0-22.3) 
20.3 (17.0-24.1) 
20.0 (16.4-24.0) 
15.4 (10.6-21.8) 
13.2 (7.2-22.8) 
Bed net use 
No 
Yes 
 
1625 
871 
 
65.1 
34.9 
 
258 
153 
 
15.9 (14.2-17.7) 
17.6 (15.2-20.2) 
 
329 
160 
 
20.2 (18.4-22.3) 
18.4 (15.9-21.1) 
Pregnant 
No 
Yes 
 
758 
203 
 
78.9 
21.1 
 
121 
31 
 
16.0 (13.5-18.7) 
15.3 (10.9-20.9) 
 
139 
41 
 
18.3 (15.7-21.3) 
20.2 (15.2-26.3) 
Fever in last 1 month 
No 
Yes 
 
2398 
98 
 
96.1 
3.9 
 
388 
23 
 
16.2 (14.8-17.7) 
23.5 (16.1-32.9) 
 
475 
14 
 
19.8 (18.3-21.5) 
14.3 (8.6-22.7) 
Nutritional status 
Normal 
Malnutrition 
Severe malnutrition 
 
2363 
100 
33 
 
94.7 
4.0 
1.3 
 
397 
12 
2 
 
16.8 (15.3-18.4) 
12.0 (6.9-20.0) 
6.1 (1.5-21.2) 
 
466 
14 
9 
 
19.7 (18.2-21.4) 
14.0 (8.5-22.3) 
27.3 (14.8-44.7) 
 
In total, 2496 individuals from 747 households were included in the survey and provided 
blood samples. The general characteristics of these individuals are presented in Table 1. The 
mean number of people sampled per household was 3. The median age of participants was 
21 years old (IQR: 7-35), and 60% (1485/2496) of individuals were female. The majority of 
the individuals came from Mimika Baru Sub-District (54%). The proportion of people 
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reporting having slept under a bed net the previous night was 35% (871/2496). Only 4% 
(98/2496) of the population reported experiencing fever in the previous month. Based on 
BMI assessment, 4% (100/2496) were malnourished, and 1% (33/2496) severely 
malnourished. There was a total of 203 pregnant women, representing 21% (203/961) of 
females over 14 years old. 
 
Parasite prevalence by PCR 
The overall PCR-based parasite prevalence was 16.5% (411/2496) for P. falciparum, 20% 
(489/2496) for P. vivax and only 2% (60/2496) for mix infections. The P. vivax prevalence was 
higher than that for P. falciparum, and this was apparent across all age groups (Table 6.1). 
The prevalence was higher in children under 15 years old than adults for both P. falciparum 
and P. vivax. The prevalence varied between sub-district, with the highest P. falciparum 
prevalence detected in Kuala Kencana (29%), and P. vivax prevalence of 20% in three sub-
districts (Mimika Baru, Wania and Iwaka). 
 
Performance of microscopy and serological assay 
Overall, only 37.5% (154/411) of P. falciparum and 30.5% (149/489) of P. vivax PCR positive 
individuals were detected by microscopy. The sensitivity and accuracy of diagnosis 
significantly decreased by age, with consistent 100% specificity for both P. falciparum and P. 
vivax in all ages. For P. falciparum, the sensitivity of microscopy test was 59% (ROC area 80% 
(95% CI: 71-89)) in 1-5 years old, 45% (ROC area 72% (95% CI: 68-77)) in 5-15 years old and 
31% (ROC area 66% (95% CI: 63-68)) in over 15 years old. For P. vivax, the sensitivity was 60% 
(ROC area 80% (95% CI:74-86) in 1-5 years old, 33% (ROC area 66% (95% CI:63-70)) in 5-15 
years old and 22% (ROC area 61% (95% CI:58-63) in over 15 years old. 
 
  
182 
 
The sensitivity, specificity, and ROC area of seropositivity to each antigen for identifying P. 
falciparum and P. vivax PCR positive individuals are presented in Table 6.2. The age-adjusted 
ROC estimates revealed that seropositivity to Etramp5.Ag1 and PvEBP were the best 
predictor for P. falciparum and P. vivax PCR positivity, respectively. Whilst the sensitivity 
increased by age, the specificity and ROC area decreased by age for both P. falciparum and 
P. vivax, likely a reflection of cumulative exposure. The ROC area for Etramp5.Ag1 was 76% 
(sensitivity 65% and specificity 88%) in 1-5 years old, 72% (sensitivity 67% and specificity 
77%) in 5-15 years old, and 64% (sensitivity 68% and specificity 60%) in over 15 years old 
population. The ROC area for PvEBP was 69% in 1-5 years old, 64% in 5-15 years old, and 51% 
in over 15 years old population.
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Table 6.2 Sensitivity (Sn), specificity (Sp) and receiver operating characteristics (ROC) area estimates of each antigen in predicting P. falciparum and P. 
vivax PCR positive 
 1-5 years old 5-15 years old > 15 years old 
Sn (95% CI) Sp (95% CI) ROC (95% CI) Sn (95% CI) Sp (95% CI) ROC (95% CI) Sn (95% CI) Sp (95% CI) ROC (95% CI) 
P. falciparum 
long-lived 
         
PfMSP-1-19 79% (62-91) 69% (64-73) 74% (67-81) 91% (85-96) 43% (38-47) 67% (64-70) 97% (93-98) 19% (16-21) 58% (56-59) 
PfAMA1 65% (47-80) 79% (75-83) 72% (64-80) 88% (81-93) 56% (52-61) 72% (68-76) 93% (89-95) 24% (22-27) 58% (56-61) 
MSP2.Ch150 47% (30-65) 86% (82-89) 66% (58-75) 59% (50-68) 81% (77-84) 70% (65-75) 70% (64-75) 49% (46-52) 59% (56-63) 
P. falciparum 
short-lived 
         
Etramp5.Ag1 65% (47-80) 88% (84-91) 76% (68-85) 67% (58-75) 77% (73-81) 72% (67-76) 68% (62-73) 60% (57-63) 64% (61-67) 
PfSEA-1 47% (30-65) 89% (86-92) 68% (60-77) 50% (41-59) 78% (75-82) 64% (59-69) 65% (59-71) 59% (56-62) 62% (59-65) 
GexP18 59% (41-75) 75% (70-79) 67% (58-76) 62% (52-70) 77% (74-81) 70% (65-74) 58% (52-64) 67% (64-69) 62% (59-66) 
P. vivax           
PvEBP 68% (55-79) 69% (64-74) 69% (62-75) 82% (75-88) 46% (42-51) 64% (60-68) 86% (81-90) 15% (13-17) 51% (48-53 
PvAMA1 60% (47-72) 74% (69-78) 67% (60-73) 62% (54-69) 55% (51-60) 58% (54-63) 80% (75-85) 23% (21-26) 52% (49-54) 
PvMSP-1-19 60% (48-72) 73% (68-78) 67% (60-73) 61% (53-68) 61% (56-65) 61% (56-65) 65% (59-71) 37% (35-40) 51% (48-54) 
PvDBPR2 40% (28-52) 84% (80-88) 62% (56-68) 41% (34-49) 70% (66-74) 56% (51-60) 47% (41-53) 51% (48-54) 49% (46-52) 
PvRBP1a 28% (17-40) 86% (81-89) 57% (51-62) 29% (22-37) 79% (75-83) 54% (50-58) 35% (29-41) 58% (55-61) 47% (43-50) 
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Seroprevalence and seroconversion rate estimates 
The median antibody responses to multiple P. falciparum and P. vivax antigens increased 
with age (Figure 6.2). The overall seroprevalence to P. falciparum long-lived antibody 
responses was 71% (1756/2485), 63% (1561/2489), and 41% (1019/2491) for PfMSP-1-19, 
PfAMA1, and MSP2.Ch150, respectively (Table 6.2). Seroprevalence to P. falciparum short-
lived antibody responses was 37% (917/2496), 36% (876/2488), and 34% (851/2493) for 
Etramp5.Ag1, PfSEA-1, and GexP18, respectively. For P. vivax, the seroprevalence was 71% 
(1762/2496), 63% (2554/2486), 53% (1326/2495), 40% (983/2496), and 32% (797/2492) to 
PvEBP, PvAMA1, PvMSP-1-19, PvDBPR2, and PvRBP1a, respectively. 
 
 
Figure 6.2 Parasite prevalence and antibody responses over age. a-b) P. falciparum and P. 
vivax parasite prevalence over age. c-d) Antibody responses to each of P. falciparum and P. 
vivax antigens over age. Etramp5.Ag1, GexP18 and PfSEA-1 are antigens associated with P. 
falciparum short-lived antibody responses. 
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The population-level SCR estimate for each of P. falciparum and P. vivax long-lived antibody 
responses suggested there was no evidence of historical changes in transmission intensity 
for either P. falciparum or P. vivax (Figure 6.3). The highest P. falciparum SCR was obtained 
from responses to PfMSP-1-19, with SCR 0.156 person-year (95% CI: 0.138-0.177). Whilst for 
P. vivax, the highest estimate was obtained from responses to PvEBP, with SCR 0.141 person-
year (95% CI: 0.124-0.159).  
 
 
 
Figure 6.3 Age-seroprevalence plots for each of P. falciparum antigens (a-c) and P. vivax 
antigens (d-h) in Mimika, 2013. Solid lines represent the fitted probability for being 
seropositive to each of the antigens. Dashed lines represent the 95% confidence interval of 
these fits, and red triangles represent the observed proportion of seropositive per age decile. 
SCR value represents the average annual rate at which the population become seropositive 
to each of the P. falciparum or P. vivax antigen.  
 
  
 
6.5 Discussion 
This study presents an epidemiological analysis of parasitological and serological data from 
a community-based cross-sectional study in southern Papua in eastern Indonesia. The 
findings highlight the potential use of short-lived antibody responses to diagnose individuals 
with P. falciparum parasitaemia, including those with very low-density infections. The ROC 
estimates suggest that the prediction was better in children compared to adults over 15 
years old as the specificity in adults decreased due to cumulative exposure to infection and 
the half-life of antibodies produced to previous infections. In addition, the analysis of P. 
falciparum and P. vivax long-lived antibody responses revealed that PfMSP-1-19 and PvEBP 
were the most immunogenic antigens enabling the utility of these antigens to measure 
transmission intensity in this high transmission setting.  
 
Seropositivity to each of the P. falciparum short-lived antibody responses (Etramp5.Ag1, 
GexP18 and PfSEA-1) had greater sensitivity for detecting any peripheral parasitaemia 
compared to microscopy alone. Whereas microscopy only detected 59% of PCR positive P. 
falciparum infection in children 1-5 years, the sensitivity of Etramp5.Ag1 in the same age 
group was 65%. Although the specificity of Etramp5.Ag1 was lower than microscopy (88% vs 
100%), the ROC area was only slightly lower than microscopy (80% vs 76%). Whilst a fairly 
good performance also seen in children 5-15 years old (ROC area 72%), the seropositivity to 
Etramp5.Ag1 was less useful for predicting PCR infection in adults (ROC 64%). In a previous 
cohort study, P. falciparum antibody responses to short-lived antigens such as Etramp5.Ag1 
and GexP18 predicted an individual’s incidence in the preceding year in Ugandan children 
[18]. Our findings support a previous study in Kenya in which multiple P. falciparum antigens 
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were used as a proxy of recent transmission [26] and further highlighted the important 
application of serology for malaria surveillance [27]. 
 
Although seropositivity to the most immunogenic P. vivax antigen (PvEBP) had greater 
sensitivity for detecting any peripheral parasitaemia compared to microscopy alone, the 
specificity of this antigen was very low (69%, 46% and 15% in 1-5 years old, 5-15, and over 
15 years old, respectively), thus is not suitable for predicting P. vivax recent exposure. Our 
study did not include antigens associated with P. vivax short-lived antibodies. However, 
suitable candidates were recently reported [28], and thus, future work should evaluate these 
in P. vivax endemic settings. 
 
The SCR estimates generated from seropositivity to the most immunogenic P. falciparum and 
P. vivax long-lived antibody responses (PfMSP-1-19 and PvEBP) revealed a higher transmission 
intensity for P. falciparum than P. vivax. Closer examination of the SCRs estimates suggested 
no step-change in transmission intensity, with population-level SCRs equating to 
approximately 156 per 1000 people seroconverting per year for P. falciparum and 141 per 
1000 people for P. vivax. These serological estimates are consistent with previous findings 
reporting higher incidence rate for P. falciparum than P. vivax (249 per 1000 person-years 
for P. falciparum and 239 per 1000 person-years for P. vivax) [23], supporting a growing body 
of evidence that serological analysis can be used to determine population-level transmission 
intensity in a wide range of endemic settings [29-33].  
 
In young children under five years old, the prevalence of P. vivax prevalence was twice as 
high as that of P. falciparum (16% vs 8%), as has been shown in previous cohort studies in 
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areas co-endemic to both species [34-36]. The SCR estimates revealed that seropositivity to 
both P. falciparum and P. vivax was higher in older children and adults compared to young 
children. These findings likely reflect the cumulative exposure in the adult population. 
However, this could also reflect a higher risk of malaria in the adult population, due to 
different behavioural activities such as forest-related jobs and night outdoor activities. These 
behavioural risks were previously reported in western Indonesia [31,37], Cambodia [38], and 
other places in Asia such as Malaysia, Bhutan, Philippines and Sri Lanka [39]. However, 
interpretation of these data is limited by the lack of information regarding the travel history 
and occupational risk that might explain the aged related differences. Whilst our study was 
conducted in the forested area, future studies will need to explore association behaviour and 
migration risks and how these relate to peripheral parasitaemia and seropositivity. 
 
6.6 Conclusion 
The serological analysis confirmed a high level of P. falciparum and P. vivax transmission 
intensity in Papua, Indonesia. Although seropositivity to Etramp5.Ag1 was a sensitive and 
specific predictor of concurrent P. falciparum PCR positivity in children, its utility was less 
useful in adults. Our study highlights the potential role of analysing multiple antigens to 
explore malaria epidemiology that can inform public health surveillance and programme 
evaluation in high transmission areas. However, analysis is ongoing to explore the best way 
to evaluate the use of serological data available in the present dataset. Future cohort studies 
evaluating P. falciparum and P. vivax antigens associated with short-lived antibodies to 
diagnose concurrent low-level parasitaemia are needed in different endemic settings so that 
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these hidden reservoirs of infection and ongoing transmission can be identified and 
eliminated. 
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7. General discussion 
7.1 Main research findings 
This thesis brings together the application of serological methods in areas of differing 
endemicities and highlights the potential use of serological markers to identify receptive areas 
in low transmission settings (Chapter 3 and 5), the continued utility of seroprevalence and 
seroconversion rate as a metric to estimate transmission for both P. falciparum and P. vivax 
(Chapter 3, 5 and 6) and starts to evaluate the use of antigens that elicit short-term antibodies 
as a proxy for diagnosis (Chapter 6). This thesis also describes the potential application of a 
mobile technology-based participatory mapping as an alternative geolocation approach for 
research and public health surveillance purposes (Chapter 4) and use of health facility-based 
surveys recruiting both patients and accompanying people as an alternative sampling strategy 
to increase passive surveillance coverage (Chapter 5).  
 
Potential markers for serological surveillance 
PfAMA1 and PvAMA-1 were identified as the most immunogenic antigens for P. falciparum and 
P. vivax in low transmission settings (Sabang and Kulon Progo). Importantly, although the spatial 
analysis of serological data did not add useful information in a high transmissions setting due to 
uniform risk of transmission in the population (Chapter 6), the spatial analysis of age-adjusted 
antibody responses to PfAMA1, PfMSP-1-19, PvAMA-1 and PvMSP-1-19 were sensitive and useful 
to identify areas at risk for malaria outbreak in very low transmission setting (Chapter 3 & 5). 
Interestingly, in the area where there was no active cases recorded in three consecutive years, 
the spatial analysis of age-adjusted antibody responses to PvMSP-1-19 revealed the high-risk 
areas that subsequently became areas of P. knowlesi outbreak in the following year after the 
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area certified as malaria-free (12), most likely because of cross-reactivity between the PvMSP-1-
19 and several P. knowlesi antigens as recently found by Herman et al. in a study in Malaysia 
(194). 
 
In the high transmission setting, Mimika, the seropositivity to the most immunogenic P. 
falciparum antigen that reflect short-term exposure (Etramp5.Ag1) was sensitive and specific in 
predicting P. falciparum PCR positive infections in children but was not useful in over 15 years 
old population. This finding suggests the potential use of Etramp5.Ag1 as a marker of recent 
exposure in children, which is important for surveillance and programme evaluation in 
elimination settings. For example, this antigen can be used to screen under 15 years old 
population as a proxy to better target area of intervention. Furthermore, PfMSP-1-19 and PvEBP 
were identified as the most immunogenic antigens, enabling good estimate of SCRs for P. 
falciparum and P. vivax in this setting. This can mean that assessment of transmission intensity 
in a high transmission setting might be better done by testing samples against these two antigens 
using ELISA instead of multiplexing using the bead-based assay. 
 
The relationship between serological and parasitological measures is presented in Figure 7.2. In 
a high transmission setting, Mimika, seroprevalence data show a poor relationship with the 
parasite prevalence data for both P. falciparum and P. vivax. This suggests that seroprevalence 
is less useful in high transmission settings, as parasite prevalence measures would be expected 
to remain sensitive. It has been known that serological measures are most useful in low 
transmission areas where conventional measures such as EIR and PR are insensitive. In low 
transmission settings where the parasite prevalence was very low (0.06% in Kulon Progo) and 
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zero (Sabang), serological measures were able to detect seropositive individuals, allowing 
identification of areas and population at risk of malaria exposure. 
 
 
Figure 7.1 Relationship between a) P. falciparum parasite prevalence and seroprevalence, b) P. 
vivax parasite prevalence and seroprevalence. 
For Mimika, seroprevalence was based on seropositivity to antigen associated with recent 
exposure (Etramp5.Ag1) for P. falciparum and to the most immunogenic long-lived antigen 
(PvEBP) for P. vivax. For Kulon Progo and Sabang, seroprevalence was based on seropositivity to 
the most immunogenic antigens i.e. PfAMA1 for P. falciparum and PvAMA-1 for P. vivax. 
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Heterogeneity and risk factors of transmission 
This thesis provided evidence on the use of serological surveillance to better understand 
transmission dynamics in three different endemic settings where P. falciparum and P. vivax are 
co-endemic. Population-level SCRs estimates obtained from three different studies (Chapter 3, 
5 and 6) highlights the heterogeneity of P. falciparum and P. vivax transmission in Indonesia 
(Figure 7.2). As expected, the SCRs estimates can clearly differentiate transmission level in the 
three study sites. The estimates also consistent with previous studies suggesting that the risk of 
exposure to both P. falciparum and P. vivax was higher in adults than children, especially in low 
transmission settings, most likely due to different behavioural activities such as forest-related 
jobs and night outdoor activities. 
 
While the malaria risk is spatially homogeneous in the high transmission setting, the spatial 
analysis of antibody responses conducted in elimination settings (Chapter 3 and 5) suggest the 
spatial heterogeneity of malaria risk, with clusters of high exposure to P. falciparum and P. vivax 
identified in forested places. Moreover, the multivariable analysis also reveals that higher 
exposure to malaria was associated with bed net use in the districts nearing elimination but not 
in the district with high transmission. Although this finding can suggest a good bed net coverage 
in areas with high exposure to malaria, this can also mean that bed net use may no longer 
effective to prevent malaria transmission in low transmission setting where majority of the 
remaining cases are related to outdoor exposure such as when working at forest or sleeping in 
farm or plantation. This explanation is also supported by previous studies suggesting malaria 
vectors in Indonesia were more likely to rest and bite outdoor (166). These findings suggest the 
importance of targeting adults and those people who work and/or live at forested areas, for both 
surveillance and intervention programmes. Alternative interventions to prevent outdoor and 
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forest-related transmission are needed to support the country achieve malaria elimination by 
2030. 
 
 
 
Figure 7.2 Population-level transmission intensity based on SCR estimates in Elimination 
(Sabang), Pre-elimination (Kulon Progo) and High transmission (Mimika) setting.  
Panel a, b and c represent P. falciparum SCR. Panel d, e and f represent P. vivax SCR. As described 
in Chapter 3 and 5, SCRs estimate for Sabang and Kulon Progo were based on seropositivity to 
any of P. falciparum and P. vivax antigens tested. SCRs estimate for Mimika was based on 
seropositivity to PfMSP-1-19 and PvEBP for P. falciparum and P. vivax, respectively. 
 
Alternative sampling and geolocation strategy 
The choice of serological sampling strategy and the geolocation approach will be influenced by 
several factors such as characteristics of the population (i.e. health seeking behaviour, mobility 
and size of population) and the geographical area (i.e. catchment areas and geographical 
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accessibility), of the setting, and the transmission level. For example, the use of health facility-
based sampling and participatory mapping approach might be suitable for low transmission 
areas with good access to health services and relatively large population or geographical 
catchment areas. The study in Chapter 5 has illustrated the feasibility of conducting serological 
surveillance utilising the existing health facility-based surveillance systems in a low transmission 
setting conducting elimination. The use of health facility surveys is appropriate for capturing 
malaria burden as shown by the high participation rates and consistency of demographical 
characteristics of people sampled over times. The inclusion of all health facility attendees 
(regardless of their symptoms) and their companions in the serological surveys was feasible and 
can improve sampling coverage of the existing health facility-based surveillance system. 
However, the use of different public facilities or different sampling approaches may be more 
appropriate in other settings. For example, active sampling may be more appropriate in areas 
where cases are associated with mobile populations and certain occupations such as mining or 
logging that make people unlikely to attend health facility to seek for treatment (167,195). The 
use of community-based collection of samples and household GPS coordinates might also be 
more suitable for moderate or high transmission areas where sample size required is small, 
and/or areas with poor access to health services due to factors such as treatment preferences 
(e.g. self-medication or traditional healing practices) or due to limited access to universal health 
coverage, and/or for hard to reach areas. Finally, the community-based method can also be 
useful for low transmission areas with relatively small population and geographical areas. 
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7.2 Future directions 
Implementation of serological surveillance: challenges and opportunities 
Different applications of serological surveillance presented in this thesis could be used to better 
target surveillance and intervention, thus resources can be efficiently allocated in the future. 
However, potential challenges will need to be assessed to enable integration into the existing 
surveillance systems in different settings in Indonesia. These challenges can range from 
technical, analytical to operational aspects of the approaches. Several example of potential 
challenges at each aspect of serological surveillance evaluated in this thesis are summarised in 
Figure 7.3. 
 
 
 
 
 
 
 
Figure 7.3 Potential challenges in implementing serological surveillance to document absence of 
transmission and stratification of transmission.  
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• Technical 
At technical level, the potential implementation challenge is mainly related to the acquisition of 
laboratory materials and the choice of serological assay and antibody target. The majority of the 
malaria antigens used in this thesis were produced by our research group at the LSHTM, UK and 
other research collaborator at the Institut Pasteur, France, for research purposes. In addition, 
reagent and consumables used for the bead-based assays were purchased in the UK and 
transferred to Indonesia. Although majority of these materials are commercially available, cost 
will be much more expensive, and time needed for purchasing and shipping will be longer if order 
made locally. Although useful for research, the use of multiplex bead-based assay may be less 
suitable for programmatic use. ELISA is more available and commonly used for malaria and other 
diseases, thus can be a suitable option for programmatic use. However, as discussed above, the 
antibody target must be carefully chosen to best suit the use case scenarios for surveillance and 
programmes need. 
 
• Analytical 
At analytical level, issues are related to what is the best analytical methods in different scenarios. 
Firstly, there is an outstanding issue related to how is the best way to define seropositivity cut-
offs for each antigen. Serological data analysis in this thesis was mainly based on reverse catalytic 
models estimating population level force of infection (SCR) which assume that seroprevalence 
will increase with age. A limitation of these approaches is that seroprevalence is potentially 
influenced by the seropositivity threshold. Seropositivity cut-offs in Chapter 3 was based on 
antibody responses of nonexposed individuals tested alongside with the studied samples. 
Individual was classified seropositive if the respective antibody levels exceed the mean plus 3 
times the standard deviation of the seronegative population. Despite ensuring a high probability 
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of correctly classifying exposed individuals, this approach has the limitation of underestimating 
seroprevalence (142). On the other hand, seropositivity cut-offs in Chapter 5 and 6 were based 
on the two-component finite mixture model (FMM). This model was used on samples under 
analysis only (without additional data on nonexposed individuals). This approach relies on the 
basic assumption that the samples are a mixture of latent seronegative or seropositive 
populations (142). Similar to the cut-off used in Chapter 3, individuals were classified as 
seropositive if the respective antibody levels exceed the mean plus 3 times the standard 
deviation of the seronegative population identified by the model. Although the FMM model 
showed a good discrimination between seronegative and seropositive population in our dataset, 
this approach may not be ideal for identifying cut-off for several new antigens associated with 
more recent exposure in other low endemic settings. 
 
Secondly, the choice of whether the analysis needs to be based on combined responses from 
multiple antigens or not can be influenced by the use case scenarios and level of transmission. 
For example, to document absence of transmission and stratify transmission, SCRs estimates in 
very low transmission settings (Chapter 3 and 5) were based on responses to multiple antigens. 
The rational for this choice was based on idea that combining responses to multiple antigens will 
increase probability/analysis sensitivity in capturing exposure in the absence of active infections, 
as individuals may respond differently to each antigen. Whilst for estimating transmission 
intensity in a high transmission setting such as in Chapter 6, estimating SCRs from responses to 
a single most immunogenic antigen was the best option as majority of individuals responded to 
this antigen therefore provided representative estimate of the population. 
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• Operational 
At the operational level, the potential challenges are there is a huge discrepancy in the existing 
malaria control program and surveillance capacity and budget allocation across districts in 
Indonesia. This is partly due to the decentralization of the health sector implemented in 2002 
that put responsibility for planning and service delivery to local governments at the district level 
(196). The different capacity and budget allocation for malaria control and surveillance activities 
can limit the application of serology and any other new tools in some districts. 
 
The serological assays used in this thesis (ELISA and bead-based assay) are relatively easy to 
perform and are available in several academic and government reference laboratories in 
Indonesia. However, while ELISA is a more commonly used platform for malaria and other 
diseases, the reagents and consumables required for the bead-based assays are relatively 
expensive for programmatic use. In addition, the time taken to order the reagents (3-6 months) 
may also affect the sustainability of using this assay for public health program. 
 
Another potential challenge is the length of time taken from processing samples to generate the 
interpretable results for programmatic use. The WHO advised that as transmission declines, 
surveillance becomes more essential and requires more frequent data analysis and reporting to 
ensure adequate response can be taken in time (38). Diagnostic platforms such as serological 
lateral flow devices (sero-RDTs) that can perform more rapid combined antibodies test will be 
more useful for public health surveillance and control programme use, and research is ongoing 
to develop this tool (96).  
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The first alternative way to tackle these operational challenges is to integrate a multi-disease 
serological surveillance system that can include malaria, vaccine-preventable diseases (VPDs), 
neglected tropical diseases, and other notifiable diseases in population. Arnold et al. recently 
discussed about the potential of integrated serological surveillance to monitor infectious disease 
transmission and their interactions in population (197). The majority of currently available 
machines in Indonesia can test up to 50 different antigens in one run, offering a highly efficient 
way to monitor multi-diseases transmission and their interaction in the population. As the bead-
based assay requires as little as 1 µl of serum to determine up to 50 antibody responses 
simultaneously, measuring antibody responses to antigens from multiple diseases in one run will 
significantly reduce costs and time. The price of a Luminex MAGPIX machine used in this thesis 
was approximately £16,000 for order made in the United Kingdom. Our costing suggests that it 
costs approximately £1.00 per sample to test a minimum of 1000 samples against 25 different 
antigens. Although the machine is more expensive than ELISA reader, it was estimated that the 
cost of running multiplex assay using the Luminex MAGPIX can be up to four times less expensive 
than comparable ELISA assay (https://www.luminexcorp.com/research-magpix/). Furthermore, 
the integration of multi-disease surveillance can also greatly reduce cost and time needed to 
perform each surveillance components from data collection, analysis (both laboratory and 
statistical), reporting into formulating public health responses needed to control the diseases. 
Examples of this approach is given in Section 7.4.  
 
Another option is to build collaboration between the ministry of health and universities and/or 
research institutes which are widely spread across Indonesia. One local example of this is the 
current ongoing collaboration between Indonesia Ministry of Health with UGM and Drakeley’s 
group at LSHTM which aimed at implementing serological surveillance to evaluate changes in 
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malaria exposure upon implementation of intervention packages in high transmission settings in 
Indonesia. If successful, this collaborative serological surveillance exercise can be a model that 
can be widely implemented in Indonesia. 
 
Identifying and targeting hotspots of transmission 
This thesis has provided evidence for how serological surveillance can be used to identify 
hotspots of malaria transmission. Methodologies discussed in Chapter 3, 4 and 5, have a strong 
potential use in identifying hotspots of transmission (defined as clusters of higher than average 
anti body responses in this thesis) that potentially become source of malaria reintroduction in 
malaria elimination settings. It has been reported that hotspots can maintain malaria 
transmission in low transmission seasons and fuel transmission in the high seasons (43). 
However, this will depend on demographical and spatial representativeness of the sampling and 
mapping approaches employed. In Chapter 4, we have demonstrated that participatory mapping 
can generate a fine scale resolution that can accurately locate household into a correct hamlet 
unit. This indicates that a hamlet or village level intervention is likely a suitable choice for 
targeting hotspot identified using this approach. 
 
Moving forward, the serological surveillance methods presented in this thesis could potentially 
be used by the malaria surveillance and control program to better target the intervention. 
Hotspot-targeted interventions has been reported as a highly efficient malaria control and 
elimination strategy that could rapidly reduce malaria burden at all levels of transmission 
intensity (43). This approach will supplement the current high-risk targeted approach such as 
providing LLINs and intermittent preventive treatment (IPT) to young children and pregnant 
women that aims to reduce severe morbidity and mortality. The hotspot-targeted interventions 
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offer a logistically attractive alternative to untargeted interventions that may need coverage 
levels nearing 100% to drive transmission lower, especially in moderate and low transmission 
settings where malaria transmission is highly heterogeneous (42,46,198). However, feasibility of 
implementing and integrating this approach into existing malaria surveillance and control 
programme needs to be assessed. 
 
In future, serological measures could also play important role in helping the stratification of 
malaria risk as suggested by the WHO, especially in areas where EIR and PR are very hard to 
measure due to very low number of infected human and mosquitoes. As serological measures 
are increasingly recorded in many settings, these data could potentially be incorporated into a 
system such as in the Malaria Atlas Project (17,18) to allow risk stratification at minimum level. 
 
7.3 Limitations 
First, while the use of health facility-based sampling is more efficient in a low transmission 
setting, this approach is likely to miss asymptomatic infections, as well as those occurring in 
people who choose not to use public facilities. However, the inclusion of all health facility 
attendees and their companions in the surveys has reduced this bias. In addition, people living 
further from facilities may be less likely to attend health facilities resulting in the methods being 
less likely to detect clusters of high exposure further from facilities. However, it is conceivable 
that iterative refinements of the maps over time with clinical and demographic data would 
improve this. Inclusion of mapping exercise in active surveillance performed by community 
health workers would be useful to capture heterogeneity in areas further from the facilities. 
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Second, although the mobile technology-based participatory mapping approach provides an 
alternative approach to remotely collect GPS coordinates of health facility attendees, the 
accuracy of this approach varied between health facilities and decreased in less populated areas 
with fewer prominent landmarks. Prior experience of using map may also influence the accuracy 
of this mapping approach. For example, younger people may have more experience in using 
digital maps compared to older. However, this factor was not evaluated in the study. Future 
studies need to improve the accuracy of this approach (i.e. adding as much as available 
landmarks), test the validity and feasibility of this approach in different settings to enable 
implementation in a broader operational context. 
 
Finally, although our findings demonstrated the promising application of analysing multiple 
antibody responses data for surveillance use, the data generated will need to be translated into 
easily interpretable metrics of transmission. As previously discussed in Chapter 5, research is still 
ongoing to investigate the best analytical approaches to analyse the complex quantitative data 
generated by the multiplex assay. Methods applied in this thesis were based on standard 
seroprevalence, SCRs and regression models that have been widely used in previous malaria 
research. However, there is a more complex and robust methods such as Bayesian hierarchical 
models (199,200) that can be used to investigate the most epidemiological informative antigens 
but were not explored in this thesis. Although standard SCR and regression analysis in this thesis 
has generated important findings, future studies will need to explore any other approaches to 
combine these into more readily usable metrics. 
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7.4 Implications for other infectious diseases 
Methodologies used in this thesis can potentially be applied for multi-disease surveillance use. 
First, the multiplex bead-based assay used in this thesis provides an opportunity to collect data 
on a large number of diseases using a single sample. Studies have started to evaluate the use of 
this platform for the detection of malaria and other pathogens. For example, a study in Haiti was 
done to differentiate a newly introduced Chikungunya Virus to endemic dengue virus and other 
pathogens by measuring antibody responses to a recombinant chikungunya virus antigen, two 
dengue virus-like particles and three recombinant P. falciparum antigens in children. This study 
found that there had been a rapid and intense dissemination of chikungunya virus in Haiti and 
concluded that the multiplex bead assay is an appropriate serological platform to monitor the 
seroprevalence of multiple pathogens simultaneously (201). Another example is an integrated 
study measuring antibody responses to P. falciparum, P. vivax, Wuchereria bancrofti, 
Toxoplasma gondii, Taenia solium, and Strongyloides stercoralis recombinant antigens as part of 
a VPDs survey in Cambodia. This study concluded that the integrated serological surveys offer 
an opportunity to systematically assess the status of multiple public health programs and 
measure progress toward Millennium Development Goals (202). 
 
Second, the mobile technology-based mapping approach validated in this thesis offers an 
attractive alternative approach to remotely collect household GPS coordinates of health facility 
attendees that can iteratively be improved and integrated with other environmental or disease 
outcomes data. This mapping approach has also been recently used to assess human mobility in 
Amazon (203). Combining this mapping approach with the multiplex bead-based assay will 
enable simultaneous investigation of malaria and other pathogens such as VPDs and NTDs 
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burden, monitor changes over time, as well as to investigate their spatial patterns and 
interactions in population. Employing this approach could generate information on the 
epidemiology and spatial pattern of multiple infectious diseases that can help Ministry of Health 
to better priorities and allocate resources for surveillance and control programme activities in 
national and sub-national level. Currently, there is an ongoing work carried out by Drakeley’s 
group to evaluate the use of multiplex bead-based assay to investigate burden and spatial 
epidemiology of NTDs and VPDs. 
 
7.5 Conclusion 
This thesis aimed to evaluate the operational application of serological surveillance for 
monitoring malaria transmission as an alternative additional approach to the existing case-based 
surveillance system in Indonesia. It has shown that the serological surveillance can provide 
additional important information that cannot be generated by the routine malaria surveillance 
which rely on standard diagnostics such as microscopy and RDT, particularly in low transmission 
settings. Firstly, analysis of community-based serological data can confirm malaria elimination 
and identify clusters with high exposure in area reporting zero cases in the last three consecutive 
years. Secondly, quarterly health facility-based serological surveillance and participatory 
mapping can predict receptive areas at risk for malaria outbreak and assess factors associated 
with exposure to malaria in a very low transmission area conducting elimination. Thirdly, whilst 
seropositivity to Etramp5.Ag1 in children is a potential marker of recent exposure, a single most 
immunogenic antigen associated to long-lived antibody responses is useful to assess 
transmission intensity in a high transmission setting. Additionally, mobile technology-based 
participatory mapping can be used to quickly obtain spatial residential information for 
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individuals presenting at health facilities in resource poor areas where formal addresses are 
typically not used, and internet connectivity is limited. Findings from this thesis could be used to 
better target disease surveillance and intervention in the region. Additionally, the collaborative 
work presented in this thesis has helped the establishment of local laboratory and capacity to 
perform a multiplex bead-based assay, participatory mapping and the associated analytical 
approaches that can be used for future malaria and other infectious diseases research in 
Indonesia. 
 
Although this thesis shows potential operational applications of serological surveillance for 
malaria elimination, there are several challenges that need to be addressed before implementing 
the approaches in wider settings. Further operational and implementation research will be 
needed to identify and address bottlenecks of integrating serological surveillance into the 
routine surveillance systems. 
 
There are ongoing serological studies of samples collected from three sites evaluated in this 
thesis. Work is ongoing for samples collected via community-based cross-sectional survey in 
2014 in Sabang and a randomized controlled trial completed in 2018 in Mimika. Further testing 
for a panel of new malaria, NTDs and VPD antigens and further analysis and mapping for P. 
knowlesi exposure is planned for samples collected in 2018 in Kulon Progo. Catchment model 
analysis can be performed utilising data collected on travel distance, estimated time and mode 
of transportation used to travel from residence to the health facility. The future work arising 
from this thesis is summarised in Table 7.1. 
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Table 7.1 Summary of future work arising from this thesis 
Future work 
Laboratory Process samples collected from Mimika in 2018 using a panel of new 
antigens for P. falciparum, P. vivax and soil transmitted helminths 
Process samples collected from Kulon Progo in 2018 using a panel of 
new antigens for P. vivax, NTDs and VPD antigens 
Identification of new antigens for measuring recent P. vivax exposure 
Analysis Sero-epidemiological analysis for P. falciparum, P. vivax and P. knowlesi 
data generated from study in Sabang 2014 
Sero-epidemiological analysis and mapping of P. knowlesi data 
generated from study in Kulon Progo 
Catchment model analysis using data collected on distance from 
residence to health facility, estimated time and mode of transportation 
used to travel to the health facility 
Operational Costing study to estimate budget needed for implementing various use 
cases scenario of malaria serological surveillance in different 
geographical settings 
Implementation research to identify and address bottlenecks of 
integrating the various use cases scenario into existing malaria 
surveillance systems 
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Annex 2: Informed consent form 
 
 
 
 
Study site: Kulon Progo district, Indonesia 
Study centre: Primary health centres in Kulon Progo district, Indonesia 
Indonesian PI: Prof. dr. Supargiyono, DTM&H, PhD, SpParK (Universitas Gadjah Mada) 
UK PI: Prof. Chris Drakeley, MI Biol, PhD (London School of Hygiene & Tropical Medicine, 
United Kingdom) 
This Informed Consent Form has two parts: 
• Information Sheet (to share information about the study with you). 
• Certificate of Consent (for signatures if you agree to take part). 
You will be given a copy of the full Informed Consent Form 
 
 
 
 
 
 
 
 
 
 
 
 
INFORMED CONSENT FORM FOR PARTICIPANTS  
Version n° 1.0 of 01 Nov 2016  
 
Optimising serological surveillance for malaria in Indonesia (OPSIN) 
(OPSIN protocol Version n° 1.0 of 01/11/2016) 
  
237 
 
PART 1: INFORMATION SHEET 
Introduction 
Dear Sir/ Madam, 
 
We are a group of researchers from Universitas Gadjah Mada, Yogyakarta and we are 
working with other researchers from London School of Hygiene & Tropical Medicine, United 
Kingdom with support from Indonesia Ministry of Health. We want to learn how to measure 
the risk of malaria in your community. 
 
For this reason, we would like to know if you (or your child) might suffer from malaria 
exposure or infection and if you (or your child) have any clinical symptoms and risk factors 
of malaria. Therefore, we are asking you if you would like to participate in our study. 
Participation is voluntary, and you have the right to refuse. I will now give you some more 
information about the study. If my words are not clear, please ask me to stop and I will take 
time to explain. If you have questions later, you can ask me or the other study staff, at any 
time.  
 
Purpose of the study 
Malaria is important public health problems in our region. Unfortunately, we do not always 
have good and appropriate methods to determine whether someone is infected or not. Some 
tests are expensive, or quite complicated to perform, other methods are not reliable. It is 
hard for malaria control programme to make sure whether some villages or sub districts are 
free from malaria infection and exposure. Another problem is that sometimes these 
infections are present in community but do not cause symptoms. It is then difficult for health 
provider to decide what controls are needed and for which areas these controls are targeted. 
 
The aim of this study is to improve the capability of surveillance system to detect and 
measure malaria infection and exposure in our region. Also, we aim to improve our 
understanding of transmission dynamics and risk factors of malaria infection in the region. 
We do not know yet in which area is malaria infection still occur and which type of malaria 
is dominant in our region nowadays, but the study will help us to find out. We also want to 
determine the number of people in the community who have the infection but are not sick. 
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The full study will last for 12 months and we will collect samples from 20,000 participating 
members of your community, both adults and children. 
 
Study procedures 
If you agree to participate in the study (or if you agree that your child participates), the study 
investigator will take your blood sample and ask you some questions about your health (or 
your child’s health), your habits and your living environment. In addition, the investigator 
will show you a digital map and you will be asked to identify in which area you are living.  
  
On the blood sample that you provide we will perform a standard malaria microscopic test 
that will be done in local health centre you attend. We also will perform additional tests to 
look for the presence of malarial antibody in your blood sample – the tests that will guide 
malaria control programme to identify presence or absence of malaria transmission in 
particular area in our region. If you agree to take part in the study, these tests will be 
conducted at Laboratory of Parasitology, Faculty of Medicine, Universitas Gadjah Mada in 
Yogyakarta. 
 
The sample leftovers will be kept for several years in the Laboratory of Parasitology, Faculty 
of Medicine, Universitas Gadjah Mada in Yogyakarta for setting up further research on 
infectious diseases. These leftovers may also be shipped to laboratories in United Kingdom. 
If you do not agree that we store these leftovers, you (or your child) can still be part of the 
main study, just inform me or the study investigator. 
 
Your participation is entirely voluntary 
It is your choice to decide whether you want to be in the study / whether you want your child 
to be in the study. Whatever your decision is, all the diagnostic tests done on your blood will 
be provided free of cost to you (or your child). Also, you can decide to join the study, and 
later change your mind. This decision will not affect the quality of your (your child’s) care. 
Just tell me or the study investigator, you don’t need to provide any justification for this. 
 
What are the risks and benefits? 
You will likely benefit from taking part in this study. Everyone who participates will find out 
whether they have malaria. If we find malaria parasites in your (or your child) blood sample, 
you will receive the proper treatment. The study will be beneficial for your community. In 
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fact, we hope it will help the malaria control programme at the district and national level to 
better understand malaria transmission dynamics in our region. 
 
There may be a small bruise or temporary mild pain on the finger or heal where the blood is 
taken. There is also a small chance of infection when blood is drawn.  However, our careful 
procedures make this very unlikely. 
 
Treatment 
This study is only about diagnostic tests and we will not test any new drug or other therapy. 
Any disease you may be diagnosed with will be treated following the current standard 
treatment in the local health center, in the district. If needed, you will be referred to another 
appropriate health facility and treated per standard of care available in Indonesia.  
What are the costs?  
You will not be paid to take part in the study, however, we will make sure that you don’t bear 
additional costs from your participation. All the diagnostic tests we do on your blood sample 
will be free of charge. The treatment of malaria infections that are detected during the study 
will also be free of charge. The study will not pay for the diagnostic tests and treatment 
related to any other health problems that you (or your child) may have.  
What do we expect from you? 
If you accept to participate in this study, we will expect you to provide the blood sample and 
to undergo the physical examination. We also expect you to answer the questions of the 
study investigator to the best of your ability. 
 
How will confidentiality be respected? 
We will not share any of your (or your child’s) personal information outside of the Universitas 
Gadjah Mada study team. Your name (or your child’s name) will not be mentioned on any 
sample, nor on the data collected during the study. You (or your child) will be given a unique 
number, which will be used to identify the samples and data collected. If the results of this 
study get published in a scientific journal, your name (or your child’s name) will not appear 
on the publication. All members of the research team commit to protect the confidentiality 
of the information you provide. The members of the Ethics Committee, auditors, and 
Sponsor’s representatives may access your (your child’s) personal information, however, all 
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these people have to respect the confidentiality, and your (or your child’s) personal 
information will not be revealed publicly. 
 
Whom to contact in case of problem or question? 
For any problem or question related to the study you may contact: 
 
Coordinating investigator: Henry Surendra, SKM, MPH on +62 817 0741253 or Principal 
Investigator: Prof. dr. Supargiyono, DTM&H, PhD, SpParK on +62 812 2735246 in Universitas 
Gadjah Mada.  
 
Otherwise, you may contact the Centre for Tropical Medicine, Faculty of Medicine, 
Universitas Gadjah Mada, Sekip Utara, Yogyakarta, 55281, Indonesia. Telephone +62 274 
547147. 
You may also contact the Medical and Health Research Ethical Committee, Faculty of 
Medicine, Universitas Gadjah Mada, telephone no. +62 274 7134 955 or by email: 
mhrec_fmugm@ugm.ac.id. 
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PART 2: CONSENT FORM 
• For adult, literate participants: 
I have read the participant information sheet, or it has been read to me, and I have 
understood the purpose of the study, the procedure to be conducted, and the risks and 
benefits related to my participation. I know that some of the samples that will be collected 
may also be sent abroad for analyses. I have had the opportunity to ask questions and all 
have been answered to my satisfaction. I consent voluntarily to participate in this study. 
Print Name of Participant__________________      
     
Signature of Participant ___________________   
Date ___________________    
Day/month/year  
 I agree that part of my samples get stored for future research on infectious diseases  
 I don’t agree that part of my samples get stored  
• For witnesses of adult, illiterate participants: 
I have witnessed the accurate reading of the consent form to the potential participant, and 
the individual has had the opportunity to ask questions. I confirm that the individual has 
given consent freely.  
Print name of witness_____________________             AND         Thumb print of participant 
 
Signature of witness ______________________ 
Date ________________________ 
          Day/month/year 
 The participant agrees that part of his/her samples get stored for future research on 
infectious diseases 
 The participant does not agree that part of his/her samples get stored  
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Statement by the researcher/person taking consent 
I, the undersigned, have defined and explained to the participants in a language he/she 
understands, the procedures of this study, its aims and the risks and benefits associated with 
his/her participation. I have informed the participant that confidentiality will be preserved, 
that he/she is free to withdraw from the study without affecting the care he/she will receive 
at the hospital. I confirm that the participant was given an opportunity to ask questions 
about the study, and all the questions asked by the participant have been answered correctly 
and to the best of my ability. I confirm that the individual has not been coerced into giving 
consent, and the consent has been given freely and voluntarily. 
A copy of this Informed Consent Form has been provided to the participant. 
 
Print Name of Researcher/person taking the consent________________________  
 
 
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________    
Day/month/year 
 
• For literate parents or guardians of participants aged 0 to 18 years (minors) 
I have read the foregoing information, or it has been read to me, and I have understood the 
purpose of the study, the procedure to be conducted, and the risks and benefits related to 
my child’s participation. I know that some of the samples that will be collected may also be 
sent abroad for analyses. I have had the opportunity to ask questions and all have been 
answered to my satisfaction.  I consent voluntarily for my child to participate in this study. 
 
Print Name of Participant____________________________ 
Print Name of Parent/Guardian_____________________     
 
Signature of Parent/Guardian ___________________    
Date ___________________ 
Day/month/year  
 I agree that part of my child’s samples get stored for future research on infectious diseases 
 I don’t agree that part of my child’s samples get stored  
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• For witnesses of illiterate parents or guardians of participants aged 0 to 18 years 
(minors)  
A literate witness must sign (if possible, this person should be selected by the participant and 
should have no connection to the research team). Participants who are illiterate should 
include their thumb print as well.   
 
I have witnessed the accurate reading of the consent form to the parent of the potential 
participant, and the individual has had the opportunity to ask questions. I confirm that the 
individual has given consent freely.  
 
Print name of witness_____________________             AND                 Thumb print of 
parent/guardian 
Signature of witness ______________________  
Date ________________________ 
                Day/month/year 
 The parent/guardian agrees that part of his/her child’s samples get stored for future 
research on infectious diseases 
 The parent/guardian does not agree that part of his/her child’s samples get stored  
 
Statement by the researcher/person taking consent 
I have accurately read out the information sheet to the parent of the potential participant, 
and to the best of my ability made sure that the person understands the procedures of this 
study, its aims and the risks and benefits associated with his/her child’s participation. I 
confirm that the parent was given an opportunity to ask questions about the study, and all 
the questions asked by the parent have been answered correctly and to the best of my 
ability. I confirm that the individual has not been coerced into giving consent, and the 
consent has been given freely and voluntarily.  
 
A copy of this ICF has been provided to the participant. 
Print Name of Researcher/person taking the consent________________________ 
    
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________   
                 Day/month/year 
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• Assent for literate participants aged 12 to 18 years: 
I have read the participant information sheet, or it has been read to me, and I have understood 
the purpose of the study, the procedure to be conducted, and the risks and benefits related to 
my participation. I know that some of the samples that will be collected may also be sent abroad 
for analyses. I have had the opportunity to ask questions and all have been answered to my 
satisfaction. I consent voluntarily to participate in this study. 
 
Print Name of Participant__________________     
            
Signature of Participant ___________________   
  
Date ___________________    
Day/month/year  
 
 I agree that part of my samples get stored for future research on infectious diseases  
 I don’t agree that part of my samples get stored  
• For witnesses of illiterate participants aged 12 to 18 years: 
I have witnessed the accurate reading of the consent form to the potential participant, and the 
individual has had the opportunity to ask questions. I confirm that the individual has given 
consent freely.  
 
Print name of witness_____________________             AND         Thumb print of participant 
 
Signature of witness ______________________ 
 
Date ________________________ 
          Day/month/year 
 
 The participant agrees that part of his/her samples get stored for future research on 
infectious diseases 
 The participant does not agree that part of his/her samples get stored  
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Statement by the researcher/person taking consent 
I, the undersigned, have defined and explained to the participants in a language he/she 
understands, the procedures of this study, its aims and the risks and benefits associated with 
his/her participation. I have informed the participant that confidentiality will be preserved, that 
he/she is free to withdraw from the study without affecting the care he/she will receive at the 
hospital. I confirm that the participant was given an opportunity to ask questions about the 
study, and all the questions asked by the participant have been answered correctly and to the 
best of my ability. I confirm that the individual has not been coerced into giving consent, and the 
consent has been given freely and voluntarily. 
  
A copy of this Informed Consent Form has been provided to the participant. 
 
Print Name of Researcher/person taking the consent________________________ 
   
 
Signature of Researcher /person taking the consent__________________________ 
 
Date ___________________________    
Day/month/year 
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Annex 3: Luminex SOP 
SOP Title: Luminex Assay 
SOP No: Luminex Assay Indonesia 
 
Version: 001 
 
Effective from: 05/06/2017 
Superseded Version Number:  
Author: 
Name:  Tom Hall 
Position: Scientific Officer 
Signature:     Date:    /04/2015 
Revision History 
 
Comments 
Reviewed by:  
 
Date:  
 
Next review due:  
Signature(s): 
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1 Overview  
 
This SOP describes the method for the screening of serum samples by Luminex bead array 
 
2 Equipment 
 
a) Bio-rad 96 well plates 
b) Protective latex or nitrile gloves 
c) Pipettes 8 or 12-channel 30-300µl, single channel 100ul and tips 
d) Vortex 
e) Magnetic rack 
f) 1.5ml Eppendorf tubes 
 
3 Reagents 
All reagents should be stored according to the instructions supplied with them and disposed of 
at the expiry date recorded on the product. 
a) Selected coupled bead regions 
 
b) PBS tablets 
 
c) Tween 
 
d) BSA 
 
e) Sodium Azide 
 
f) PVA 
 
g) PVP 
 
h) Casein  
 
i) Ecoli extract  
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4  Preparation of Buffer Solutions  
All buffer solutions should be clearly labelled with:  
 * Reagent name  
 * Expiry date  
 * Preparation date  
 * Name of person who prepared the buffer 
Table 1- Preparation of buffer solutions 
Buffer solution Reagent/chemical Amount/Volume 
1xPBS  
 
Oxoid PBS tablets 1 
Milliq water 100ml 
Make up as needed daily, dispose of unused solution at the end of each day  
Wash buffer (1xPBS Tween) 
 
PBS 1X 1000ml 
0.05% Tween 20  0.5ml 
Make up as needed daily, dispose of unused solution at the end of each day  
Buffer A (PBS-TBN) 
1x PBS 1000ml 
0.05% Tween 0.5ml  
0.5% BSA  5g  
0.02% Sodium Azide  0.2g 
Store at room temperature 
Buffer B 
Buffer A 1000ml 
0.1% Casein  1g 
0.5% PVA 5g 
0.5% PVP  5g 
Ecoli Extract  
1.4ml of 10.865ug/ml 
stock 
 (15.25ug/ml) 
Centrifuge at 3000 RMP for 30 minutes and Store at +4. 
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5 Buffer B Prep and sample dilution  
 
1. Prepare buffer B and leave mixing until large lumps are dissolved, may require mixing 
overnight.  
 
2. Centrifuge buffer B at 3000 RPM for 30 minutes. Use a pipette gun and a 10ml glass 
pipette to remove most of the centrifuged buffer, aspirate slowly to avoid resuspending 
the particulate matter. Discard the last 10ml. 
 
3. Prepare sample at least a day before testing.  
 
4. Dilute samples at 1/200 (460ul of buffer B added to a 4.5mm blood spot) and leave over 
night mixing at 300 RMP. Dilution in buffer B reduces the background noise caused by non 
specific antibody binding. 
 
5. Leave samples mixing on a rotating platform for at least 8 hours to allow the full elution of 
the blood spot. 
 
6 Multiplex magplex assay protocol 
 
1. Remove all the buffers, coupled beads, samples and controls from the fridge/freezer. 
 
2. Measure out 5ml of buffer A per plate and add to a trough, 20ml will be required for 4 
plates.  
 
3. Calculate the required volume of beads; 8ul is required per plate (32ul for 4 plates). 
 
4. Vortex the beads to resuspend and add the required volume to the buffer A in the trough. 
(protect beads from light at all times) 
 
5. Once all bead sets are added to the buffer A mix well by tilting the trough up and down. 
  
6. Mix again by aspirating and dispensing the liquid using as multichannel pipette set to 50ul. 
 
7. Add 50ul of the bead mixture to all wells. 
 
8. Place the plate on the magnetic separator for 2 minutes. Protect the plate from light 
between the incubations using aluminium foil or a plate lid. 
 
9. With the microplate is still attached to the magnet remove the supernatant by rapid 
inversion with a sharp shake down the sink. Gently blot the plate on a paper towel to 
remove as much residual as possible. 
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10. Remove plate from the magnetic separator. 
 
11. Wash the microplate once by adding 100ul of 1xPBS/T, place the microplate onto the 
magnetic separator and pause for 2 minute. Pour the liquid down the sink (rapidly invert 
plate while still attached to magnet) and blot on a paper towel.  
 
12. Add 25ul of buffer B to wells A1 to H10. This is required to dilute samples to 1/400.  
 
13. Using a multichannel pipette 25µl of prepared samples from a deep well plate onto the 
plate containing washed beads. Use the layout in figure 1. 
 
14. Add 50ul of the required control (already diluted to 1/400) to the correct locations- see 
layout in fig 1. Add 50ul of buffer B to wells 11G/H and 12G/H 
 
15. Cover plate with a lid, secure on a vibrating shaker.  Mix at 200 rpm for 1.5 hrs at room 
temperature (RT).   
 
16. Place the plate on the magnetic separator for 2 minutes. While the plate is still on the 
magnetic separator, pour off the supernatant by a rapid inversion with a sharp shake. 
Gently blot the plate on a paper towel to remove as much residual as possible. 
 
17. Wash the plates three times with 100ul of 1xPBS/T as above, point 11. 
 
18. Prepare secondary antibody at 1/200 in buffer A. For one plate add 25ul of the secondary 
antibody to 5ml Buffer A. For 4 plates 100ul of secondary will be added to 20ml of buffer 
A. (protect secondary from light). 
 
19. Mix the buffer A and secondary mixture well (as in points 5 and 6) and add 50 µl/well of 
secondary antibody to each well.  
 
20. Cover plate with a lid and secure on shaker. Mix at 200 rpm for 1.5 hrs at RT.   
 
21. Wash plate X3 with 100ul of 1xPBS/T as above. 
 
22. Add 50 µl of buffer A per well.  Cover with lid, secure on shaker and shake at 200 rpm for 
30 minutes at RT. 
 
23. Wash plate 1X with 100ul of 1xPBS/T. 
 
24. Add 100 µl of 1XPBS per well. 
 
25. Leave plates over night in the fridge (+4OC) and read the follow day. 
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Figure 1: Plate layout 
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H 
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Annex 4: OPSIN questionnaire version 2.0 21 February 2017 (installed into GeoODK) 
Interviewer initial: ____________ 
Health facility: ____________________________ 
Participant ID: _______________ 
Date of enrollment: _________________(DD/MM/YYYY) 
Part I – DEMOGRAPHIC DATA 
Participants < 6 months must not be included in the study. 
1. Date of birth: ___________(DD/MM/YYYY) or Age: ______(Year) ______(Month) 
2. Gender: 
a. MALE 
b. FEMALE 
3. Participant status: 
a. PATIENT 
b. ACCOMPANYING PERSON 
Part II – GEOGRAPHIC INFORMATION 
1. Hamlet _____________________________________ 
2. Village Name ________________________________ 
3. Head of Household ___________________________ 
4. Nearest Market ______________________________ 
5. Nearest Primary School ________________________ 
6. Nearest Health Facility _________________________ 
7. How did you travel here today: 
a. WALK 
b. MOTORBIKE 
c. BICYCLE 
d. CAR 
e. OTHER (SPECIFY) 
8. How many minutes did it take you to get here by [answer of Q7] ____________ 
9. Locate residence on map using geolocation application (coordinates populated by app) 
a. LAT __________________________ 
b. LONG _________________________ 
c. NOT ABLE TO LOCATE (skip to part III) 
10. Are you willing to have your house labeled on the map as a point of interest to help other 
people find their house?  
a. YES 
b. NO 
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Part III – CLINICAL DATA 
1. Current symptoms (Check all that apply): 
a. FEVER 
b. HEADACHE 
c. CHILLS 
d. STOMACHACHE 
e. VOMITING 
f. NAUSEA 
g. OTHER (SPECIFY) 
h. NOT APPLICABLE 
2. Temperature reading ______ 0C 
3. Has the participant been ill with a fever at any time in the last 2 weeks? 
a. YES 
b. NO (if no skip to Q6) 
c. NOT SURE 
4. Did the participant seek advice or treatment for the fever from any source? 
a. YES 
b. NO (if no, skip to Q6) 
5. Where did the participant seek advice or treatment? (Check all that apply) 
a. PUBLIC HOSPITAL 
b. PRIMARY HEALTH CENTER 
c. PUBLIC HEALTH POST 
d. MOBILE CLINIC 
e. FIELD WORKER 
f. OTHER PUBLIC MEDICAL 
g. PRIVATE HOSPITAL/CLINIC 
h. PHARMACY 
i. PRIVATE DOCTOR 
j. OTHER PRIVATE MEDICAL (SPECIFY)__________________ 
k. SHOP 
l. TRADITIONAL PRACTITIONER 
m. OTHER (SPECIFY)__________________ 
6. Has the participant had a fever in the last 24 hours? 
a. YES 
b. NO 
c. DON’T KNOW 
7. Has the participant taken any drugs in the last 2 weeks? (Check all that apply) 
a. SP/FANSIDAR 
b. CHLOROQUINE (alone) 
c. CHLOROQUINE + primaquine 
d. AMODIAQUINE 
e. QUININE 
f. COARTEM 
g. OTHER ANTIMALARIAL (SPECIFY)___________________ 
h. ASPIRIN 
i. ACETAMINOPHEN/PARACETAMOL 
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j. IBUPROFEN 
k. OTHER (SPECIFY)___________________ 
l. DON’T KNOW 
 
Part IV – RISK FACTORS DATA 
1. What is the occupation of the participant? 
a. FARMING 
b. COCONUT/PALM TAPPING 
c. MINING 
d. FOREST RELATED JOBS 
e. HOUSEWIFE 
f. OTHER 
g. JOBLESS 
h. NOT APPLICABLE 
 
2. Does the participant sleep where the farm is situated? 
a. YES 
b. NO 
c. Not Applicable 
3. Has the participant travelled outside (THIS HAMLET) in the last 4 weeks? 
a. YES 
b. NO (Skip to Q7) 
c. DON’T KNOW (Skip to question Q7) 
4. How many trips has the participant made outside (THIS HAMLET) in the last 4 weeks? ____ 
5. When did the participant come back from the participant’s most recent trip? 
a. <2 WEEKS AGO 
b. 2-4 WEEKS AGO  
c. >4 WEEKS AGO 
6. Which Hamlet did the participant spend most time in during that trip? ____________ 
7. Does the participant’s household have any mosquito nets that can be used while sleeping? 
a. YES 
b. NO (if no, skip to Q11) 
8. How many mosquito nets does the participant’s household have? ____________ 
9. Did the participant sleep under a bed net last night? 
a. YES 
b. NO  
10. If NO, why not? (Check all that apply) 
a. IT IS TOO HOT UNDER THE NET 
b. THERE IS NOT ENOUGH SPACE UNDER THE NEXT/I FEEL TOO CLOSED IN 
c. IT DOES NOT PROTECT AGAINST MOSQUITOES/INSECTS 
d. NO MOSQUITOES AROUND 
e. IT IS FOR ONLY CHILDREN/PREGNANT WOMEN 
f. BEDNET USED BY PARENTS 
g. BEDNET USED BY SIBLINGS 
h. BEDNET BEING WASHED 
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i. BEDNET OLD 
j. BEDNET KEPT FOR VISITORS 
k. IT IS TOO EXPENSIVE/CANNOT AFFORD ENOUGH NETS FOR EVERYONE 
l. IT IS NOT THE RAINY/MALARIA SEASON 
m. CANNOT HANG IT OVER MY SLEEPING PLACE/SLEEPING OUTSIDE 
n. CHANGE MY SLEEPING PLACE TOO OFTEN 
o. DO NOT KNOW 
p. OTHER 
11. What material is the flooring of the participant’s house made of? 
a. DOESN’T HAVE FLOORING 
b. BAMBOO OR OTHER WOOD 
c. CEMENT 
d. CERAMIC 
12. What material is the exterior wall of the participant’s house made of? 
a. NONE 
b. WOVEN SPLIT BAMBOO 
c. BAMBOO 
d. CEMENT 
13. What material is the roof of the participant’s house made of? 
a. NONE 
b. NIPA 
c. BAMBOO 
d. ROOF TILES 
e. GALVANIZED IRON SHEETS 
f. ASBESTOS 
 
Part V – LAB DATA 
1. Blood films prepared? 
a. YES 
b. NO  
2. Filter paper blood spots prepared? 
a. YES 
b. NO  
3. Microscopy Result 
a. POSITIVE 
b. NEGATIVE 
c. NOT DONE 
Barcode Number: _______________________ (scan in) 
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Annex 5: LSHTM Ethical Clearance
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Annex 6: UGM Ethical Clearance
 
